University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2019

Drug-Drug Interactions And Kidney Disease In Hospitalized
Patients
Todd Anthony Mianno
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Epidemiology Commons

Recommended Citation
Mianno, Todd Anthony, "Drug-Drug Interactions And Kidney Disease In Hospitalized Patients" (2019).
Publicly Accessible Penn Dissertations. 3395.
https://repository.upenn.edu/edissertations/3395

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/3395
For more information, please contact repository@pobox.upenn.edu.

Drug-Drug Interactions And Kidney Disease In Hospitalized Patients
Abstract
As polypharmacy becomes increasingly common in patients with kidney disease, drug-drug interactions
(DDIs), the phenomenon of one drug altering the effect of another drug, grow as potential sources of
preventable harm in this vulnerable population. The clinical impacts of DDIs are poorly understood,
particularly in the hospital setting, where up to half of patients have acute or chronic kidney disease.
Further, the potential for bidirectional relationships between kidney disease and DDIs—with kidney
disease functioning as both an outcome of DDIs and a baseline factor that alters DDI
severity—complicates epidemiologic study and necessitates novel methodologic approaches.
We undertook three distinct but related projects that explored the bidirectional relationships between
kidney disease and DDIs. First, we proposed and provided theoretical justification for a novel study
design, the dual control design, which specifically addresses unique challenges that are posed by the
study of pharmacodynamic DDIs. Second, we applied this novel design to determine the risk of acute
kidney injury during concomitant exposure to nonsteroidal anti-inflammatory drugs and inhibitors of the
renin angiotensin system during inpatient admission. Third, we conducted a retrospective, longitudinal
cohort study of patients on inpatient warfarin therapy that that examined the effect of renal dysfunction
on the magnitude of the known interaction between warfarin and amiodarone, which is mediated by
CYP2C9 enzyme inhibition.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Epidemiology & Biostatistics

First Advisor
Sean Hennessy

Keywords
active comparator designs, acute kidney injury, drug-drug interactions

Subject Categories
Epidemiology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/3395

DRUG-DRUG INTERACTIONS AND KIDNEY DISEASE IN HOSPITALIZED PATIENTS
Todd Anthony Miano
A DISSERTATION
in
Epidemiology and Biostatistics
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2019

Supervisor of Dissertation

________________________
Sean Hennessy
Professor of Epidemiology
Graduate Group Chairperson

________________________
Nandita Mitra
Professor of Biostatistics
Dissertation Committee
Michael Shashaty, Assistant Professor of Medicine
Athena Zuppa, Associate Professor of Anesthesiology, Critical Care and Pediatrics
Peter Yang, Associate Professor of Biostatistics
Jeremiah Brown, Associate Professor of Epidemiology, Dartmouth College

DRUG-DRUG INTERACTIONS AND KIDNEY DISEASE IN HOSPITALIZED PATIENTS
COPYRIGHT
2019
Todd Anthony Miano

ABSTRACT
DRUG-DRUG INTERACTIONS AND KIDNEY DISEASE IN HOSPITALIZED PATIENTS
Todd Anthony Miano, PharmD, MSCE
Sean Hennessy, PharmD, PhD

As polypharmacy becomes increasingly common in patients with kidney disease,
drug-drug interactions (DDIs), the phenomenon of one drug altering the effect of another
drug, grow as potential sources of preventable harm in this vulnerable population. The
clinical impacts of DDIs are poorly understood, particularly in the hospital setting, where
up to half of patients have acute or chronic kidney disease. Further, the potential for
bidirectional relationships between kidney disease and DDIs—with kidney disease
functioning as both an outcome of DDIs and a baseline factor that alters DDI severity—
complicates epidemiologic study and necessitates novel methodologic approaches.
We undertook three distinct but related projects that explored the bidirectional
relationships between kidney disease and DDIs. First, we proposed and provided
theoretical justification for a novel study design, the dual control design, which
specifically addresses unique challenges that are posed by the study of
pharmacodynamic DDIs. Second, we applied this novel design to determine the risk of
acute kidney injury during concomitant exposure to nonsteroidal anti-inflammatory drugs
and inhibitors of the renin angiotensin system during inpatient admission. Third, we
conducted a retrospective, longitudinal cohort study of patients on inpatient warfarin
therapy that that examined the effect of renal dysfunction on the magnitude of the known
interaction between warfarin and amiodarone, which is mediated by CYP2C9 enzyme
inhibition.
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CHAPTER 1: POLYPHARMACY, DRUG-DRUG INTERACTIONS, AND KIDNEY
DISEASE IN HOSPITALIZED PATIENTS

The occurrence of drug-drug interactions (DDI), the phenomenon of one drug
altering the effect of another drug, is an important and growing public health problem.62,67
The prevalence of prescription drug use has increased steadily over the past two
decades, reaching ubiquitous levels in older Americans, where 90% take at least one
drug and 50-75% take more than five in a given month.104,116,77 These high rates of drug
use create substantial public health risk from DDIs,19,66 which are responsible for an
estimated 13% - 17% of all adverse drug events (ADEs) in the outpatient setting114,53 and
4.8% of hospital admissions.10
Defining drug-drug interactions
DDIs can be classified broadly into two categories based on the mechanism of
interaction: pharmacokinetic or pharmacodynamic. Pharmacokinetic DDIs occur when
one drug (the precipitant or perpetrator drug) alters the extent of exposure to another
drug (the object, or victim drug), via effects on one or more mechanisms of absorption,
distribution, or clearance.62,67 Altered drug effects are due to changes in exposure to the
object drug. Interaction mechanisms that lead to excessive exposure (e.g. when a
precipitant drug inhibits the metabolism of the object drug) may increase the risk for
adverse effects. Conversely, interaction mechanisms that lead to reduced object drug
exposure (e.g. when a precipitant drug induces the metabolism of the object drug) may
increase the risk for treatment failures.62,67 Although many pharmacokinetic DDIs involve
a single mechanism (e.g. precipitant inhibition of object drug metabolism by a single
CYP-enzyme), complex DDIs can occur that involve multiple pharmacokinetic
1

mechanisms; bidirectional exposure alterations (each drug alters exposure to the other
drug); or more than two drugs.62,67
Pharmacodynamic DDIs occur when the mechanisms of action of two drugs act
synergistically (or antagonistically), resulting in a combined effect on outcome risk that is
larger (or smaller) than the effect of either drug alone.62 Pharmacodynamic interactions
do not involve alterations of exposure. Some pharmacodynamic DDIs may be the result
of competition for the same drug receptors, but more commonly the mechanisms are
indirect.98 Given the wide variety of potential mechanisms, it’s difficult to systematically
classify pharmacodynamic interactions beyond the level of the common physiologic
system involved. Examples of potential pharmacodynamic interactions include
concomitant exposure to opioid analgesics and benzodiazepine anxiolytics (synergistic
sedation); concomitant exposure to the oral anticoagulant warfarin and the antiplatelet
agent aspirin (synergistic bleeding risk); and concomitant exposure to a nonsteroidal
anti-inflammatory drug (NSAIDs) and an inhibitor of the renin angiotensin system (RAS)
(synergistic reductions of glomerular filtration rate). Although estimates vary, data from
both the inpatient and outpatient setting suggest that pharmacodynamic DDIs are more
common than pharmacokinetic DDIs, accounting for roughly two-thirds of all potential
DDIs.98,155,37
Evidence for the adverse health effects of DDIs
Although prior studies have attempted to estimate the harm due to
DDIs,19,66,114,53,10 the DDI evidence base remains weak. Of the nearly 100,000 potential
DDIs that can be predicted based upon mechanistic data,87,61 few have been rigorously
examined to determine the true risk of adverse health effects.89,81,133,119 The majority of
2

information stems from in-vitro models and small clinical studies in healthy volunteers.67
Data from these highly controlled settings often fail to identify clinically relevant DDI in
real world populations, which are characterized by significant comorbid illness and
polypharmacy. Knowledge of the actual clinical impact of DDIs often derives from case
reports, accounting for up to 80% of the primary literature in the case of warfarin.67,61
Given the potential adverse public health consequences of DDIs, a recent national DDI
stakeholder conference highlighted the need for additional research as its leading
recommendation.67
One of the least understood aspects of DDI pharmacoepidemiology is the risk of
adverse outcomes from DDIs in the hospital setting. The complexity of polypharmacy
increases greatly in persons admitted to the hospital, where extensive outpatient
regimens intersect with inpatient drug therapy. The number of medications given to
patients during an average hospital admission increases 2-3-fold from baseline
outpatient regimens.155,71 In this high-risk setting, 40%-80% of patients are exposed to
drug combinations that have the potential to interact to produce adverse health
outcomes.155,37,34,120 Unfortunately, clinicians have virtually no direct evidence to guide
practice, as no previous studies have examined health outcomes related to DDI that
occur in the hospital setting. Moreover, evidence from other settings may have limited
applicability, due to the unique characteristics of the inpatient population. This group
often has acute illness (e.g. infection, surgery, disease exacerbation) and acute changes
of organ function that may render them more susceptible to the adverse effects of a
given DDI.120,94,3,96 In addition, the timescale of exposure is different, involving treatment
durations of a few days or weeks in the inpatient setting versus chronic exposure over
periods of months or years. Lastly, inpatients are often closely monitored relative to
other settings, allowing for early identification and intervention to mitigate possible
3

adverse effects. Each of these factors can alter the risk for DDI associated adverse
effects. As a result, the clinical relevance of most DDIs in the inpatient setting is
uncertain. Given the burden of hospitalization in the United States (an estimated 35
million admissions in 2016104), the potential public health impact of DDIs in the inpatient
setting is enormous. Improving the safety of polypharmacy in the hospital setting thus
requires additional research that determines which DDIs are clinically relevant in the
inpatient setting, and which factors explain heterogeneity of risk among individual
patients.
Drug-drug interactions and kidney disease in the hospital setting
Kidney disease is one of the most frequently encountered disease states in the
hospital setting. Chronic kidney disease (CKD) is present at admission in 25-40% of
patients,138,59,17 and a substantial proportion of patients will experience further worsening
of renal function during admission. Acute kidney injury (AKI) occurs in 16-18% of
hospitalized patients161,167 and up to 40-75% of patients in high-risk settings such as the
intensive care unit or after major surgery.16,70,83 Importantly, these various forms of
kidney disease may play a role in many clinically important DDIs that occur in the
hospital setting, functioning as both an outcome of DDIs and a factor that directly alters
the occurrence and clinical impact of DDIs (Figure 1.1). First, drug toxicity and DDIs in
particular may be an important and underappreciated cause of AKI in this high-risk
population.122,48,88,11,46,36,166 Second changes in kidney function may directly alter
mechanisms that underlie DDI pharmacology (e.g. altered CYP enzyme expression and
function, altered protein binding).164,105 Consequently, renal function may be an important
source of heterogeneity in drug-drug interaction magnitude. Understanding the interplay
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between kidney disease and DDI may thus greatly enhance the safety of
pharmacotherapy in hospitalized patients.
DDIs that lead to AKI may be a substantial source of morbidity and mortality in
the hospital setting. The development of AKI is associated with increased short and
long-term mortality,16,121,68,27 prolonged duration of hospitalization,24 increased healthcare
costs,24 and subsequent progression to chronic kidney disease (CKD) and end stage
renal disease (ESRD).28,23,75 Patients requiring renal replacement therapy for AKI have
mortality rates ranging from 40% to 80%.25,144 These rates are similar in magnitude to
postoperative cardiac arrest and more striking than those of perioperative myocardial
infarction, postoperative stroke, and coma.25,144 No treatments exist for AKI, making the
identification and avoidance of potentially nephrotoxic drugs and drug combinations a
cornerstone of management in the inpatient setting.8,113 Importantly, the evidence
supporting most nephrotoxic drug combinations is based on expert opinion and casereports.61,83,25
One clinically important potential DDI that may lead to excess AKI episodes
during hospitalization is between NSAIDs and RAS inhibitors. This pharmacodynamic
interaction is thought to be due to synergistic effects on renal blood flow through the
renal nephrons, leading to reductions of glomerular filtration rate.112,137,1,146 The
prevalence of concomitant exposure to NSAIDs and RAS inhibitors during
hospitalizations may be increasing as clinicians shift towards opioid alternatives.64,145 In
chapter five of this dissertation, we describe the results of a large cohort study that
applies a novel study design to determine the effect of this potential DDI on kidney
outcomes during hospitalization.
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Drug-drug interaction heterogeneity
Although a primary goal of DDI pharmacoepidemiology is to determine which
potential DDIs represent truly harmful DDIs, quantification of adverse effects at the
population level is often insufficient because of substantial interindividual variability in
DDI response.104,32,95 Indeed, most patients tolerate drug combinations that are known to
cause harm.95 This “unpredictability” of DDI associated adverse events confounds
treatment decisions, leading to unnecessary avoidance of potentially beneficial
combinations in many patients, while also resulting in harmful combinations being
prescribed to those susceptible to adverse effects. Elucidation of the sources of DDI
heterogeneity is thus a clinical imperative.
Heterogeneity of interaction severity is an important concept for both
pharmacodynamic and pharmacokinetic mechanisms of interaction. However, given the
wide variety of mechanisms that mediate pharmacodynamic interactions, many of which
are unique to a give drug pair, it’s especially challenging to identify systematic sources of
variability. In contrast, pharmacokinetic interactions involve a limited number of
mechanisms types, each encompassing many distinct DDI pairs.94 One of the most
common mechanisms is competitive inhibition of CYP enzyme metabolism.94,95 which
exhibits large interindividual variability. Five-fold differences in the magnitude of
response to a CYP-inhibition interaction is not uncommon, with ranges as high as 100fold in some cases.95 Although inhibition heterogeneity may be linked to several factors
(e.g. dose, route of administration, degree of hepatic extraction), variation of baseline
metabolic activity may be the most important modifying factor.95,90,43,86
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Prior evidence suggests that the change in exposure that results from competitive
CYP inhibition is directly proportional to the basal rate of drug metabolism for each
individual.95,90,43,86 This phenomenon has been demonstrated in studies that examine
the effect of CYP P450 genetic polymorphisms on the extent of competitive inhibition
DDI. Multiple such studies have shown that the impact of a given inhibitor on exposure is
substantially larger in subjects with an extensive metabolizer phenotype vs. poor
metabolizer phenotype.95,90,43,86 The relation can be shown by the Michaelis-Menten
equation,94 which predicts the rate of CYP enzyme (Vo) metabolism for a given CYP
enzyme:
𝑉" = 𝑉%&' × )-

[+]

. /[+]

0

1.1

where Vmax represents the maximum rate achieved by the system when enzyme binding
is saturated, Km is the substrate concentration producing 50% of Vmax, and [S] is the
substrate concentration. The total enzyme content of the liver determines Vmax, whereby
higher amounts of enzyme results in a higher maximum rate.94,95 Vmax can thus be
thought of as a measure of the baseline metabolic capacity of the individual. The
equation shows that reaction rate depends on the proportion of enzyme that is bound to
substrate, which is a function of the substrate concentration and the enzyme-substrate
binding affinity.94 The rate of CYP enzyme metabolism in the presence of competitive
inhibition (Vi) is given by

[+]

𝑉1 = 𝑉%&' × 2

[5]
67

-. × 34/ 8/[+]
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where I is the concentration of the inhibitor and Ki is the inhibition constant of the
inhibitor. The equation shows that competitive inhibition acts only to increase Km.
7

1.2

Intuitively, competition between the inhibitor and substrate for the same enzyme binding
site effectively decreases the apparent binding affinity of the substrate. Equation 1.2 also
shows that the magnitude of the change in metabolism that results from enzyme
inhibition is directly proportional to the baseline metabolic capacity (Vmax). This relation
between DDI magnitude and baseline metabolic capacity suggest that heterogeneity of
DDI magnitude might be mediated by any factor that effects baseline CYP enzyme
metabolic activity.
An additional factor that might mediate the magnitude of CYP enzyme inhibition is
drug protein binding. Drug that is bound to plasma proteins is sequestered from the
liver,134 which has a rate-limiting effect on hepatic clearance for highly protein bound
drugs such as warfarin or amiodarone. The well-stirred160 hepatic clearance model
shows this:
𝐶𝑙< = 𝑄> × )

?@ A BC7DE
FG/ ?@/BC7DE

0

1.3

where Clh is hepatic clearance, Qh is blood flow, Clint is intrinsic clearance (the sum total
of CYP activity), and fu is the unbound drug fraction. The equation shows that, in addition
to baseline CYP activity (i.e. Clint), metabolic clearance is directly proportional to the
unbound drug fraction. It follows from equations 1.2 & 1.3 that reduced protein binding
should magnify the effect of CYP enzyme inhibition.
Theoretical links between kidney disease and DDI pharmacology
A growing body of evidence suggests that renal impairment has direct suppressive
effects on hepatic and intestinal CYP P450 activity.164,105 Experimental models of various
severities of kidney disease show significantly reduced protein expression and activity
8

for all the major drug-metabolizing CYPs (i.e., 1A, 2C, 2D, 3A).164,105 Other studies show
that human uremic serum directly inhibits CYP P450 oxidative metabolism in rat and
human liver microsomes.164,105 These findings are supported by numerous clinical
studies of in-vivo drug metabolism: more than 75 drugs exhibit altered non-renal
clearance in patients with renal impairment.164 The degree of CYP suppression is
proportional to the severity of renal impairment, with up to 3-6 fold reductions in drug
clearance observed in patients with moderate to severe renal impairment (GFR < 50
ml/min).105 Taken together, these data provide strong evidence that CYP enzyme
metabolic capacity (i.e. Vmax) is suppressed by renal impairment; this suppression would
be expected to reduce the impact of DDI that are mediated via CYP inhibition. To date,
no studies have explored this potential mechanism.
In addition to reduced CYP-enzyme expression, kidney disease is also characterized
by in reductions in drug protein binding.130 As shown above, reduced protein binding
should magnify the effect of CYP enzyme inhibition. As a result, the net effect of kidney
disease on DDI severity depends on the interplay between CYP suppression, drug
protein binding, and the specific physiochemical characteristics of the drugs in question.
Virtually no prior studies have explored these complex drug-drug-disease interactions. In
chapter six of this dissertation, we describe the results of a large cohort study that
directly tests whether the magnitude of a CYP-enzyme inhibition DDI is altered by the
presence of kidney disease. Using the well described interaction between warfarin and
amiodarone as a test case, we directly examine the potential drug-drug-disease
interaction between warfarin, amiodarone, and kidney disease by comparing the effects
of amiodarone on warfarin dose response across levels of baseline renal function.

9

FIGURE 1.1 Hypothesized relationships between drug-drug interactions and kidney
disease

Object

PK

Concentration
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AKI / Renal
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Other
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The figure shows potential pathways by which drug-drug-interactions can lead to
deleterious effects on kidney function and potential pathways by which changes in
kidney function may produce variability in DDI severity. A given precipitant drug can lead
to altered effects of an object drug by either impacting a pharmacokinetic or
pharmacodynamic mechanism, which may lead to toxic effects on the kidney. In turn,
changes in kidney function may lead to changes in one or more pharmacokinetic or
pharmacodynamic mechanisms, which might mediate altered DDI magnitude.
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CHAPTER 2: CONCEPTS OF INTERACTION

The defining characteristic of drug-drug interaction pharmacoepidemiology is the
use of epidemiologic tools to quantify the health effects of drug-drug interactions. A key
aspect of the field is the incorporation of clinical pharmacology concepts into study
design. In the previous chapter we reviewed the definition of drug-drug interaction and
clarified the pharmacological differences between pharmacokinetic and
pharmacodynamic mechanisms. In this chapter we view drug-drug interactions as
special cases of the epidemiologic phenomenon of interaction considered broadly. Our
goal is to understand how the epidemiologic measures of interaction derived from
pharmacoepidemiologic studies relate to underlying mechanistic theories that define
drug-drug interactions. The focus here is on the theoretical concepts that define
interaction and epidemiologic measures available to quantify interaction. Where
applicable, discussion assumes absence of confounding and other biases. Issues
related to the control of confounding will be addressed in chapters three and four.
Defining interaction
Merriam-Webster defines interaction as “mutual or reciprocal action or
influence”.101 This definition aligns with the epidemiological concept of interaction, which
can be defined as the phenomenon of one exposure modifying the effect of another
exposure.129 The idea of one factor modifying the effect of a second factor motivates the
term “effect modification”, which is often used interchangeable with the term interaction.
As we shall see however, recent work draws clear distinctions between the two terms.154
Other notions of interaction include the statement that two exposures have
11

“interdependent effects”;102,50 or that two exposures participate in “causal coaction”.50,128
Common to these descriptions of interaction is the idea that, when interaction is present
between two exposures A and B, the effect of A cannot be determined unless the value
of B is known; and, the effect of B cannot be determined unless the value of A is known.
It is also notable for our purposes that these notions of interaction coincide precisely to
definition of drug-drug interaction discussed in the previous chapter.
If we have two exposures A and B, quantitative interaction occurs if the
magnitude of effect for A is either larger or smaller in the presence of B compared to the
absence of B, but the direction of effect is the same.150 For example imagine that A is a
drug that lowers blood pressure and B is a gene that leads to reduced expression of the
binding receptor for drug A. Quantitative interaction between the drug and gene would
occur if the drug lowers blood pressure in persons with and without the gene, but by a
smaller amount in those with the gene compared to those without the gene. Qualitative
interaction occurs if the direction of effect due to A differs in the presence of B compared
to the absence of B.150 In the previous example, qualitative interaction would occur if
drug A lowers blood pressure in persons without the gene, but raises blood pressure in
persons with the gene. Semiqualitative interaction occurs if an exposure has an effect
that is either present or absent depending on the presence of another exposure.150
Continuing with our example, semiqualitative interaction would occur if drug A lowers
blood pressure in persons without the gene, but has no effect on blood pressure (either
positive or negative) in persons with the gene.
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Epidemiologic measures of interaction
The preceding definitions of interaction will be intuitive to many readers, as they
coincide with the common notion of disease outcomes being multifactorial in nature.
Difficulty arises however, when these notions are translated to the analysis of
epidemiologic data, because the presence of “interaction” depends on the scale of
analysis.
If interaction between exposures implies an effect under combined exposure that
differs from the effect of either exposure alone, then a natural approach to assessing
interaction would be to examine the extent to which the effect of combined exposure
exceeds the effect of each exposure when considered in isolation.150 The following
formulations are based on incidence (i.e. risks), but the ideas extend directly to other
measures of occurrence, including rates, hazards, and odds.129
Let Rxz denote the average risk when X = x and Z = z, with each of X and Z
coded as 1 = exposed and 0 = unexposed. On the difference scale, the interaction
contrast (ICD) is defined as:
𝐼𝐶I = 𝑅44 − 𝑅LL − (𝑅4L − 𝑅LL ) − (𝑅L4 − 𝑅LL )

2.1

the presence of interaction is defined as ICD ¹ 0, i.e. when the risk difference for
combined exposure compared to absence of both exposures is larger or smaller than the
sum of the risk differences for either exposure alone.129 Positive interaction (e.g.
superadditivity) is defined as ICD > 0 while negative interaction (subadditivity) is defined
as ICD < 0 . The above contrast can equivalently be expressed as:
𝐼𝐶I = (𝑅44 − 𝑅4L ) − (𝑅L4 − 𝑅LL )
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2.2

𝐼𝐶I = 𝑅44 − 𝑅4L − 𝑅L4 + 𝑅LL

2.3

with 2.2 corresponding more directly with the intuition for “one exposure altering the
effect of another exposure”, as the contrast is of the risk difference for one exposure
across strata of the other exposure.129 On the ratio (i.e. multiplicative) scale, the
interaction contrast (ICR) is defined as:
𝐼𝐶P = 𝑅44 ∕ 𝑅LL ∕ (𝑅4L ∕ 𝑅LL ) × (𝑅L4 ∕ 𝑅LL )

2.4

so that interaction is said to be present when ICR ¹ 1, i.e. when the risk ratio for
combined exposure compared to absence of both exposures is larger or smaller than the
product of the risk ratios for either exposure alone.129 Positive interaction (e.g.
supermultiplicativity) is defined as ICR > 0 while negative interaction (submultiplicativity)
is defined as ICR < 0 . The above contrast can equivalently be expressed as a ratio of
relative risks (RR):
𝐼𝐶P = (𝑅44 ∕ 𝑅4L ) ∕ (𝑅L4 ∕ 𝑅LL )

2.5

with 2.5, like 2.2, being a contrast of the effect of one exposure across strata of the other
exposure.129 Examination of interaction in other measures (e.g. rates) can be made by
substituting risk estimates with the applicable occurrence measure.
To illustrate the scale dependence of interaction assessment, consider the data
in Table 2.1, which shows the rates of death in a cohort study that examined the effect of
asbestos exposure and smoking on the risk of death from lung cancer.55 The interaction
contrast for the difference scale is (601.6 – 11.3) – (122.6-11.3) – (58.4 – 11.3) = 431.9
deaths /100,000 person-years, which suggests considerable positive interaction. The
excess deaths under combined exposure (590.3) is larger than what would be expected
from the total of excess deaths from each exposure separately (47.1 + 111.3) = 158.4.
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On the ratio scale, the interaction contrast is (601.6 / 11.3) / [(122.6 / 11.3) x
(58.4 / 11.3)] = 0.95. The relative increase in death rate under combined exposure ( RR
= 53.2) is somewhat smaller than what would be expected from the product of relative
increases in death due to each exposure (10.85 x 5.17) = 56.1. The analysis of rate
differences shows positive interaction, while the analysis of the rate ratios shows
negative interaction. Given these contradictory results, how should the data be
interpreted? Is there interaction between the two exposures? This and other examples of
seemingly contradictory results from the analysis of interaction on the additive versus
multiplicative scale created substantial uncertainty regarding the nature of interaction,103
and controversy regarding the correct scale for analysis.129,102,50,128,103 Subsequent
contributions from Rothman, Greenland, Miettinen, and others provided eventual clarity
regarding the definition and analysis of interaction. Important conceptual advancements
included the distinction between statistical and biologic interaction,127 and the definition
of interaction using causal models.129,102,50,128,153,152
Refining the definition of interaction
Rothman127 proposed that the understanding of interaction could be facilitated by
distinguishing among the various contexts in which interaction is evaluated, highlighting
four broad contexts of interest: statistical interaction, biologic interaction, public health
interaction, and interaction in individual decision making.
Statistical interaction refers to the interdependence of associations between two
or more factors within a given model.127 Statistical interaction does not directly reflect
biology, but instead reflects properties of certain mathematical models. Whether
statistical interaction exists depends on the scale of assessment (additive or
15

multiplicative). Rothman has shown that when both exposures have effects,
homogeneity of the risk differences for one exposure across strata of the other exposure
implies, by definition, heterogeneity of the risk ratio for one exposure across strata of the
other exposure.129 We can show here that heterogeneity on at least one scale must exist
due to the resultant differences in base rate that exist when both factors have effects.
This can be seen by examining the relationship between risk differences and risk ratios.
For a given exposure X, write R1 for the risk when exposed to X (X=1), and R0 for
the risk when unexposed to X (X=0). Then the risk difference for X (RDx) is R1 – R0, and
the risk ratio (RRx) is R1 / R0. We can express the risk difference as a function of the risk
ratio and baseline risk in the unexposed as follows:
𝑅𝐷A = 𝑅4 − 𝑅L = (𝑅𝑅A × 𝑅L ) − 𝑅L

2.6

If the relative risk for X is held constant, then differences of baseline risk in the
unexposed will lead to differences in the magnitude of the risk difference. Similarly, if risk
difference is held constant, differences of baseline risk in the unexposed implies
differences in the relative risk. Now consider, as in 2.2 above, the evaluation of a
statistical interaction between two exposures X and Z, assuming each exposure has an
effect on the outcome of 𝑅𝑅A = 𝑅𝑅S > 1 and multiplicity holds for the relative risks. If we
compute the risk difference for exposure to Z separately for those exposed to X and
unexposed to X, and substituting in 2.6, we have
𝐼𝐶I = V(𝑅𝑅S × 𝑅4L ) − 𝑅4L W − V(𝑅𝑅S × 𝑅LL ) − 𝑅LL W

2.7

Because X has a positive effect on the outcome (𝑅𝑅A > 1), the base rate for those
unexposed to Z will differ across strata of X, i.e. 𝑅4L > 𝑅LL . This nonequivalence of the
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baseline risks forces the risk differences for Z to differ across strata of X, even though
the relative effect of Z is constant across strata of X.
The scale dependence of statistical interaction directly applies to the evaluation
of pharmacodynamic DDIs, as the mechanism of interaction involves the interdependent
actions between two drugs that have an effect on the outcome. However, the scale
dependence of interaction typically does not hold for DDIs that have a pharmacokinetic
mechanism. Consider the pharmacokinetic DDI between warfarin and amiodarone.
Amiodarone inhibits the metabolism of warfarin, which can lead to excessive warfarin
exposure, supratherapeutic anticoagulation intensity, and consequent increased risk of
bleeding.100,60,108 In the absence of amiodarone exposure, warfarin increases bleeding
risk, but the same is not true for amiodarone, which has no known effect on bleeding risk
in the absence of warfarin. Thus, only one exposure involved in the interaction has an
effect on the outcome. We can apply 2.7 to evaluate this interaction between warfarin
and amiodarone, with Rxz denoting the average risk of the four exposure combinations
for two binary indicators X and Z, representing amiodarone and warfarin respectively.
Because amiodarone has no effect on the bleeding risk (𝑅𝑅A = 1), the base rate for
those unexposed to warfarin will remain constant across strata of amiodarone exposure,
i.e. 𝑅4L = 𝑅LL . Under this equivalence of baseline risks, if there is multiplicativity of the
risk ratios for warfarin exposure, there must be additivity of the risk differences for
warfarin exposure. Similarly, if there is departure from multiplicativity, there must be
departure from additivity. These results indicate that in the applied setting, assessments
of the presence and direction of a pharmacokinetic DDI should be similar across the
ratio and difference scales. Any differences in conclusions based on one scale versus
the other would be expected to be due to differences in statistical power for tests of
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homogeneity of measures on the ratio versus difference scales that has been observed
in various contexts.115
Given the inherent scale dependence of interaction assessment, Rothman
recommends using the term “effect measure modification” to distinguish the
phenomenon of statistical interaction from other notions of interaction.127,129 In addition,
statements regarding interaction should clearly specify the scale of analysis. Thus, in the
analysis of death rates due to asbestos and smoking exposure presented in Table 2.1,
we would say that there is no statistical interaction on the risk ratio scale and positive
statistical interaction on the risk difference scale. Notably, such statements give no
preference to one scale or the other as being more representative of “true” interaction
between exposures.
When considering the public health significance of interaction, and the
importance of interaction for individual decision making, the additive scale is generally
agreed upon as being the most relevant for evaluation. The public health impact of an
interaction is a function of the number of additional cases of disease that derive from the
interaction. If the number of cases that would be observed in a population depends on
the frequency of two exposures occurring together in the same individuals, the two
exposures can be considered to interact from a public health perspective.127 Similar
intuition holds for the evaluation of interaction in individual decision making. Consider the
potential DDI between non-steroidal anti-inflammatory drugs (NSAIDs) and inhibitors of
the renin angiotensin system (RAS), which may cause acute kidney injury (AKI). Assume
a fixed AKI risk ratio for NSAID exposure of 1.5 in those exposed or unexposed to RAS.
Additionally, assume a baseline AKI risk of 5% in persons unexposed to RAS, versus
15% for persons exposed to RAS. In this scenario, although the relative effect of NSAID
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exposure is not altered by RAS exposure, the absolute increase in AKI risk due to
NSAID exposure is 2.5% in those unexposed to RAS, compared to 7.5% in those
exposed to RAS. Although the relative effect of NSAID exposure is unchanged by RAS
exposure, the probability of experiencing an adverse event is meaningfully increased by
RAS exposure, due to a higher baseline AKI risk.
Biologic interaction is defined as the “interdependent actions of two or more
causes to produce disease”.127 Consideration of interaction in the biologic context more
closely aligns with the intuitive notions of interactions discussed above, and the definition
of drug-drug interaction introduced in chapter one. Conceptions of biologic interaction
are based upon specific hypothesized mechanisms of disease. In theory, a given
biologic model for the physical interaction of exposures to cause a given disease
outcome may inform testable predictions regarding the expected patterns of disease
occurrence. For example, some authors have suggested that interaction mechanisms
that are characterized by two factors acting in the same step of a disease pathway will
correspond to an additive model, while interaction mechanisms that act at different steps
in a disease pathway will correspond to a multiplicative model.127 However, such
inferences are limited, primarily because any given data pattern can be predicted from
multiple different purported mechanisms of disease.147 Alternatively, consideration of
biologic interaction within the framework of a general causal model may allow for
insights to be gleaned about nature of the potential mechanisms underlying a given
interaction without the need for precise specification of physical interaction. The two
most important causal models relevant to interaction evaluation are the potential
outcomes model132 and the sufficient cause model.128
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The potential outcomes model of causation
The potential outcomes framework defines causal effects by contrasting the
outcomes that would occur when exposed to a given factor with the outcomes that would
occur in the absence of exposure to a given factor.129,132 Consider the exposure variable
X (1: treated, 0: untreated) and a binary outcome variable Y (1: death, 0: survival). Let
Yx=1 be the outcome variable that would have been observed under exposure (x = 1),
and Yx=0 be the outcome variable that would have been observed under no exposure (x
= 0). Yx=1 and Yx=0 are random variables. A causal effect for a given exposure in an
individual is then defined as Yx=1 ¹ Yx=0. The variables Yx=1 and Yx=0 are referred to as
potential outcomes, or equivalently as counterfactual outcomes.132 For each individual,
only one potential outcome can be observed, rendering individual causal effects
unidentifiable. However, under certain assumptions, the causal effect of exposures can
be inferred by contrasting the average outcomes in a population with that of a separate
population. The average causal effect of exposure X on outcome Y corresponds to a
difference in the expectation of the average potential outcomes under exposure
compared to the expectation of the average potential outcomes under no exposure, i.e. if
Pr[Yx=1 = 1] ¹ Pr[Yx=0 =1] in the population of interest.129,132 Causal effects can be
identified if we can assume exchangeability of populations being compared (i.e., no
unmeasured confounding), positivity (i.e., all persons in the populations have nonzero
probability of receiving treatment), independence (i.e., treatment received by one
individual does not affect the outcomes of other individuals), and consistency (i.e., that
the observed outcomes for individuals with X = x are equivalent to their potential
outcomes if they had been given X = x).129,132

20

Interaction in the potential outcomes model
Let X and Z denote binary indicators resulting in four possible exposure
combinations: X=1, Z=1; X=0, Z=1; X=1, Z=0; X=0, Z=0. Let Y = 1 if a person
experiences the outcome during follow-up and Y = 0 if they do not. Let Rxz denote the
potential outcomes for each exposure combination. With four exposure combinations,
and two potential outcomes for each exposure, there are 16 potential outcomes to
consider, which are shown in table 2.2. These 16 response types were first enumerated
by Miettinen,71 and later further classified by Poole and Greenland.72 If we substitute the
potential outcomes Rxz into equations 2.1 – 2.5, we can obtain interaction contrasts that
can be interpreted as measures of causal interaction effects between the two
treatments. Response types that show a non-zero interaction contrast are defined as
interaction response types, with 10 of the 16 response types indicating causal
interaction. Response type 8 is of note – denoting individuals who will experience the
outcome when both exposures are present, but not if either exposure is absent, thus
representing the classic conception of synergistic effects. The common characteristic of
the 10 interaction types is that the effect of X cannot be determined without knowing the
status of Z.
Poole and Greenland recognized that the reference condition for many
exposures may not be obvious based on subject matter knowledge. They use the
example of biologic sex as a variable participating in an interaction. One might arbitrarily
code the sex variable as male = 1 and female = 0 (i.e., male is the exposed condition);
but the reverse coding of female as being the exposed condition may be equally
plausible for a given hypothesized mechanism of interaction. If the risk of a given
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outcome is higher in males versus females, there may be no way to differentiate
causative effects of being male sex from preventative effects of being female sex.
Notably, they show that such recoding leads to changes in the classification of
certain interaction response types. For example, reverse coding of Z in Table 2.2 results
in type 8 individuals (causal synergism) being classified as type 14 (causal antagonism).
By enumerating the set of changes observed among the response types upon recoding,
they reclassify the 16 response types into seven “equivalence classes”, as shown in
Table 2.3. The ten interaction types are now classified into three classes: Class 4 (types
where the two exposures exhibit mutual antagonism); Class 5 (types where disease
occurs for only one exposure combination, with each type consistent with causal
synergism under at least one coding scheme); and Class 6 (types where disease occurs
for three exposure combinations, with each type consistent with preventive synergism
under at least one coding scheme). Note that, if there are clear reference conditions for
the exposures involved in a putative interaction (for example two drug exposures), then
the 16 response types can be plausibly be considered as invariant to recoding. However,
the dependence of interaction types on coding is of particular interest when interpreting
the results of DDI studies that employ the use of active comparators, where it may be
impossible to distinguish causal effects of an exposure of interest from preventative
effects of the chosen active comparator (or vice versa).
Relation between epidemiologic measures of interaction and response types
Following Rothman,129 if we specify pk as the proportion of individuals in a
population with response type k (k = 1, . . ., 16), we can determine the average risk for a
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given exposure combination by summing the pk for the response types where Y=1 for
the exposure combination.129 We thus have
𝑅44 = 𝑝4 + 𝑝Y + 𝑝Z + 𝑝[ + 𝑝\ + 𝑝] + 𝑝^ + 𝑝_

2.8

𝑅L4 = 𝑝4 + 𝑝Y + 𝑝Z + 𝑝[ + 𝑝` + 𝑝4L + 𝑝44 + 𝑝4Y

2.9

𝑅4L = 𝑝4 + 𝑝Y + 𝑝\ + 𝑝] + 𝑝` + 𝑝4L + 𝑝4Z + 𝑝4[

2.10

𝑅LL = 𝑝4 + 𝑝Z + 𝑝\ + 𝑝^ + 𝑝` + 𝑝44 + 𝑝4Z + 𝑝4\

2.11

If we use 2.8-2.10 to determine average risk under the four exposure combinations, and
then calculate the difference-in-differences with 2.2, we can determine conditions
sufficient for interaction types to be present in the population. If all 10 interaction types
are removed from a hypothetical cohort, the result is additivity among the risk
differences.50 Thus, departure from additivity on the risk difference scale implies that
there must be some interaction types present. This finding has notable implications for
the interpretation of epidemiologic measures of interaction. For example, consider the
common scenario where the results of an interaction evaluation show multiplicativity of
risk ratios with departure from additivity of risk differences. Within the potential outcomes
framework, we would conclude that there is causal interaction despite the presence of
multiplicativity.
As shown earlier in 2.6 and 2.7, in the setting of a pharmacokinetic DDI, where
only one drug has direct effects on the outcome, there will be a one to one
correspondence of departure from additivity and multiplicativity. Thus, for the special
case of pharmacokinetic DDIs where only one drug has effects on outcome, each model
would similarly indicate the presence or absence of interaction types. It is important to
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note that, although departure from additivity implies the presence of interaction types,
additivity does not imply the absence of interaction types. Under additivity, there may be
synergistic response types within the population that are canceled out by antagonistic
response types, highlighting again the limits of the inferences that can be made from
epidemiologic data about underlying mechanisms.
VanderWeele later showed that, if it can be assumed that neither factor is ever
preventive (i.e. positive monotonicity of effects), positive departure from additivity (ICD >
0) can occur only when synergistic response types (i.e. type 8) are present in the
population.153 Equivalently, this condition can be described as the presence of
individuals within the population who would experience the outcome if exposed to both
factors, but not if exposed to either factor in the absence of the other (i.e. R11 = 1, but R01
= R10 = 0).150 Under positive monotonicity, supermultiplicativity would also indicate the
presence of synergistic response types. However, it can be shown that, under positive
monotonicity, at least under certain circumstances, supermultiplicativity is a stronger
condition than superadditivity. Consider the common scenario where both exposures
have positive effects and the baseline risk is low (i.e. < 0.2). Under these conditions, the
expected risk under multiplicativity is larger than the expected risk under additivity
V(𝑅4L / 𝑅LL ) 𝑥 (𝑅L4 / 𝑅LL )W 𝑥 𝑅LL > V(𝑅4L − 𝑅LL ) + (𝑅L4 − 𝑅LL )W + 𝑅LL

2.12

Thus, under positive monotonicity, superadditivity is the minimally sufficient condition for
synergism between treatments. This finding has direct relevance for pharmacodynamic
DDI evaluations, as the positive monotonicity assumption will often be plausible.
If positive monotonicity cannot be assumed, VanderWeele153 showed that
presence of synergistic effects can be inferred under the following stronger condition:
24

𝑅44 − 𝑅4L − 𝑅L4 > 0

2.13

Thus, in the absence of positive monotonicity, positive departures from additivity, or the
presence of statistically significant interaction tests in regression models may not
necessarily reflect synergistic effects.
We end this section by briefly noting that it can be shown that definition of
synergistic effects in the potential outcomes framework corresponds directly to the
notion of interaction in the sufficient cause framework.128 Two exposures can be said to
participate in a sufficient cause interaction if they both act in the same sufficient cause to
produce a disease outcome.128 Equivalently, sufficient cause interaction indicates that
there are sufficient causes for the outcome which require both exposures to be
present.128 Thus, DDIs may generally be viewed as being examples of sufficient cause
interaction.
Choosing a scale for interaction evaluation in DDI studies
There are a number of reasons why the difference scale might be the preferred
scale for the evaluation of potential DDIs in the context of pharmacoepidemiologic
studies. As we have seen, the difference scale is the most relevant in the context of
judging the public health consequence of interaction, and in making treatment decisions
for individual patients. In addition, given that departure from additivity on the difference
scale is a fundamental indicator of the presence of interaction types generally,40 and
synergistic effects under positive monotonicity,153 the additive scale might be viewed as
the preferred measure for judgements regarding mechanisms underlying a given DDI,
particularly if the hypothesized mechanism is pharmacodynamic. As we have shown
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however, when the mechanism is pharmacokinetic, evaluation on the additive and
multiplicative scales will generally be in concordance.
Arguments can also be made in favor of the multiplicative scale. It is generally
easier to fit multiplicative models – additive models are known to commonly have
problems with convergence.150 This rationale has grown less compelling in recent years,
given advances in statistical software, and a variety of methods for obtaining measures
of additive interaction from multiplicative models.150 From a mechanistic perspective,
some data suggests that the multiplicative scale is inherently less heterogenous
compared to the additive scale.83,86-88 If multiplicative scales exhibit less heterogeneity,
and this indicates something about mechanisms underlying the “usual effects” of an
exposure, this could be viewed as a reason to prefer detecting interaction on the
multiplicative scale rather than the additive scale.150 However, at least in some settings,
the multiplicative scale has been shown to have lower power for detecting heterogeneity
compared to the additive scale. Careful consideration of the confidence intervals for
interaction contrasts may facilitate such judgements in a given study setting. Some
authors advocate for the routine reporting of interaction analysis on both the
multiplicative and additive scales,150 which may often be the preferred approach.
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Table 2.1. Age-standardized lung cancer death rates stratified by asbestos and cigarette
smoking exposure.
Exposure status
Death ratea
Rate difference
Neither smoking or asbestos
11.3
ref.
Smoking only
58.4
47.1
Asbestos only
122.6
111.3
Both smoking and asbestos
601.6
590.3
a- death rates are per 100,000 per year; Data from reference 73.
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Rate ratio
ref.
5.17
10.85
53.24

Table 2.2. Potential outcomes for two binary variables
Type

X=0,
Z=1
1

X=1,
Z=0
1

X=0,
Z=0
1

IC

Description

Classification

1

X=1,
Z=1
1

0

Doomed

2

1

1

1

0

-1

3

1

1

0

1

1

4

1

1

0

0

0

5

1

0

1

1

1

6

1

0

1

0

0

7

1

0

0

1

2

8

1

0

0

0

1

9

0

1

1

1

-1

10

0

1

1

0

-2

11

0

1

0

1

0

12

0

1

0

0

-1

13

0

0

1

1

0

14

0

0

1

0

-1

15

0

0

0

1

1

16

0

0

0

0

0

Absence of both prevents
outcome
X preventive, but this effect is
blocked by Z
Z causative independent of X,
which has no effect
Z preventive, but this effect is
blocked by X
X causative independent of Z
which has no effect
Either exposure is preventive
alone, but each blocks the
other with joint exposure
Outcome occurs only occurs
when both exposures are
present
Outcome is prevented only
when both exposures present
Each causative when alone,
but not when together
X preventive independent of
Z which has no effect
Z causative, but this effect is
blocked by X, which has no
effect
Z preventive independent of
X which has no effect
X causative, but this effect is
blocked by Z, which has no
effect
Absence of both causes
outcome
Immune

No effect of
either exposure
Preventive
synergism
Preventive
antagonism
Independent
effects
Preventive
antagonism
Independent
effects
Preventive
antagonism
Causal
synergism
Preventive
synergism
Causal
antagonism
Independent
effects
Causal
antagonism
Independent
effects
Causal
antagonism
Casual
synergism
No effect of
either exposure

Each row of the table indicates the value of Y (Y=1 if the outcome occurs, Y=0 if not) for
the type of person under each of the exposure combinations. The interaction contrast
(IC) is computed as 𝐼𝐶 = 𝑅44 − 𝑅4L − 𝑅L4 + 𝑅LL . Non-zero values indicate interaction
response types.
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Table 2.3. Equivalence classifications for the interaction potential outcome types
Equivalence description

Response Type

Class 1: Disease always occurs

1

Class 2: X is effective, but Z is not

6, 11

Class 3: Z is effective, but X is not

4, 13

Class 4: Both X & Z exhibit mutual antagonism

7, 10

Class 5: Disease occurs for only one exposure combination; All
can be viewed as synergistic causation under recoding

8, 12, 14, 15

Class 6: Disease occurs for three exposure combinations; All
can be viewed as synergistic prevention under recoding

2, 3, 5, 9

Class 7: Disease never occurs

16
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CHAPTER 3: THE ROLE OF ACTIVE COMPARATOR DESIGNS FOR ESTIMATING
THE CAUSAL EFFECTS OF DRUG EXPOSURES ON SAFETY OUTCOMES

In the previous chapter we reviewed the epidemiologic notions of interaction
relevant to DDI pharmacoepidemiology, including the key measures of interaction, the
scale dependence of statistical interaction, and the theoretical grounding of interaction
within the potential outcomes framework, which provides a basis for linking interaction
measures with mechanistic interpretations under certain conditions. In doing so, we
highlighted a number of important implications for the study of DDIs. First, we showed
that the scale dependence of statistical interaction applies to pharmacodynamic (both
drugs have direct effects on outcome), but not pharmacokinetic DDIs (only one drug has
an effect on outcome). Second, we discussed prior work that identified departure from
additivity on the difference scale as the fundamental indicator of synergism between two
exposures. Third, we noted that the definition of interaction types in the potential
outcomes framework depends on whether the exposed versus unexposed condition is
considered the reference condition, which may render ambiguous any mechanistic
interpretation of findings from DDI studies that employ active comparators.
Building on these insights, we move the focus towards the estimation of
epidemiologic measures of interaction. In this chapter we will consider the role of the
active comparator design for the control of confounding in the general case. We
characterize the causal effects that are targeted with this design and the assumptions
required for identification in the general setting. In chapter four we will examine the
existing implementations of this design for studies of pharmacokinetic and
pharmacodynamic DDIs.
30

Confounding in the study of DDI health effects
Most studies that aim to quantify the health effects of DDIs are observational,
due frequent lack of equipoise to randomize patients to potentially harmful drug
combinations, and the need very large study populations to quantify interaction effects.62
Given their observational nature, the most important source of bias in DDI outcome
studies is confounding.62 Confounding arises when the treatment groups being
compared have different baseline risks for the study outcome, resulting from an
imbalance of risk factors between groups.126,51 Imbalance is generated when factors
associated with disease risk are also associated with treatment status.126 When this
occurs, the effect of treatment is “mixed” with the effect of the imbalanced risk factors.126
The presence of confounding makes it difficult to determine whether observed
differences in outcome are due to the treatment, to the effect of the confounding factors,
or a mixture of both. Confounding is especially important in studies of drug effects,
because the reasons for needing treatment are often related to patient
prognosis.62,13,156,12 This so-called “confounding-by-indication” is the result of good
prescribing practice: treatments are not given at random, but instead are given to those
patients judged to be at an acceptable risk of adverse effects and likely to benefit from
treatment.12 The selective nature of drug prescribing generally results in treated patients
being quite different from untreated patients in terms of baseline prognosis.
Active comparator designs in pharmacoepidemiology
One approach to estimating treatment effects from observational data is through
covariate adjustment.13 This approach can be used to identify causal effects of drug
exposures if the indication for treatment can be adequately measured. Unfortunately,
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this is rarely, if ever feasible: it is generally the case that many factors related to
treatment decisions for a given drug are either unmeasured or measured only
poorly.12,13,156 Thus, studies that compare treated patients to untreated patients have a
high risk of bias from unmeasured confounding, even in the setting of covariate
adjustment.12,13,156,97 An important methodological innovation to deal with this
unmeasured confounding is the use of an “active comparator design”,97,85,47,136,72 where
users of the treatment of interest are compared to users of an alternative treatment that
is used for the same (or a similar) indication.97 The goal of the active comparator design
is to condition the causal contrast on treatment indication,85,97 thereby controlling
confounding that exists between indication and outcome. Previous research has shown
that observational studies that use active comparator designs produce improved
covariate balance compared to studies that employ untreated controls, and treatment
effect estimates that are more consistent with those from randomized trials of the same
treatments.136 However, few prior studies have characterized the causal effects that can
be identified with the active comparator design. Huitfeld72 studied one version of a
comparator design, the “inactive comparator design”, which involves comparing patients
who initiate the treatment of interest to patients who initiate a treatment that does not
share the same indication and is not used in the same way as the treatment of
interest.72,49 In the next section, we focus on the true active comparator design, where
the treatment of interest is compared to an alternative treatment that is used for the
same indication, as this version of the design is most applicable to the study of DDIs,
where the key scientific interest is in adverse effects of treatment, rather than the a
comparison of putative beneficial effects (i.e. comparative effectiveness). We use causal
graphs49,143 and the potential outcomes framework to formally identify the causal effects
that can be derived when this design is used.
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Causal structure of active comparator designs
The directed acyclic graph (DAG) in figure 3.1 encodes the structural
assumptions of a typical active comparator design. The structure is characterized by a
patient who develops some type of treatable disease, which progresses in severity over
time, eventually leading the patient to seek healthcare, where a decision is made to
either initiate or withhold treatment. If the clinician and patient opt for treatment initiation,
there may be multiple treatments available. This decision to initiate treatment may be
affected by the type and severity of disease, other observed covariates (demographics,
documented comorbid illness, documented concomitant treatments), and potentially
other unmeasured variables. Further, once the decision to initiate treatment has been
made, the choice of treatment from a pool of one or more alternative treatments may be
similarly conditioned. As shown in the DAG, a variable in any one of the domains that
condition treatment probability will confound the association between the treatment and
an exposure of interest if the variable has causal effects on the outcome, or if it is
associated with other causal factors for the outcome. As noted previously, it is generally
the case that many factors related to treatment decisions for a given drug are either
unmeasured or measured only poorly (indicated in the DAG as grey nodes). In
particular, it is often difficult to fully capture disease severity, which is often associated
with the outcome of interest and is a key factor that determines whether treatment is
initiated.
The key structural assumption of the DAG is that, conditional on observed
covariates, the treatment decision represents the singular event through which factors
associated with treatment indication (i.e., disease type and severity, and other
unmeasured factors) condition treatment probability.125 If this assumption holds,
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conditioning on the decision to initiate treatment serves to control confounding that exists
between indication and outcome. The active comparator design achieves this by
restricting the population to individuals for whom the decision was to initiate treatment. In
causal graph terminology, we would say that the DAG results in a minimally sufficient
adjustment set that contains the treatment decision and observed covariates. Note that
the absence of any paths from disease severity (or other unmeasured covariates) to
exposure indicates that, conditional on observed covariates, the choice between the
treatment of interest versus a pool of one or more potential alternatives treatments is
independent of baseline risk for the outcome of interest. If this assumption does not hold,
then causal effects are not identifiable. In practice, when multiple treatment options exist,
this assumption may only be plausible for a limited subset of the available alternatives.
Conditions for identification of causal effects with and without active comparators
When the assumptions of the active comparator design are encoded with a
causal graph, the “treatment decision event “ emerges as the fundamental structural
element that defines the conditions under which an active comparator design renders
unconfounded treatment estimates. This intuition mirrors the “preference tree model”,
discussed by Rosenbaum,125 (who drew on ideas from Tversky),148 where “generic
biases” are controlled if they are associated with the decision to initiate treatment, but
not with the choice among alternative treatments.125 Treatment decisions were similarly
identified by Brookhart as key events that can be used to anchor cohorts for the study of
questions related to treatment augmentation, switching, or restarting.14 In the following
section, we argue that the “treatment decision event” also serves as a key idea that
justifies the active comparator design in the potential outcomes framework. We begin
with an examination of the problems with identifying causal effects when comparing
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treated and untreated populations, followed by an introduction and comparison with the
active comparator design.
Identification without active comparators
The treatment decision event identifies the population of individuals who have a
treatable disease and who were evaluated for treatment. This population will often be the
target population for causal inference.14,22 Thus, again we see that the treatment
decision can be viewed as an anchoring event that defines the target causal effects.14 As
we will show, the causal effects that are identified depend on whether the decision is
cast as “initiate versus withhold treatment” or “treat with one drug versus another drug”.
The decision to “initiate versus withhold treatment” coincides with the
randomization event in an experimental design, where patients who have an indication
for treatment and are otherwise judged to be eligible for treatment are randomized to
treatment or no treatment. Randomization is justified by the key assumption that there
exists equipoise between initiating versus withholding treatment within the target
population. Such equipoise often does not exist for studies that aim to examine adverse
effects, but an observational study could be designed to quantify the causal effect of
initiating versus withholding treatment on some safety outcome. Consider as an example
a hypothetical study of patients presenting to an outpatient clinic with asymptomatic,
incident atrial fibrillation. The study aims to determine the risk of acute liver injury (ALI) in
patients who were evaluated for treatment with amiodarone, where treatment was either
initiated or withheld. Let Y (1=yes, 0=no) denote the occurrence of ALI during the year
following the index date, (A=1) denote usual care plus treatment with amiodarone and
(A=0) denote usual care without treatment with amiodarone. Let Ya define the vector of
counterfactuals Ya=1 and Ya=0 denoting the occurrence of ALI when treated and not
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treated with amiodarone, respectively. A subject’s observed outcome Y is equal to Ya=1 if
the subject initiated amiodarone treatment; otherwise Y is equal to Ya=0. Lastly, let X
denote a vector of observed covariates.
One causal effect that is commonly of interest is the average treatment effect
(ATE), which for our hypothetical population is
𝐴𝑇𝐸 = 𝐸[𝑌 hi4 ] − 𝐸[𝑌 hiL ]

3.1

which contrasts the one-year risk of ALI in the entire population of patients evaluated for
treatment had those patients received treatment with amiodarone vs. the one-year risk of
ALI in the entire population of patients evaluated for treatment had they not received
treatment with amiodarone. We focus here on the difference in average risk, but the
logic generalizes to other measures of effect (e.g. risk ratios) and occurrence (e.g. rates,
time-to-event). The specified ATE is a contrast of potential outcomes. The key challenge
of causal inference is that, for each individual, only one potential outcome can be
observed. However, the specified ATE can be identified from an observational contrast
of different populations under the following conditions: exchangeability of populations
being compared (i.e., no unmeasured confounding) conditional on observed covariates;
positivity (i.e., all persons in the populations have nonzero probability of receiving
treatment); independence (i.e., treatment received by one individual does not affect the
outcomes of other individuals); and consistency (i.e., that the observed outcomes for
individuals with A = a are equivalent to their potential outcomes if they had been given A
= a). 132,63,131 When these conditions hold, then the observational contrast
𝐸[𝑌 | 𝑋, 𝐴 = 1] − 𝐸[𝑌 | 𝑋, 𝐴 = 0]

3.2

identifies the ATE of initiating versus withholding amiodarone treatment on the risk of ALI
in the population of patients defined by the treatment decision event. Unfortunately, for
the studies of the type specified in our example, one or more of these conditions often
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does not hold. Below we define the conditions formally and consider their plausibility in
the context of our representative example:

1) Exchangeability: can be equivalently defined as 𝐴 ∐ 𝑌 h , i.e. that treatment is
independent of potential outcomes; or 𝐸[𝑌 h | 𝐴 = 𝑎] = 𝐸[𝑌 h ], i.e. that the
treatment groups being compared have similar distributions of potential
outcomes. In the observational setting, this assumption is reformulated as
conditional exchangeability: 𝐴 ∐ 𝑌 h |𝑋, where X represents a vector of observed
covariates. As noted above, even conditional exchangeability is often implausible
for comparisons of treated versus untreated populations in the observational
setting, which is the key motivation for the active comparator design.

h7 ho

2) Independence: 𝑌1

h7hop

= 𝑌1

i.e., that the potential outcome for subject i is the

same regardless of the treatment receive by subject j. Equivalently, treatment
received by one individual does not affect the outcomes of other individuals. This
assumption is also referred to as the lack of treatment “interference”. This
assumption can usually be assumed to hold in studies of drug effects.

3) Consistency: 𝑌 "qr = 𝑌(𝑎, 𝑘) 𝑖𝑓 𝑎 = 𝐴 , no matter the value of k, i.e. the observed
outcomes for individuals with A=a are equivalent to their potential outcomes if
they had been given treatment level A=a.31 Here k denotes the set of possible
means of exposure assignment or delivery. The set of k for a drug treatment
might include factors such as dose, frequency, and route of administration. This
statement encapsulates the idea of a “well defined intervention”.63 The
assumption is that exposure has been defined in a manner that captures all of
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the “causally relevant features”.31 In the absence of a well-defined intervention,
the causal effects derived from a contrast across levels of treatment A are
rendered ambiguous. One perhaps less appreciated implication of this definition
is that the assumption applies to all levels of treatment (e.g. A=1 and A = 0),
meaning in this case that both treatment and the “withholding of treatment” are
well defined. This latter aspect of the assumption has direct implications for the
interpretation of studies that compare treated and untreated individuals.
Specifically, what does it mean to be untreated – withholding the treatment of
interest (amiodarone)? Or, withholding all available treatments? Within a
population of patients with treatable disease who are evaluated for treatment, it is
likely that the population of those “untreated with the exposure of interest”
includes patients who are treated with alternative agents, unless the study design
clearly specifies otherwise.

4) Positivity: 𝑃𝑟(𝐴 = 𝑎) > 0, for all individuals in the study population.131,158 This is
equivalently stated as all subjects in the population having a nonzero probability
of receiving all levels of treatment under consideration. Intuitively, this means
there are no individuals within the population for which the treatment would be
contraindicated (i.e. Pr(A=1) = 0; similarly, there are no individuals within the
population for which withholding treatment would be contraindicated (i.e., Pr(A=0)
= 0. This requirement parallels the conditions of a randomized clinical trial, where
the study population is comprised of patients who are eligible for treatment and
for whom equipoise exists between initiating versus withholding treatment. This
assumption is likely untenable in our example. In a population defined by the
decision to initiate or withhold treatment, the subgroup of patients who were
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untreated may include individuals who have zero indication for treatment – those
with only very mild disease, or those who had suspected disease, with the
diagnosis subsequently being ruled out (such a scenario is not uncommon in
studies that use diagnosis codes to define the presence of disease).135 Similarly,
the treated subgroup likely contains individuals for whom it would be unsafe to
withhold treatment, due to a high disease severity.

For the same treatment A, the average treatment effect in the treated (ATT) is
defined as
𝐴𝑇𝑇 = 𝐸[𝑌 hi4 | 𝐴 = 1] − 𝐸[𝑌 hiL | 𝐴 = 1]

3.3

which contrasts the outcome rate in the treated population had those patients received
treatment vs. the outcome rate in the treated population had they not received treatment.
The ATE and ATT effects may differ if the characteristics of the target populations that
correspond to each estimate differ in ways that are related to the study outcome. The
conditions for identifying ATT are much the same as for ATE, with the key exception that
the exchangeability assumption can be relaxed to the weaker assumption of partial
exchangeability, defined as 𝐸[𝑌 hiL | 𝑋, 𝐴 = 1] = 𝐸[𝑌 hiL | 𝑋, 𝐴 = 0] = 𝐸[𝑌| 𝑋, 𝐴 = 0], i.e.
that the observed outcomes in the untreated are representative of the potential
outcomes if untreated for the treated subjects.52 Notably, partial exchangeability does
not assume that the observed outcomes in the treated are representative of the potential
outcomes if treated for the untreated subjects.52 However, this is warranted because the
ATT estimate only applies to the treated population, where the potential outcomes under
treatment are assumed (by consistency) to be observed, i.e. as 𝐸[𝑌 hi4 | 𝑋, 𝐴 = 1] =
𝐸[𝑌| 𝑋, 𝐴 = 1]. If partial exchangeability holds (in addition to independence, consistency,
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and positivity), then the ATT can be identified by the observational contrast specified in
3.2. Although conditional partial exchangeability is a weaker assumption, it too will often
be implausible in study designs that compare treated with untreated patients.
In sum, in the preceding section, we have specified the conditions required to
identify causal effects with a nonuser comparator design. After close inspection of each
of the key assumption, we see that for perhaps most scenarios where drugs are
prescribed in a nonrandom fashion, in response to an indication for treatment, it is
implausible that the assumptions required to identify causal effects would hold. Key
issues include the high risk for unmeasured confounding, potential violations of the
consistency assumption if the definition of being “untreated” is not carefully considered,
and likely violations of the positivity assumption.
Identification with active comparators
Let us now modify our hypothetical study design to include an active comparator.
In lieu of comparing patients who initiate amiodarone to patients who do not, we will
compare amiodarone initiators to a group of patients who initiate treatment with an
alternative drug that is used to treat atrial fibrillation. As we will show, this change
modifies the question being asked from one of “initiate versus withhold treatment” to
“treat with one drug versus another drug”. The latter decision coincides with the
randomization event in an experimental design, where patients who have an indication
for treatment and are otherwise judged to be eligible for treatment are randomized to
treatment with one drug versus another drug.
To proceed with our active comparator example, we will designate our active
comparator to be metoprolol, a selective beta-blocker that is one of the most commonly
used treatments for patients with atrial fibrillation. Write B=1 for subjects who initiate
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treatment with metoprolol, and B=0 for subject who do not. With two treatments to
consider, there are four possible exposure combinations: A=1, B=1; A=0, B=1; A=1,
B=0; A=0, B=0. Write Ya,b for the potential outcomes under treatment values A=a and
B=b, although, with implementation of the active comparator design, we place
restrictions on the exposure combinations that are included. In the previous section, we
described a treatment decision event that defined a population of patients who
presented with atrial fibrillation and were evaluated for treatment. The defining clinical
question was “should treatment be initiated or not”. The active comparator design
restricts the study population to the subset of patients for whom the answer to this
question was yes. As we will see, this restriction controls confounding by indication if,
within the treated population, the choice of treatment is independent of all aspects of
indication, conditional on observed covariates.
There are different versions of the active comparator that can be implemented.
Huitfeldt72 specified three contrasts for the inactive comparator design, which also apply
here:
𝐸[𝑌|𝑋, 𝐴 = 1, 𝐵 = 𝑏] − 𝐸[𝑌|𝑋, 𝐴 = 0, 𝐵 = 1], which is equivalent to
𝐸[𝑌|𝑋, 𝐴 = 1] − 𝐸[𝑌|𝑋, 𝐴 = 0, 𝐵 = 1]

3.4

𝐸[𝑌|𝑋, 𝐴 = 1, 𝐵 = 0] − 𝐸[𝑌|𝑋, 𝐴 = 0, 𝐵 = 1]

3.5

𝐸[𝑌|𝑋, 𝐴 = 1, 𝐵 = 1] − 𝐸[𝑌|𝑋, 𝐴 = 0, 𝐵 = 1]

3.6

with 3.4 being the contrast of all initiators of A (with or without B) versus initiators of B
without A; 3.5 being the contrast of all initiators of A without B versus initiators of B
without A; and 3.6 being the contrast of all initiators of A of both A and B versus initiators
of B without A. Huitfeldt compares the conditions for identification of causal effects with
the three designs, noting that the most valid option will likely vary depending on the
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specific context and study question.72 For our purposes, we will focus on 3.4, the
comparison of all initiations of A versus initiators of B without A.
Let us first consider the implications of restricting the population to the treated
subgroup on the causal effects that may be identified. In the previous section we
described both the ATE and ATT as potential causal effects of interest. Given this
restriction, is it possible to identify these causal parameters for the population identified
by the originally specified treatment decision (initiate versus withhold treatment?
Consider first the ATE. The first problem is that the realizations of the potential outcomes
under no treatment are not observed, since untreated patients are excluded. Thus, for
the ATE to be identified, a treated group (amiodarone or the active comparator) must
have potential outcomes that are representative of the potential outcomes under
treatment for those patients for whom amiodarone treatment was withheld, i.e. one of the
following must hold: 𝐸[𝑌 hi4 | 𝑋, 𝐴 = 0, 𝐵 = 0] = 𝐸[𝑌 hi4 | 𝑋, 𝐴 = 1 ];
or 𝐸[𝑌 hi4 | 𝑋, 𝐴 = 0, 𝐵 = 0] = 𝐸[𝑌 hi4 | 𝑋, 𝐴 = 0, 𝐵 = 1 ]. As we’ve noted previously, these
are very likely untenable assumptions; if either were plausible, the active comparator
approach likely wouldn’t be needed in the first place. It is clear then that the originally
specified ATE for a comparison of initiating versus withholding treatment is not identified
by a study that employs an active comparator design, even if the active comparator is
chosen such that it has no direct effect on the outcome of interest – a common scenario
for safety studies with active comparators. However, this may not be a limitation, and in
fact may be an advantage. It has been pointed out that comparisons of safety outcomes
among available active treatments is likely a more clinically relevant question. In a
population of patients that need treatment, the choice is often not one of initiation versus
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withholding all treatments due to a safety concern, but rather, withholding one treatment
in lieu of another treatment.22
Although the originally specified ATE is unidentifiable, there are conditions under
which we may identify the ATT that may be plausible. If our interest is in determining
whether amiodarone exposure increases the risk of ALI, our first assumption must be
that the active comparator does not have a direct effect on the outcome, i.e.
𝑌 h,qi4 = 𝑌 h,qiL = 𝑌 h , for all patients in the population. Without this assumption, our
research question must necessarily change to one of comparative safety of the two
drugs, where the active comparator is viewed as more than just a stand-in for indication.
The next key assumptions are related to exchangeability. We noted previously in the
discussion of the DAG in figure 3.1 that the key assumption was that conditional on
observed covariates, the treatment decision represents the singular event through which
indication conditions treatment probability. Further, if this assumption holds, restricting to
the treated population serves to control confounding that exists between indication and
outcome. We arrive at essentially the same assumptions here – if we can assume
consistency, positivity, and independence, then we may identify the ATT under the
following exchangeability assumptions: 𝐸[𝑌 hiL | 𝐴 = 1, 𝐵 = 1] = 𝐸[𝑌 hiL |𝐴 = 1, 𝐵 = 0] =
𝐸[𝑌 hiL |𝐴 = 0, 𝐵 = 1], i.e., the potential outcomes under no treatment with amiodarone
are equivalent in those exposed to both amiodarone and metoprolol, only amiodarone,
and only metoprolol.72 This assumption would allow us to identify the effect of
amiodarone exposure versus no exposure in patients exposed to amiodarone. If we
further assume that the potential outcomes under treatment with amiodarone are
equivalent across groups, i.e. [𝑌 hi4 | 𝐴 = 1, 𝐵 = 1] = 𝐸[𝑌 hi4 |𝐴 = 1, 𝐵 = 0] =
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𝐸[𝑌 hi4 |𝐴 = 0, 𝐵 = 1], then we identify a different ATT – the effect of amiodarone in
initiators of metoprolol.72
If both sets of assumptions hold, we identify the effect of amiodarone in all
subjects who initiate either amiodarone, metoprolol, or both.72 Alternatively, these
separate ATT estimates might be viewed as an ATE for amiodarone versus control
within the population defined by the study criteria, in this case, it would be a contrast of
the one-year risk of ALI in the entire population of patients treated with either
amiodarone or metoprolol, or both had those patients received treatment with
amiodarone vs. the one-year risk of ALI in the entire population of patients treated with
either amiodarone or metoprolol, or both had they not received treatment with
amiodarone. As noted previously, if amiodarone and metoprolol are two alternative
treatments for the same indication, this treatment effect would provide valuable
information to clinicians who are weighing the risk versus benefit of the two treatments.
Summary
We have clearly enumerated the exchangeability assumptions and the resulting
causal effects that may be identified. Whether the assumptions are plausible will depend
on the specific study question and the drugs involved. However, it will often be the case
that these assumptions have stronger plausibility compared to a design that employs
unexposed comparators.97,85,47,136,72
Beyond exchangeability, it is important to also consider the implications of an
active comparator design on other key assumptions, namely consistency and positivity.
It can be argued that restricting to a treated population increases the plausibility of both
assumptions. The exclusion of patients who received neither treatment would be
expected to increase the plausibility of positivity, as it would remove from the population
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those patients with misdiagnosed disease, or only very mild disease that does not
require treatment. It could also increase the plausibility of consistency, as the
comparator group is now composed of a population that is also consistently receiving a
treatment for the underlying indication. Nevertheless, adequate specification of the other
“causally relevant aspects of exposure” would be required for both the amiodarone and
metoprolol groups.
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Figure 3.1. Directed acyclic graph (DAG) of the assumed causal structure that underlies
a representative active comparator study design.

Each line depicts a causal pathway between nodes (specified causal factors) of the
graph. Nodes that are shaded grey represent unmeasured factors. The node designated
“Treatment” represents a vector containing a set of alternative treatments T, (T = 1,…,t).
The node designated “Observed covariates” represents a vector of observed covariates
X. Similarly, the node designated “Unobserved covariates” represents a vector of
unobserved covariates U. The “Decision to treat” node represents the documentation of
a treatment decision by a clinician within the medical record. The DAG results in a
minimally sufficient adjustment set that contains the nodes “Decision to treat” and
“Observed covariates”.
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CHAPTER 4: ACTIVE COMPARATOR DESIGNS FOR QUANTIFYING THE HEALTH
EFFECTS OF DRUG-DRUG INTERACTIONS

In the previous chapter we used causal graphs and the potential outcomes
framework to clarify the assumptions required for identifying causal effects of a drug
exposure on a safety outcome of interest. We highlighted the challenges of making such
causal inferences when comparing exposed patients to unexposed patients, and
introduced the active comparator design as an alternative approach that is likely to
provide more valid estimates. In this chapter we will examine the key implementation of
this design for studies of pharmacokinetic DDIs, and show that the standard design does
not provide for the identification of causal interaction effects when the mechanism of
interaction is pharmacodynamic. Finally, we propose and justify a novel “dual control”
design, which addresses the methodological challenges entailed in the study of
pharmacodynamic DDIs.
Unique characteristics of pharmacokinetic DDIs.
The active comparator design has emerged as a key design option for studies
that examine the health effects of pharmacokinetic DDIs.62 The key features of
pharmacokinetic interactions include 1) they result from one drug (the precipitant)
altering the extent of exposure to another drug (the object), via effects on one or more
mechanisms of absorption, distribution, or clearance.62,67 And 2) the precipitant drug
often does not have a direct effect on the outcome of interest. Thus, any adverse health
effects that result are likely to be due to changes in exposure to the object drug. A
common scenario leading to a pharmacokinetic DDI is the inhibition of hepatic
cytochrome P450 (CYP) metabolism of an object by a precipitant drug, leading to excess
47

exposure to the object drug and potential adverse effects. These characteristics have
direct implications for the implementation of active comparator designs.
Implications of restricting analysis to individuals exposed to the object drug
Consider our prior hypothetical study of patients presenting to an outpatient clinic
with asymptomatic, incident atrial fibrillation for potential treatment with amiodarone. Let
us now imagine that these patients are treated with the oral anticoagulant warfarin,
which exhibits a pharmacokinetic DDI with amiodarone. This DDI is mediated by an
inhibitory effect of amiodarone on warfarin metabolism by the CYP2C9 enzyme, leading
to exaggerated warfarin exposure. A key question is whether this DDI leads to clinically
meaningful increases in the risk of bleeding during warfarin therapy.100,60,108 Following
the notation specified in chapter 2, we can define a contrast of potential outcomes for
this interaction by writing Y (1=yes, 0=no) for the occurrence of bleeding in a population
of patients with atrial fibrillation, W=1 and W=0 for initiation versus withholding of
warfarin anticoagulation, and A=1 for initiation of amiodarone, A=0 for non-treatment
with amiodarone. Let the counterfactuals Yw,a denote the outcome of interest Y when
treated with one of the four treatment combinations for the two treatment indicators W=1,
A=1; W=1,A=0; W=0, A=1, and W=0,A=0. Lastly, let X denote a vector of observed
covariates. We can now specify the following contrast for the causal interaction between
warfarin and amiodarone
𝐼𝐶 z,h = 𝐸[𝑌𝑤=1,𝑎=1 − 𝑌𝑤=1,𝑎=0 ] − 𝐸[𝑌𝑤=0,𝑎=1 − 𝑌𝑤=0,𝑎=0 ]

4.1

if we can assume conditional exchangeability across these exposure categories, i.e.,
𝐸[𝑌 z,h | 𝑋, 𝑊 = 𝑤, 𝐴 = 𝑎] = 𝐸[𝑌 z,h | 𝑋], then this causal interaction contrast would
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represent a contrast of average treatment effects, which can be identified with the
following observational contrast
𝐼𝐶 = {𝐸[𝑌|𝑋, 𝑊 = 1, 𝐴 = 1] − 𝐸[𝑌|𝑋, 𝑊 = 1, 𝐴 = 0]}
−{𝐸[𝑌|𝑋, 𝑊 = 0, 𝐴 = 1] − 𝐸[𝑌|𝑋, 𝑊 = 0, 𝐴 = 0]}

4.2

As noted in the previous chapter, this type of contrast (exposed versus unexposed) is
unlikely to provide unconfounded effect estimates. Recognizing this, DDI researchers
have employed two key design features: first, restriction of the population to those
treated with the object drug (warfarin); and second, compare the effect of the precipitant
drug (amiodarone) with that of an active comparator, rather than an unexposed group.62
Note that, these design features can be inverted with no meaningful impact from a
causal inference perspective (i.e., restrict to the precipitant drug exposure and compare
the effect of object drug exposure with an active comparator). What impact do these
design features have on the causal contrasts that can be identified?
In the previous chapter, we noted that the “treatment decision” represents a key
event for the design of active comparator studies – the treatment decision defines the
population that is identified by any resulting causal effect parameters; and, it serves as
the key structural feature that links observational contrasts to the target causal
parameters. In the case of DDI studies, there are two treatment decisions to consider,
one for each drug involved in the interaction, each potentially having a unique set of
confounding variables. In our example, patients and clinicians must decide whether to
initiate warfarin, and separately, whether to initiate amiodarone. Following the causal
logic in the preceding chapter, conditioning on these treatment decisions can, under
certain assumptions, identify causal interaction effects.
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Restricting the base study population to individuals who initiated treatment with
the object drug can be viewed as a matching procedure, where all patients have the
treatment decision for the object drug set to “yes”. A consequence of this restriction is
that the interaction contrast specified in 4.2, a differences-in-differences, is now
undefined. In our example, this is a contrast of the effect of amiodarone in warfarin
exposed patients with the effect of amiodarone in warfarin unexposed patients. Since all
individuals in the study are exposed to the warfarin (the object drug), the only observed
component of the differences-in-differences is
𝐸[𝑌|𝑋, 𝑊 = 1, 𝐴 = 1] − 𝐸[𝑌|𝑋, 𝑊 = 1, 𝐴 = 0]

4.3

i.e., the risk of bleeding in warfarin patients exposed to amiodarone versus the risk of
bleeding in warfarin patients unexposed to amiodarone. With the following two
assumptions, we will show that 4.3 can be used to estimate the causal interaction
contrast specified in 4.1:
1) The precipitant drug has no direct effect on the outcome of interest in the
absence of object drug, i.e., 𝑌 ziL,hi4 = 𝑌 ziL,qiL = 𝑌 ziL
2) Within the cohort of patients exposed to the object drug, and conditional on
observed covariates, patients who initiate the precipitant drug are exchangeable
with those who do not initiate the precipitant drug, i.e., 𝐸[𝑌 zi4,h | 𝑋, 𝑊 = 1, 𝐴 =
𝑎] = 𝐸[𝑌 zi4,h |𝑋, 𝑊 = 1]
Proof:
𝐸[𝑌|𝑋, 𝑊 = 1, 𝐴 = 1] = 𝐸[𝑌 zi4,hi4 |𝑋, 𝑊 = 1, 𝐴 = 1]

by consistency

𝐸[𝑌|𝑋, 𝑊 = 1, 𝐴 = 0] = 𝐸[𝑌 zi4,hiL |𝑋, 𝑊 = 1, 𝐴 = 0]

by consistency
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𝐸[𝑌 zi4,hi4 |𝑋, 𝑊 = 1, 𝐴 = 1] = 𝐸[𝑌 zi4,hi4 |𝑋, 𝑊 = 1, 𝐴 = 0]

by (2)

𝐸[𝑌 zi4,hiL |𝑋, 𝑊 = 1, 𝐴 = 0} = 𝐸[𝑌 zi4,hiL |𝑋, 𝑊 = 1, 𝐴 = 1]

by (2)

Thus, we have
𝐸[𝑌|𝑋, 𝑊 = 1, 𝐴 = 1] − 𝐸[𝑌|𝑋, 𝑊 = 1, 𝐴 = 0] = 𝐸[𝑌 zi4,hi4 − 𝑌 zi4,hiL |𝑊 = 1]

and
𝐸[𝑌 zi4,hi4 − 𝑌 zi4,hiL |𝑊 = 1] = {𝐸[𝑌 zi4,hi4 − 𝑌 zi4,hiL ] − 𝐸[𝑌 ziL,hi4 − 𝑌 ziL,hiL ]}, by (1)

We have shown that when assumption 1 holds, the difference-in-differences specified in
4.2 simplifies to the contrast specified in 4.3, because the effect of the precipitant in
those unexposed to the object drug is zero by definition. Thus, if conditional
exchangeability can be assumed, the simple contrast of precipitant exposed versus
unexposed nested in the object drug cohort suffices to estimate the causal interaction
contrast. Although assumption 1 may be plausible in the setting of a pharmacokinetic
DDI, conditional exchangeability between exposed versus unexposed is likely
implausible. However, if there are alternative drug treatments that are used for the same
indications as the precipitant drug, we may be able to use an active comparator
approach.
The nested active comparator design for pharmacokinetic DDIs
Figure 4.1 depicts the nested active comparator design for studying the health
effects of pharmacokinetic DDIs. This hybrid design uses two distinct approaches to
condition on each of the treatment decision events that define the DDI cohort: restriction
is used to condition on the object drug treatment decision; and, an active comparator is
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used to condition on the precipitant drug treatment decision. In a sense, both methods
are conditioning on the treatment decision to be “yes”. They differ in that one restricts to
treatment with only one drug (the object treatment decision), while the other restricts to
treatment with any drug from a specified pool of alternative treatments (the precipitant
treatment decision). In chapter 3, we specified and discussed the assumptions required
to estimate causal effects with an active comparator design, and that logic extends
directly to the current context. The DAG depicted in Figure 3.1 can be assumed to
encode the structural assumptions of a typical nested active comparator design if we
simply specify that the DAG is nested in a cohort of individuals that are treated with the
object drug if interest. We showed in chapter 3 that comparing patients who initiate
amiodarone to patients who initiate metoprolol (an active comparator) is likely to provide
more plausible estimates of causal parameters compared to the use of an unexposed
control group. Further, we showed that the resulting contrast may be viewed as an ATE
for amiodarone versus control within the population defined by the study criteria. In this
case, it would be a contrast of the risk of bleeding in the entire population of warfarin
treated patients who were treated with either amiodarone or metoprolol, or both, had
those patients received treatment with amiodarone vs. the risk of bleeding in the entire
population of warfarin treated patients who were treated with either amiodarone or
metoprolol, or both, had they not received treatment with amiodarone. As shown in the
proof from the previous section, the key assumption that enables this design is the
assumption of no direct effect of the precipitant drug in the absence of the object drug. If
this assumption does not hold, the interaction contrast is undefined. We will show in the
next section that this assumption is untenable for pharmacodynamic DDIs, thus limiting
the utility the nested active comparator design for those types of study questions.
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Important characteristics of pharmacodynamic DDIs.
In contrast to pharmacokinetic DDIs, pharmacodynamic DDIs do not involve
alterations of object drug exposure. Rather, pharmacodynamic DDIs result from
synergistic (or antagonistic) combined direct effects of two or more drugs on the
outcome of interest.62 This mechanism violates the key assumption of the nested active
comparator design: it cannot be assumed that the precipitant drug has no direct effect on
the outcome that is not shared by the control precipitant. In fact, pharmacodynamic DDI
studies must assume the opposite: that the precipitant drug has a direct effect on the
outcome that is distinct from the control precipitant, which leads to synergistic (or
antagonistic) effects with the object drug. Because both drugs have an effect on the
outcome of interest, attempts at using the nested active comparator design would result
in an undefined interaction contrast, and ambiguous results regarding the presence of
any synergism or antagonism between the two treatments. Alternative study designs are
thus required to study this DDI mechanism.
A novel study design to quantify the health effects of pharmacokinetic DDIs.
Figure 4.2 depicts a novel study design that may allow for the identification of the
causal effects of pharmacodynamic DDIs -- the dual-control design. The key difference
between the dual-control and the nested active comparator design is that the study
population is not nested within person time exposed to the object drug. Rather, in
addition to a control precipitant, there is a control object drug (i.e. there are two active
comparators). Thus, the designs differ only in the approach to conditioning on the
treatment decision event for the object drug. Whereas the nested active comparator
design can be thought of as an observational design that seeks to emulate a parallel
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group randomized trial, the dual control design can be thought of as an observational
design that seeks to emulate a 2x2 factorial randomized trial.154
To illustrate the dual control design, consider as an example the potential DDI
between non-steroidal anti-inflammatory drugs (NSAIDs) and inhibitors of the renin
angiotensin system (RAS). This DDI is thought to have a pharmacodynamic mechanism,
resulting from synergistic modulation of intraglomerular pressure in the nephrons of the
kidney, which may reduce glomerular filtration rate in the kidney and lead to acute
kidney injury (AKI).112,137,1,146 Similar to the previous example, this DDI is characterized
by two treatment decisions: one decision to initiate or refrain from initiating treatment
with an analgesic; and a second decision to initiate or refrain from initiating treatment
with an antihypertensive medication. The goal of the dual control design is to control
confounding of the interaction contrast by conditioning on each treatment decision with
the use of an active comparator design. Each treatment decision is conditioned to be
“yes”, by restricting the population to patients who were treated with any drug from a
specified pool of alternative treatments for that particular treatment decision. The
resulting structural assumptions of this design are encoded in the DAGs depicted in
Figure 4.3. The DAG contains two independent causal structures, one for each
treatment decision, where each identifies a minimally sufficient adjustment set that
contains the corresponding treatment decision and set of observed covariates. The DAG
does not contain paths which connect the two causal structures through either observed
or unobserved covariates; However, if any such links are assumed to act conditionally
through the treatment decision, we would arrive at the same adjustment set.
In our example, the study would restrict the population to patients who initiated
both analgesia and antihypertensive treatment. The active comparator for NSAIDs will
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be oxycodone, a commonly used opioid analgesic. The active comparator for RAS
inhibitors will be amlodipine, a commonly used calcium channer blocker antihypertensive
(thorough clinical justification of these active comparator choices is discussed in chapter
5 of this dissertation). We can define a contrast of potential outcomes for this interaction
by writing Y (1=yes, 0=no) for the occurrence of acute kidney injury in a population of
patients admitted to the hospital for some acute illness. We write N=1 for initiation of
NSAID treatment, and N = 0 for withholding NSAID treatment; C=1 for initiation of
oxycodone treatment, and C = 0 for withholding oxycodone treatment; R=1 for initiation
of RAS inhibitor treatment, and R=0 for withholding RAS inhibitor treatment; and finally,
B=1 for initiation of amlodipine treatment, and B=0 for withholding amlodipine treatment.
With two interacting drugs, two active comparators, and each having two potential
outcomes, the potential outcome vector is defined as Yn,r,c,b , representing 256 potential
outcome response types for the sixteen potential drug exposure combinations.
Importantly, these categories can be simplified. For causal effects to be identified, we
must assume that neither active comparator drug has a direct effect on the outcome of
interest, i.e., 𝑌 •,€,•i4,qi4 = 𝑌 •,€,•i4,qiL = 𝑌 •,€,•iL,qi4 = 𝑌 •,€,•iL,qiL = 𝑌 •,€ . Under this
assumption, we can simplify the notation as P=1 for initiation of analgesia with an
NSAID, and P = 0 for initiation of analgesia with oxycodone; A=1 for initiation of
antihypertensive treatment with a RAS inhibitor, and A=0 for initiation of antihypertensive
treatment with amlodipine. We now let the counterfactuals Yp,a denote the outcome of
interest Y when treated with one of the four treatment combinations for the two treatment
indicators P=1, A=1; P=1,A=0; P=0, A=1, and P=0,A=0. Lastly, let X denote a vector of
observed covariates that are drawn from a causal structure that conditions the decision
to initiate analgesia, and V denote a vector of observed covariates that are drawn from a
causal structure that conditions the decision to initiate antihypertensive treatment. We
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can now specify the following contrast for the causal interaction between warfarin and
amiodarone
𝐼𝐶 ƒ,h = 𝐸[𝑌𝑝=1,𝑎=1 − 𝑌𝑝=1,𝑎=0 ] − 𝐸[𝑌𝑝=0,𝑎=1 − 𝑌𝑝=0,𝑎=0 ]

4.4

if we can assume conditional exchangeability across these exposure categories, i.e.,
𝐸[𝑌 ƒ,h | 𝑋, 𝑉, 𝑃 = 𝑝, 𝐴 = 𝑎] = 𝐸[𝑌 z,h | 𝑋, 𝑉], then this interaction contrast would represent a
causal contrast of average treatment effects within the population defined by the study
criteria, which can be identified with the following observational contrast
𝐼𝐶 = {𝐸[𝑌|𝑋, 𝑉, 𝑃 = 1, 𝐴 = 1] − 𝐸[𝑌|𝑋, 𝑉, 𝑃 = 1, 𝐴 = 0]}
−{𝐸[𝑌|𝑋, 𝑉, 𝑃 = 0, 𝐴 = 1] − 𝐸[𝑌|𝑋, 𝑉, 𝑃 = 0, 𝐴 = 0]}

4.5

Thus, by introducing a second active comparator, the original interaction contrast is
preserved, and no assumptions are required regarding the presence or absence of direct
effects of either of the drugs of interest participating in the DDI (i.e. NSAIDs or RAS
inhibitors). The design is thus consistent with the underlying mechanism of interaction.
A note on causal interaction versus effect modification.
When estimating interaction contrasts in observational studies, the specification
of the sufficient set of confounding variables is an essential task. Historically, there
existed ambiguity regarding the sources of confounding for a given interaction contrast
of interest.154 Specifically, does confounding of both exposures involved in the interaction
need to be controlled? Or only one of the variables? Consider again our example DDI
between NSAIDs and RAS inhibitors. Assume further that our interaction contrast is a
differences-in-differences, i.e., a contrast of the “difference in AKI risk between NSAID
exposure and control” in RAS users versus the “difference in AKI risk between NSAID
and control” in RAS nonusers. Lastly, assume that within strata of RAS exposure,
NSAID users are exchangeable with controls (i.e., NSAID treatment can be considered
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randomized within RAS strata). Are these conditions sufficient to obtain an
unconfounded interaction contrast? What, if any, are the implications of nonexchangeability of RAS users (i.e., within strata of NSAID exposure, RAS users are not
exchangeable with RAS nonusers).
In a key paper published in 2009, VanderWeele154 clarified the sources of
confounding of a given interaction contrast, and provided an intuitive means for
distinguishing between the terms “effect modification” and “interaction”. This distinction is
defined in terms of whether there is only one primary exposure of interest (effect
modification” or two exposures of interest (interaction). Consider again the NSAID+RAS
interaction example. If NSAID exposure is unconfounded within strata of RAS exposure,
but RAS exposure is confounded within strata of NSAID exposure, the resulting
interaction contrast identifies effect modification and not interaction. Since the NSAID
effect estimate is unconfounded, differences in the NSAID effect across RAS strata
represent true differences. However, since RAS exposure is confounded, we cannot be
sure what is driving the differences in NSAID effect across RAS strata – the variation of
NSAID effect may be due some effect of RAS exposure, or, it may be due to the effect of
an extraneous variable that is correlated with RAS exposure. If this were the case,
intervening on RAS exposure would not have an effect on the NSAID exposure effect.
In comparison, interaction is defined by the presence of two exposures, where
interest lies in intervening on both exposures. If quantification of interaction is the goal,
then unconfounded effect estimates for both exposures involved in the interaction is
required. In the NSAID+RAS example, this implies that we would need to control
confounding of RAS exposure within strata of NSAID exposure, in addition to
confounding of NSAID exposure within strata of RAS exposure.
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It is important to note that interaction contrast in 4.4 specifies a causal interaction
contrast, i.e., the target of inference is to identify interaction between the two drug
exposures and not merely effect modification of one drug across strata of the other drug.
Thus, there are two sets of confounding variables, one for each treatment decision that
defines the DDI. If, however, our goal was to identify effect modification, there would
only be one set of confounding variables. For illustration, assume that our primary
interest is in the effect of NSAID exposure across RAS strata. Our interaction contrast
would then be specified as
𝐼𝐶 = {𝐸[𝑌 •i4 |𝑋, 𝑅 = 1] − 𝐸[𝑌 •iL |𝑋, 𝑅 = 1]}
− {𝐸[𝑌 •i4 |𝑋, 𝑅 = 0] − 𝐸[𝑌 •iL |𝑋, 𝑅 = 0]

4.6

Given that most DDIs (either pharmacokinetic or pharmacodynamic) involve two drug
exposures, each of which may be intervened upon, we suggest that the identification of
interaction be the primary aim of DDI studies.
Choosing a study design
In this chapter we have formally identified the conditions required for identifying
causal interaction using the nested active comparator design, a standard approach for
the assessment of pharmacokinetic DDIs. We’ve shown that the validity of this design
rests on the assumption of “no direct effect of the precipitant drug in absence of the
object drug”, an assumption that does not hold when the DDI has a pharmacodynamic
mechanism. To address this limitation, we introduce the dual-control design, an
extension of the nested active comparator designs that employs a second active
comparator, which removes the need for restriction of the base cohort to population that
is uniformly treated with one of the drugs. The choice between these designs will depend
58

on the suspected mechanism of interaction, the availability of active comparators, and
the plausibility of conditional exchangeability assumptions between exposures of interest
and the corresponding active comparators.
The key advantage of the dual control design is that it allows a direct examination of the
causal interaction contrast, without needing to make assumptions about the effects of
the interaction drugs. Thus, if the interaction is known to have a pharmacodynamic
mechanism, or if the mechanism is uncertain, the dual control design might be preferred,
as it would facilitate distinguishing main effects of exposures from synergistic or
antagonistic interaction effects. However, the dual control design makes stronger
assumptions regarding exchangeability compared to the nested active comparator
design. Thus, if the mechanism of interaction is known to be pharmacokinetic in nature,
or there is a lack of plausible active comparators for one of the drugs involved, the
nested active comparator design may be preferred. Alternatively, investigators might
apply both approaches to study a given interaction, especially when the mechanism of
interaction is uncertain
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Figure 4.1. The nested active comparator design

Key Assumptions:

1) No unmeasured confounding
by indication of precipitant vs.
control precipitant

Precipitant

2) No interaction between control
precipitant and object

Object Drug

3) No effect of precipitant that is
not shared by control
precipitant in absence of object

Control
Precipitant
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Figure 4.2 The dual control design

Assumptions:
1. No unmeasured confounding of
precipitant vs. control precipitants

Object +
Precipitant

Control Object +
Precipitant

Object

Control
Object

2. No unmeasured confounding of
object vs. control object
3. No interaction between control
precipitant and object
4. No interaction between control
precipitant and control object

Object + Control
Precipitant

5. No interaction between control
object and precipitant
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Control Object +

Control Precipitant

Figure 4.3. Directed acyclic graph (DAG) of the assumed causal structure that underlies
a representative dual-control study design.

Each line depicts a causal pathway between nodes (specified causal factors) of the
graph. Nodes that are shaded grey represent unmeasured factors. The node designated
Treatment T1 represents a vector containing a set of alternative treatments T1, (T1 =
1,…,t1). The node designated Treatment T2 represents a vector containing a set of
alternative treatments T2, (T2 = 1,…,t2). The node designated “Observed covariates X”
represents a vector of observed covariates X which condition treatment decision T1. The
node designated “Observed covariates V” represents a vector of observed covariates V
which condition treatment decision T2. The node designated “Unobserved covariates
U1” represents a vector of unobserved covariates U1. The node designated
“Unobserved covariates U2” represents a vector of unobserved covariates U2. The DAG
results in a minimally sufficient adjustment set that contains the nodes “Treatment
decision T1”, “Observed Covariates X”, “Treatment decision T2”, and “Observed
covariates V”.
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CHAPTER 5: COMBINED EXPOSURE TO NONSTEROIDAL ANTIINFLAMMATORY
DRUGS (NSAIDS) AND INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM (RAS).

Introduction
As previously discussed in chapter one, kidney disease is one of the most
frequently encountered disease states in the hospital setting. Chronic kidney disease
(CKD) is present at admission in 25-40% of patients,17,59,138 and a substantial proportion
of patients will experience further worsening of renal function during admission. Acute
kidney injury (AKI) occurs in 16-18% of hospitalized patients161,167 and up to 40-75% of
patients in high-risk settings such as the intensive care unit or after major surgery.16,70,83
The development of AKI is associated with increased short and long-term
mortality,16,27,68,121 prolonged duration of hospitalization,24 increased healthcare costs,24
and subsequent progression to chronic kidney disease (CKD) and end stage renal
disease (ESRD).23,28,75 No treatments exist for AKI, making the identification and
avoidance of potentially nephrotoxic drugs and drug combinations a cornerstone of
management in the inpatient setting.8,113 DDIs may be an important and
underappreciated cause of AKI. A common and clinically important example is the
potential drug-drug interaction (DDI) between NSAIDs and RAS inhibitors.
Although NSAIDS are commonly used in the hospital setting, many clinicians avoid
NSAIDs in patients receiving RAS inhibitors because of the reported association
between NSAID-RAS exposure and nephrotoxicity.1,112,137,146 The hypothesized
mechanism of this potential DDI is pharmacodynamic interaction: NSAIDS can cause
vasoconstriction of the afferent arterioles of the glomerulus,159 while RAS inhibitors
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cause vasodilation of the efferent arterioles.9 The combined effects on the glomerulus
can act synergistically to reduce transglomerular pressure and compromise glomerular
filtration rate (GFR), particularly in patients with sodium and/or volume depletion.
1,112,137,146

However, whether the combination reduces total renal blood flow relative to

NSAID monotherapy is uncertain.
NSAID mediated vasoconstriction can reduce renal parenchymal blood flow and lead
to ischemic acute tubular necrosis (ATN).112,159 In contrast, RAS inhibition does not
reduce renal blood flow,42,106 and it is unclear how downstream vasodilation via RAS
inhibition could enhance reductions in renal blood flow mediated by NSAID exposure.
Thus, the synergistic effects of the combination may be limited to changes in GFR,
without increasing the risk of ischemic injury. This is an important distinction, because
short-term functional changes in GFR may not have the same prognostic significance as
true renal injury.16,27,112,111 The uncertain clinical relevance of this DDI is major
knowledge gap, as inpatient NSAID use may increase substantially in the coming years
as part of efforts to reduce the use of opioids.
The United States is facing an epidemic of prescription drug misuse, addiction, and
overdose deaths.109 Prescribed opioids constitute the main supply of these drugs for
70% of opioid abusers.141 Opioid use is widespread in hospitalized patients; with over
50% of admitted patients receiving at least one opioid dose.64 Inpatient opioid use may
increase the risk of chronic use and abuse,18,21,78 highlighting hospitalization as a target
for opioid reduction interventions.145,26,65 Given the high prevalence of use, even small
shifts from opioids to NSAID prescribing would represent a marked increase in NSAID
exposure, translating into potentially millions of additional patients exposed to
concomitant NSAID-RAS exposure in the inpatient setting each year. The objective of
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this study was to compare the rate of AKI during concomitant NSAID+RAS exposure vs.
a negative control of concomitant opioid-RAS exposure in hospitalized patients. We
hypothesized that NSAID+RAS combinations increase the incidence of short term,
functional changes in renal function without having long-term detrimental effects on
kidney health.
Methods
Overview of study design causal contrasts
We compared the rate of AKI in patients exposed to NSAID+RAS combinations vs.
control patients utilizing the “dual-control” design proposed in Aim 1, which is an
extension of standard active control methods62,97 for the study of PD-DDIs. Oxycodone
was chosen as the active comparator for NSAID exposure because oxycodone was the
most commonly used analgesic in the University of Pennsylvania Health System (UPHS)
during the study period;64 it does not interfere with the metabolism of any of the RAS
inhibitors of interest; and it has no known effects on renal blood flow autoregulation, thus
precluding any plausible mechanisms of interaction with RAS-inhibitors to increase the
risk of AKI. Amlodipine, a dihydropyridine calcium channel blocker, was chosen as the
active comparator for RAS-inhibitor exposure. Amlodipine was chosen because it has
the closest set of indications compared to RAS-inhibitors of any existing antihypertensive
drug;76 it does not exhibit any pharmacokinetic interaction with the analgesics of interest;
and it does not have any vasodilatory effects on the efferent arterioles,58 which is the key
mechanism that is postulated to mediate the potential synergistic interaction with NSAID
exposure.1,137,146
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Using these medication classes, we compared the incidence rate (IR) of AKI in four
distinct cohorts: those exposed to NSAID+RAS (IR11), those exposed to NSAID+CCB
(IR10), those exposed to opioid+RAS (IR01), and those exposed to opioid+CCB (IR00). A
synergistic DDI between NSAID and RAS inhibitors was defined as departure from
additivity on the risk difference scale as follows:
𝐼𝑅44 − 𝐼𝑅LL = (𝐼𝑅4L − 𝐼𝑅LL ) + (𝐼𝑅L4 − 𝐼𝑅LL )
Testing this null hypothesis allowed us to determine whether combined NSAID+RAS
exposure increases the rate of AKI vs. control to a greater extent than either NSAIDs
alone or RAS-inhibitors alone.62 Because both NSAIDs and RAS inhibitors have been
associated with AKI when given alone, such a contrast is required to differentiate
synergistic effects of the combination from additive or multiplicative effects of either
agent.
We further examined the nature of NSAID+RAS effects on the kidney by comparing
the severity and duration of AKI across the cohorts. Previous studies suggest that AKI
episodes of low severity and short duration have limited prognostic significance
compared to more severe forms, suggesting that brief changes in estimated renal
function may not associated with significant renal injury.16,27,56 If our hypothesis is
correct, we expect to find an increased incidence of low severity (stage 1) AKI that has a
short duration (i.e. 1- 2 days) among NSAID+RAS exposed patients vs. control, without
differences in higher severity stages and/or longer duration AKI events.
Patient population
The study population was sampled from the population of patients admitted to
one of four hospitals within the UPHS from January 1, 2004 - June 30, 2017. Inclusion
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criteria were age > 18 years at the time of admission and exposure to at least 24 hours
of concomitant exposure to a drug pair of interest during admission (exposure duration
was determined by comparing the date and time stamps of consecutively administered
doses). Exclusion criteria were the presence of relative contraindications to NSAID
exposure (baseline platelet count < 100 x1011 cells/L, end stage renal disease and/or
renal replacement therapy and/or AKI and/or creatinine > 2 mg/dL within 72 hours prior
to cohort entry); presence of documented relative contraindications to RAS and/or CCB
exposure (admission for childbirth); lack of a baseline creatinine within 72 hours of
cohort entry and/or lack of ≥ 1 follow up creatinine; and a history of solid organ
transplant. The rationale for this latter exclusion was that patients with transplant were
uncommon in the cohort (< 2% of patients); and baseline renal dysfunction and
exposure to multiple nephrotoxins is common in this group. We thus judged exclusion of
these patients to be the best approach to control of potential confounding from this
factor. In patients with multiple episodes of concomitant exposure to a drug pair of
interest, only the first exposure episode meeting study criteria was included.
Exposures and follow-up
The source population of antihypertensive person-time consisted of patients who
received ≥ 48 hours of exposure to either a RAS inhibitor or amlodipine (the active
comparator). Courses were defined by consecutive doses where each dose was
administered within 36 hours of the previous dose. The duration of each course was
extended for 24 hours after the date and time of the last administered dose, based on
the average duration of effect for the antihypertensives of interest. Eligible RAS inhibitors
included the angiotensin-converting-enzyme (ACE) inhibitors (lisinopril, enalapril,
ramipril, benazepril, quinapril, and captopril) and the angiotensin II receptor blockers
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(ARB) (losartan, irbesartan, and valsartan). ACE inhibitors and ARBs were studied
collectively because prior studies have shown these classes to produce similar effects
on efferent arteriolar vascular tone and GFR.4 The specific drugs within these classes
were selected because they were on the UPHS drug formulary during the study period.
Within the source population of antihypertensive person-time, we identified
patients who received concomitant analgesics, defined as ≥ 24 hours of exposure to
either a NSAID or oxycodone (the active comparator). Analgesic courses were defined
by consecutive doses where each dose was administered within 24 hours of the
previous dose. The duration of each course was extended for 12 hours after the date
and time of the last administered dose, based on the average duration of effect for the
analgesics of interest. Eligible NSAIDs included ibuprofen, ketorolac, indomethacin, and
nabumetone. These specific NSAIDS selected because they were on the UPHS drug
formulary during the study period.
Follow up began at the date and time of the first dose of concomitant exposure
(i.e. the index date) and continued until one of the following: lapse in concomitant
exposure of at least 48 hours, occurrence of AKI, hospital discharge, death, or at 14
days after the index date.
Outcomes
The primary outcome was the occurrence of AKI during the initial 14 days of
concomitant antihypertensive and analgesic exposure. The rationale for this time interval
is that we are interested in AKI events that are attributable to drug exposure and prior
data suggests that NSAID+RAS effects can have a rapid onset (i.e. within 1-2 days); and
the vast majority of analgesic courses in the inpatient setting have a duration ≤ 14 days.
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Patients who developed AKI were followed for up to 7 days from the date of AKI to allow
for AKI severity staging and to assess AKI duration.
AKI was defined according to the Kidney Disease: Improving Global Outcomes
(KDIGO) criteria (Table 5.1).84 The KDIGO criteria have been validated against previous
AKI criteria and are used widely in current studies of AKI. Compared to prior consensus
criteria, KDIGO identifies more patients with AKI, while retaining strong associations with
mortality.167 KDIGO defines AKI according to absolute increases in serum creatinine;
relative changes from baseline; and changes in urine output (UOP). We did not consider
changes in UOP because this variable is not reliably available in the EMR database; in
addition, prior studies have validated the prognostic significance of AKI defined by
creatinine changes alone, which has been shown to correlate more closely with mortality
risk compared to UOP changes.79 Baseline creatinine was defined as the last serum
creatinine obtained prior to the index date.
Secondary outcomes included AKI severity stage, the percent change in GFR from
baseline to hospital discharge, and the duration of AKI. Duration of AKI was determined
by counting the number of days required for serum creatinine to return to within 25% of
the baseline value.16 AKI duration was categorized into three strata: Short (≤ 2 days),
Medium (3-6 days), Long (≥ 7 days).16 Previous data has shown stepwise increases in
both short and long term mortality across these categories.16,56 Patients who required
renal replacement therapy (RRT) were categorized as long duration regardless of the
number of days that serum creatinine remained elevated.16
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Data collection
All study data were obtained from the Penn Data Store (PDS), a warehouse that
records medications, laboratory values, demographics, procedures, and discharge
diagnosis data from all patients admitted to UPHS. PDS contains information on all
medication orders placed into the hospital’s computer physician order entry system,
including dose, frequency, route, and the dates and times of dosage administration.
Laboratory data within PDS includes the result values, date & time that the laboratory
tests were ordered, and the date and time of the result report. PDS also contains data on
all orders for RRT procedures, which were used to ascertain RRT status (including
intermittent dialysis and continuous renal replacement therapy).
Potential confounding variables were selected a priori based on clinical
knowledge and prior literature and included only those with biologically plausible
associations with acute kidney injury (demographics, hospital admission characteristics,
comorbidities, laboratory measures, and concomitant medication exposures (Table 5.3).
Comorbidities were ascertained from discharge diagnosis codes following the algorithm
of Quan117 and Elixhauser.38 Pre-exposure AKI was defined by applying the KDIGO
criteria from hospital admission up to the time of exposure. Baseline creatinine for the
pre-exposure AKI assessment was defined as the average of prior outpatient and / or
prior hospital discharge values available during the period from 365 days before to 7
days before the index hospitalization admission date. Where this data was missing, the
baseline value was defined as the lowest value available during the initial seven days of
hospitalization, up to the index date. Medications and laboratory data were assessed
during the 72-hour period prior to the index date. For each laboratory measure, the value
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most proximate to cohort entry was collected. Baseline glomerular filtration rate (GFR)
was estimated using the CKD-EPI equation.91
Data analysis
Descriptive statistics
The distributions of baseline covariates were compared among the four treatment
groups using standardized mean differences (SMD),6 with the reference group being
those exposed to NSAID+RAS. Absolute values of SMDs >0.1 were considered as
evidence for meaningful differences between groups.7 For each group, we calculated the
incidence rates of AKI with 95% CIs. Contingency tables of AKI occurrence in the 4
groups were constructed to calculate unadjusted measures of interaction on the
multiplicative and additive scales.
Inverse probability of treatment (IPT) weighting analysis
Estimation of the causal synergistic interaction between NSAID+RAS exposure
requires adjustment for confounding variables among the four treatment groups. We
adjusted for such potential confounding using IPT weighting analysis.99,123 This approach
has two steps: 1) estimation of the IPT weights; and 2) constructing a weighted outcome
model using the IPT weights. IPT weights were estimated using multinomial propensity
scores as described by McCaffrey.99 Multinomial PS extends standard PS methods to
scenarios that evaluate multiple, non-ordered treatment groups, as is the case here. The
multinomial PS was calculated using a generalized boosted model (GBM).99 GBMs are
nonparametric machine-learning classifiers that use an iterative process with multiple
regression trees to capture complex and nonlinear relationships between treatment and
the pretreatment covariates.99 GBM iteratively selects the PS model that minimizes both
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the mean and maximum SMD across all covariates.99 The GBM included all covariates
listed in Table 5.3. Balance of individual covariates were reassessed in the weighted
sample. Covariates with residual imbalance (SMD>0.1) were included as covariates99,82
in the weighted outcome models described below.
Primary outcome model
Adjusted measures of interaction were estimated using a Poisson regression
model with robust variance estimation168 that was weighted using IPT weights99,123
estimated above. The base model specification was as follows:
log [AKI rate | X)] = β0 + β1(N) + β2(R) + β3(N*R)
where N is an indicator variable for NSAID vs. opioid exposure, R is an indicator variable
for RAS vs. amlodipine exposure, and N*R is the interaction term, which provides a
direct estimate of interaction on the multiplicative scale.150 Interaction on the additive
scale was determined by contrasting the predicted marginal rates of each exposure
group.107 Population average marginal effects are estimated by first calculating the
predicted rate for each person in the analysis and then taking the average across the
entire population.107 These marginal effects can be interpreted as rate in the entire
population had those patients received the specified treatment vs. the rate in the entire
population had they not received treatment (i.e. an average treatment effect). If no
interaction was observed on either scale of the analysis, modeling was repeated without
the interaction term to evaluate the main effects of pain and antihypertensive exposure
groups.
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Secondary outcome models:
Separate models were constructed for the secondary outcomes of interest, each
weighted using the IPTWs estimated above. Duration of AKI (short vs. medium vs. long)
and KDIGO stage were examined using IPT weighted multinomial logistic regression
models. The rationale for using multinomial logistic regression (in lieu of ordinal logistic
regression) to model these ordered outcome variables is based on the hypothesized
mechanism underlying the potential interaction between NSAIDs and RAS inhibitors. We
hypothesized that the effects of the interaction on the kidney are largely functional
effects on glomerular filtration which lead to reduced creatinine clearance without
synergistic effects on nephrotoxicity. If this hypothesis is true, we would expect the
interaction to produce an excess of low severity (i.e. stage 1), short duration AKI events,
with lesser (or no) effects on higher severity, longer duration AKI event types. This
pattern of effects would violate the proportional odds assumption of ordinal logistic
regression (i.e., the effect of exposure is the same for each category of the outcome).
Lastly, the percent change in GFR at hospital discharge was estimated using an IPT
weighted linear regression model.
Sensitivity analyses
All primary analyses were repeated using multivariable adjusted Poisson
regression. The rationale was to determine if our inferences were sensitive to modeling
assumptions; and because IPTW may have less power compared to multivariable
regression.99,123 Details of the model building procedures are included in the appendix.
Analysis were also repeated after excluding patients with heart failure and/or a
history of chronic kidney disease. The rationale for this exclusion is that the indication for
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RAS inhibitors in these groups is particularly strong, such that amlodipine may not be an
adequate control in these scenarios; similarly, NSAIDs are often avoided in patients with
heart failure. Lastly, analysis was repeated after restricting the population to patients
who received concomitant exposure for at least three days. The rationale for this latter
analysis was to evaluate for a potential duration response relationship between
combined NSAID+RAS exposure and AKI risk.
Results
General population characteristics
The selection of patients into the study is depicted in figure 5.1. Our initial query
identified 114,491 unique episodes of concomitant exposure to a drug pair of interest
during the study period, of which 61,360 courses (in 43,201 patients) were of at least 24hour duration. From this population, 27,741 patients were included in the final study
population. The median duration of exposure to combined analgesic and
antihypertensive treatments was approximately two days in all study groups, reflecting
the short-term, acute pain indications that are common in the inpatient setting (Table
5.2). Patients typically had one serum creatinine value measured each day during follow
up. Roughly two-thirds of patients had at least one prior ambulatory or discharge
inpatient creatinine value measured during the year preceding the index hospitalization,
while roughly half of patients had a post-discharge creatinine available. The most
common RAS inhibitors were lisinopril (an ACE inhibitor) and losartan (an ARB). The
most common NSAIDS were ibuprofen and ketorolac.
The characteristics of the unweighted population are shown in Table 5.3. The
overall median age of the cohort was 63 years (IQR 55-72), with a slight predominance
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of male gender. Most patients presented to the hospital through the emergency
department or directly to the operating room, and relatively few patients were in an
intensive care unit or on mechanical ventilation at index date. Approximately ninety
percent of patients had a diagnosis of hypertension and exposure to multiple
antihypertensive medications was common. Notable differences in patient characteristics
across groups are discussed below
Characteristics of pain treatment groups in RAS inhibitor exposed patients
In patients treated with RAS inhibitors, NSAID exposed patients compared to
oxycodone patients tended to be younger, female medical patients admitted through the
emergency department. They were less likely to have heart failure, atrial fibrillation,
peripheral vascular disease, and chronic kidney disease. As expected, NSAID patients
had higher baseline renal function compared to oxycodone patients.
Characteristics of pain treatment groups in amlodipine exposed patients
In patients treated with amlodipine, NSAID exposed patients compared to
oxycodone patients tended to be younger, female medical patients admitted through the
emergency department. They were in the hospital for an additional day on average
before DDI exposure. They were less likely to have heart failure, peripheral vascular
disease, chronic kidney disease, and were less likely to receive vancomycin. As
expected, NSAID patients had higher baseline renal function compared to oxycodone
patients.
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Contrasts of the differences in characteristics of pain exposure groups across strata of
antihypertension exposure groups
When contrasting the SMD for NSAID exposed patients vs. oxycodone patients
across antihypertensive groups, some characteristics showed different patterns of
covariate balance. These differences might be indicative of scenarios where the
potential drug-drug interaction between NSAIDs and RAS inhibitors is specifically
avoided; or, scenarios where both classes tend to be avoided, but not necessarily
because of concern for the potential interaction. NSAIDs exposure was less common in
RAS users compared to amlodipine users at Pennsylvania Hospital compared to other
centers. NSAIDS exposure was also less common in RAS exposed patients when
initially admitted to the ICU compared to CCB exposure, where the frequency was the
same. This might be because both NSAIDS and RAS are avoided in ICU settings.
NSAIDS were used one day later in CCB users, whereas there was no difference in prior
LOS in RAS users. NSAIDS were a bit less likely to be used peri-operatively in RAS
users than in CCB users. Again, this could be driven by the avoidance of both RAS and
NSAIDs in the perioperative setting. NSAIDS were also avoided more often in those with
myocardial infarction in RAS users vs. CCB users. Renal function was higher in NSAID
users vs. oxycodone users in both groups, but the difference was larger in CCB patients.
Lastly, NSAIDs were more often avoided in RAS users vs. CCB users in the setting of
vasopressor exposure. Similar to the above scenarios, this might be driven by the fact
that both RAS and NSAIDS are more often avoided in the peri-shock period compared to
CCB and / or oxycodone.
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Characteristics of antihypertensive treatment groups in NSAID exposed patients
In patients treated with NSAIDS, RAS exposed patients compared to amlodipine
exposed patients were less likely to be treated at Pennsylvania Hospital and less likely
to be in the ICU or in the perioperative period at baseline. RAS users more often had
heart failure, myocardial infarction, and other cardiovascular disease. RAS users were
also more likely to have diabetes mellitus type II. RAS users had lower baseline renal
function and were more likely to be exposed to concomitant diuretic therapy.
Characteristics of antihypertensive treatment groups in oxycodone exposed patients
In patients treated with oxycodone, RAS exposed patients compared to
amlodipine exposed patients were less likely to be black race, less likely to be in the
perioperative period or to be mechanically ventilated, although this latter characteristic
was uncommon in both groups. RAS patients were more likely to have heart failure and
other cardiovascular diseases, and were more likely to have diabetes mellitus type II.
RAS users were also more likely to be have concomitant exposure to beta-blockers and
diuretic therapy.
The differences in the differences of baseline characteristics of pain groups
across antihypertensive groups mirror those discussed above for antihypertensive group
characteristics across strata of pain exposure groups. This is expected from the
transitive relation that characterizes the set of exposure groups being compared (e.g., a
differential difference in baseline renal function in NSAID vs. oxycodone groups across
strata of antihypertension groups is the same as a differential difference in baseline renal
function in RAS vs. amlodipine groups across strata of pain exposure groups.

77

Comparisons of patient characteristics in the IPT weighted population
The weighted population characteristics are shown in Table 5.4, and the change
in SMDs after weighting is shown in Figure 5.2. IPT weighting successfully balanced
measured covariate distributions of NSAID exposed patients compared to oxycodone
patients in both the RAS exposed and amlodipine exposed populations. Similarly,
covariate balance was achieved for RAS exposed patients compared to CCB exposed
patients across strata of pain treatment. Small degrees of residual imbalance were
observed for heart failure, myocardial infarction, and loop diuretic exposure in the
weighted population. These variables were included as covariates in the weighted
outcome models.
Acute kidney injury rate and associations with mortality
There were 2,486 AKI events observed during a total of 98,752 person-days of
follow up, corresponding to incidence rate of 25 AKI events / 1000 person-days and an
incidence of 8.9 %, (95% CI 8.6%, 9.3%). Table 5.5 shows the severity and duration of
AKI events and the crude associations between AKI and 30-day in-hospital mortality.
Although the overall mortality risk was low (132 deaths; 0.48%), the AKI phenotype
showed strong associations with mortality that increased in magnitude with increasing
severity and duration. This observed prognostic significance of the AKI phenotype in the
study population supports the validity of our phenotyping algorithm.
Acute kidney injury rate in drug-drug interaction groups
Analysis of the unadjusted AKI incidence rates and measures of association
(Table 5.6) were notable for the lack of an association between NSAID exposure and
AKI rates, a small increase in AKI rates associated with RAS exposure, and no
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interaction between NSAID and RAS exposure, either on the multiplicative or additive
scales. Results of the IPT weighted outcome analysis are shown in Table 5.7. The
pattern of results in the weighted analysis are more consistent with an interaction
between NSAID and RAS exposure: the AKI rate in the NSAID+RAS exposed group was
higher than what would be predicted by additivity, however the difference was small and
the confidence intervals around this estimate included values consistent with no
interaction. Repeating the analysis without the interaction term showed a significant
association between NSAID exposure and increased AKI rates and a weaker
association between RAS exposure and increase AKI rates, although the latter estimate
was not significant.
AKI severity stage, duration, and discharge GFR.
Of the 2486 AKI events observed in the population, the vast majority were stage1 (2005/2486 [80%]) with Stage-2 & Stage-3 events representing 13.6% & 5.8% of
observed events, respectively. Renal replacement therapy was uncommon (26 events;
0.1%). The effect estimates from the IPT weighted multinomial logistic regression model
are shown in Table 5.9 (odds ratios and multiplicative measures of interaction) and the
estimated marginal distributions of severity stage are shown in Figure 5.3. Although the
pattern of results is consistent with our a priori hypothesis (i.e., NSAID+RAS exposure
associated with excess stage-1 events, but not with stage-2 or stage-3), the difference in
stage-1 events was small and the confidence intervals around the interaction parameters
included values consistent with no interaction. Similarly, we did not observe significant
interactions in the analysis of AKI duration (Table 5.10, & Figure 5.4).
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The average estimated glomerular filtration rate at hospital discharge was close
to the baseline value on average, but with considerable variability around this estimate
[mean change -0.7 (SD 12.2) ml/min/1.73m2], Figure 5.5. No interaction was observed
between NSAID and RAS exposure (IPT weighted additive interaction estimate -0.59
ml/min/1.73m2 (95% CI -1.44, 0.26). In the analysis for main effects, NSAID exposure was

associated with decline in GFR at discharge of 0.53 ml/min/1.73m2 from baseline (95%
CI 0.17, 0.88 ml/min/1.73m2) compared to oxycodone exposure; and RAS exposure was
associated with decline in GFR at discharge of 0.49 ml/min/1.73m2 from baseline (95%
CI 0.13, 0.85 ml/min/1.73m2) compared to amlodipine exposure.
Sensitivity analyses
The results of the multivariable regression-based analyses are shown in Tables
5.11-5.13, which are consistent with findings from the primary analysis. Namely, the
absence of interaction between NSAID and RAS exposure is noted across all analyses.
Additionally, the magnitude of the effect estimates for the interaction parameters are
somewhat attenuated compared to the primary IPT weighted analysis. The main effect
estimates for the primary outcome analysis are shown in Table 5.8, which show a higher
rate of AKI in patients exposed to NSAIDs vs. oxycodone, and a smaller, non-significant
increase for RAS exposure compared to amlodipine.
Repeating analysis after exclusion of patients with chronic kidney disease and
heart failure produced similar results to the primary analysis: IPT weighted analysis of
1161 AKI events in 18281 showed no significant interaction (0.81, 95% CI 0.58, 1.32).
Repeating analysis after restricting to patients who received at least three days of
concomitant exposure (1217 AKI events in 9799 patients) produced results that were
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more consistent with an interaction between NSAID+RAS exposure (Table 5.14), with
the estimate for excess AKI events due to the interaction increased relative to the
primary analysis. However, the confidence interval around this estimate included values
consistent with no interaction.
Discussion
The need for acute pain control is common during hospitalization and there are
relatively few analgesic options for clinicians to choose from. Over the past two decades,
opioids have been the mainstay of acute pain treatment.64 However, in recent years the
potential harms associated with inpatient opioid exposure145,18,21,26,65,78,109,141 have
become increasingly apparent, leading clinicians to search for alternative treatments.
The NSAID class of analgesics is a key alternative to opioids, but their use is often
hindered by concerns for nephrotoxicity, particularly in the setting of predisposing risk
factors such as DDIs. Although reports of enhanced NSAID toxicity during RAS inhibitor
exposure were first published nearly two decades ago,146 there has remained substantial
confusion regarding the true nephrotoxic propensity of this drug combination, with large
scale pharmacoepidemiologic studies in the outpatient setting showing conflicting
results.36,88 The effects of short-term exposure to this combination during hospitalization
is even less clear, as there have been no large-scale studies that have examined the
interaction in this population. Moreover, quantification of the health effects of this
potential DDI is complicated by the purported pharmacodynamic mechanism underlying
the interaction, which may render standard pharmacoepidemiologic study designs
ineffective for detecting true causal interaction.
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Against this backdrop, we leveraged our electronic health record database to
conduct a large-scale pharmacoepidemiologic analysis of this interaction, using a novel
study design and rigorous procedures for the control of confounding. The key findings of
our analysis are that 1) short term (2-3 days) NSAID exposure is associated with a
roughly 20% relative increase in the rate of AKI which translated into an extra 5 AKI
events per 1000 person days of exposure; 2) the majority of AKI episodes were low
severity events; 3) the nephrotoxicity of short-term NSAID exposure does not appear to
be meaningfully enhanced by concomitant exposure to RAS inhibitors; and 4) the use of
a dual-control study design facilitated the differentiation of synergistic effects between
NSAIDs and RAS inhibitors from the main effects of either agent in isolation.
A key design aspect for studies that aim to quantify the health effects of DDIs is
the approach to controlling confounding by indication.62 Because at least two drugs are
involved in a DDI, there generally are at least two key sources of confounding by
indication. For a given pair of potentially interacting drugs, a common approach to
minimize confounding is to nest a comparison of exposure vs. no exposure to one of the
drugs within person-time exposed to the other drug.62 By restricting the underlying
population to persons exposed to one of the drugs, the design provides complete control
of confounding by indication for that drug. The design also typically includes an active
comparator, which is intended to control confounding-by-indication of the second drug.62
An example of this approach would be to compare NSAID exposed patients to
oxycodone patients in a cohort of patients exposed to RAS inhibitors. This design works
well when the mechanism of the drug-drug interaction is based on pharmacokinetic
alterations, and it can be assumed that the interacting medication does not have direct
effects on the outcome.
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This design poses difficulty, however when examining a pharmacodynamic
interaction, because it cannot be assumed that one of the drugs in the DDI-pair lacks a
direct effect on the outcome. In a study that compares NSAID exposed patients to
oxycodone patients in a cohort of patients exposed to RAS inhibitors, it would be
impossible to determine whether any observed differences between the exposure
groups is due to interaction between NSAID and RAS, or rather, the independent effect
of NSAID exposure. This limitation was the key motivation for the dual-control design. By
introducing a second control drug, the dual-control design allows for direct examination
of interaction between the exposures of interest on the multiplicative and additive scales,
facilitating the differentiation of additive or multiplicative effects from synergistic (or
antagonistic) effects.
In our analysis, tests for differential effects of NSAID exposure across strata of
antihypertensive class did not provide convincing evidence of synergistic interaction.
This statement regarding the absence of interaction between NSAIDs and RAS inhibitors
must be viewed in light of the confidence intervals around the interaction parameters. In
the primary analysis, the upper bound of the confidence interval for interaction on the
additive scale was 10 AKI events / 1000 days of concomitant exposure. This translates
into 3 extra AKI cases in a population of 100 patients treated with three days of
concomitant NSAID+RAS exposure. Given the low severity of most AKI events in the
population, many clinicians might judge the upper bound of our interaction estimate to
represent an acceptable risk compared to alternative analgesia with oxycodone.
In the analysis for the main effect of NSAIDs (which was nested in person time of
RAS exposure), we showed a significant increase of AKI rates in comparison to
oxycodone. Without the dual-control design, this independent effect might be mistaken
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for evidence of synergistic interaction. This is notable, as the presence of synergistic
versus additive or multiplicative effects of two drug exposures is relevant to clinical
decision making at the bedside. The presence of a synergistic interaction between two
exposures suggests that there are persons for whom the outcome would occur if both
exposures were present but not if only one or the other of the exposures were
present.128,152,153 This idea clarifies the importance of quantifying potential synergistic
effects of the NSAID and RAS combination. If the drug pair acts synergistically, the
presence of RAS exposure might render toxicity during NSAID exposure in a patient who
would otherwise not experience an adverse effect. Our results suggest that, at least for
short term (2-3 day) exposure, RAS exposure does not alter the probability of
experiencing acute kidney injury during NSAID analgesia. Thus, in patients who would
otherwise be deemed candidates for NSAID therapy, RAS inhibitor exposure may not be
a reason to choose an alternative analgesic (e.g. opioid) in lieu of an NSAID.
Beyond determining whether concomitant NSAID and RAS exposure enhances
the risk of creatinine defined AKI, additional questions exist regarding the clinical
relevance of creatinine-defined kidney injury outcome measures for the evaluation of this
interaction, because the combined effects of NSAID and RAS exposure may be limited
to functional effects on glomerular filtration rate. In an attempt to examine this aspect, we
evaluated the impact of the potential DDI on both the severity and duration of AKI
episodes. We hypothesized that, if the interaction is merely a functional interaction, we
would see a pattern of higher rates of low severity, short duration AKI episodes during
NSAID+RAS exposure, with no effects on more sever types of injury. In our analysis of
AKI severity stage, the pattern of results was consistent with this hypothesis:
NSAID+RAS exposure showed a suggestion of increased stage-1 AKI, without any
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effects on higher severity stages. However, the effects were small, and the confidence
intervals around the interaction parameter included values that were consistent with no
interaction. The results of our analysis of AKI duration were similarly inconclusive.
Additional larger studies, and studies that utilize non-creatinine biomarkers of kidney
injury are required to understand the effects of the interaction on true kidney tissue
ischemic injury.
Our study has a number of limitations. First, the nonrandomized cohort design is
susceptible to residual confounding. We minimized bias from confounding by collecting
and controlling for all available potential confounding variables in an inverse probability
of treatment weighted regression and conducted a number of sensitivity analyses to
examine the robustness of our findings. Second, although the use of active comparators
may help to reduce bias from confounding, this approach may also limit the
generalizability of the findings. Strictly speaking, our results suggest that combined
NSAIDs and RAS inhibitor exposure may not synergistically enhance AKI risk in
comparison to amlodipine, a calcium channel blocker. It may be the case that our
inability to detect a meaningful interaction was driven by similar degrees of toxicity
enhancement by both of the studied antihypertensive classes, rather than the absence
of synergistic toxicity. Although this is possible, it seems unlikely given the proposed
effects of amlodipine on renal vascular tone.58 Third, although the confidence intervals
around the interaction estimates in our primary analysis included excess AKI estimates
that may be judged as clinically irrelevant, this might not hold if the baseline rate of AKI
was higher in the population. Lastly, it’s important to highlight that our findings may not
apply to longer durations of concomitant NSAID and RAS exposure. In the sensitivity
analysis of patients who received at least 3 days of combined exposure, the suggestion
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of a synergistic interaction was stronger, although the confidence intervals included
values consistent with no interaction. Our results suggest however, that such long
durations of concomitant exposures are relatively uncommon during typical hospital
admissions where acute pain control is indicated: only 20% of the 114,491 episodes of
concomitant antihypertensive and analgesia episodes were of 3 days or longer.
Conclusion
In this large cohort study of short courses of concomitant exposure to analgesia
and antihypertensive drug exposure, RAS exposure did not appear to meaningfully alter
the risk of acute kidney injury during NSAID exposure. Additional, larger studies will be
required to determine the effect of longer durations of concomitant exposure.
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Tables and Figures
Table 5.1 Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury
criteria
Stage
Stage 1
Stage 2
Stage 3

Creatinine criteria
≥ 0.3 mg/dl increase within 48 hours –or-- 1.5- 1.9 x baseline
within 7 days
2-2.9 x baseline
3 x baseline –or-- Scr > 4.0 mg/dl –or-- renal replacement
therapy
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Table 5.2. Exposures and creatinine monitoring
Variable

NR
4250
2.0 (1.4, 3.0)

NC
1181
2.0 (1.4, 3.0)

OXR
17610
2.5 (1.5, 4.0)

OXC
4700
2.4 (1.5, 3.7)

Exposure duration,
median (IQR)
Creatinine values per
1.0 (0.7, 1.6)
1.1 (0.7, 1.6)
1.1 (0.7, 1.7)
1.2 (0.8, 1.7)
day, median (IQR)
Pre-hospitalization
2606 (61.3%)
748 (63.3%)
10909 (61.9%) 3255 (69.3%)
creatinine
Post-hospitalization
2307
647
9486
2682
creatinine
(54.3%)
(54.8%)
(53.9%)
(57.1%)
RAS inhibitor type
Benazepril
106 (2.5%)
na
413 (2.4%)
na
Captopril
51 (1.2%)
na
197 (1.1%)
na
Enalapril
551 (13.2%)
na
2459 (14.1%)
na
Irbesartan
87 (2.1%)
na
276 (1.6%)
na
Lisinopril
1924 (46.0%)
na
7881 (45.2%)
na
Losartan
589 (14.1%)
na
2483 (14.2%)
na
Quinapril
92 (2.2%)
na
318 (1.8%)
na
Ramipril
226 (5.4%)
na
1030 (5.9%)
na
Valsartan
555 (13.3%)
na
2368 (13.6%)
na
Amlodipine
718 (16.9%)
1181 (100%)
2702 (15.3%)
4700 (100%)
NSAID type
Diclofenac
10 (0.2%)
3 (0.3%)
na
na
Ibuprofen
1822 (44.1%)
450 (38.8%)
na
na
Indomethacin
152 (3.7%)
40 (3.4%)
na
na
Ketorolac
1680 (40.6%)
575 (49.6%)
na
na
Nabumetone
58 (1.4%)
11 (0.9%)
na
na
Naproxen
414 (10.0%)
81 (7.0%)
na
na
Oxycodone
1314 (30.9%)
390 (33.0%)
17610 (100%) 4700 (100%)
NR- NSAID+RAS inhibitor group; NC- NSAID + calcium channel blocker (amlodipine)
group; OXR- oxycodone + RAS inhibitor group; OXC- oxycodone + calcium channel
blocker (amlodipine) group; IQR- interquartile range

88

Table 5.3 Baseline characteristics in the unweighted population
NR
(n=4250)

OXR
(n=17610)

NC
(n=1181)

OXC
(n=4700)

SMD

60.2 (13.5)

63.6 (12.8)

0.262

60.1 (14.5)

64.3 (12.8)

0.319

2243
(52.8%)

7943
(45.1%)

0.154

632 (53.5%)

2332
(49.6%)

0.078

Other / Unk

2235
(52.6%)
1616
(38.0%)
399 (9.4%)

9807
(55.7%)
6002
(34.1%)
1801
(10.2%)
31.2 (8.3)

0.062

599 (50.7%)

0.078

0.082

494 (41.8%)

0.028

88 (7.5%)

2201
(46.8%)
2052
(43.7%)
447 (9.5%)

BMI, mean (SD)

31.4 (8.8)

0.023

30.5 (8.5)

30.4 (8.1)

0.006

SMD

Demographics
Age, years, mean
(SD)
Female sex
Race
White
Black

0.038
0.069

Hospital admission characteristics
Center
CCH

53 (1.2%)

127 (0.7%)

0.062

14 (1.2%)

27 (0.6%)

0.073

HUP

2143
(50.4%)
844 (19.9%)

0.066

540 (45.7%)

0.102

310 (26.2%)

0.012

317 (26.8%)

0.157

699 (59.2%)

2009
(42.7%)
1137
(24.2%)
1527
(32.5%)
3201
(68.1%)

0.060

1210
(28.5%)
2331
(54.8%)

8299
(47.1%)
4266
(24.2%)
4918
(27.9%)
11001
(62.5%)

1560
(36.7%)
253 (6.0%)

4905
(27.9%)
1526 (8.7%)

0.197

424 (35.9%)

0.191

0.100

78 (6.6%)

1283
(27.3%)
277 (5.9%)

1043
(24.5%)
1188
(28.0%)
206 (4.8%)

4462
(25.3%)
5488
(31.2%)
1229 (7.0%)

0.018

341 (28.9%)

0.032

0.070

274 (23.2%)

0.078

64 (5.4%)

1291
(27.5%)
1239
(26.4%)
610 (13.0%)

3.0 (4.8)

3.1 (4.6)

0.003

3.3 (5.6)

2.6 (3.8)

0.155

511 (12.0%)

2955
(16.8%)

0.129

201 (17.0%)

851 (18.1%)

0.029

3306
(77.8%)
81 (1.9%)

13110
(74.4%)
275 (1.6%)

0.076

810 (68.6%)

0.034

0.026

31 (2.6%)

3294
(70.1%)
130 (2.8%)

PAH
PMC
Surgical
Admission
Location of initial
presentation
ED
ICU
OR
Floor
Other
LOS prior to
index, days,
mean (SD)
ICU care at index
date
Peri-operative
recency
Not peri-op
POD zero

89

0.048
0.125
0.184

0.026

0.069
0.277

0.010

POD one

461 (10.8%)

0.028

207 (17.5%)

754 (16.0%)

0.044

251 (5.9%)

2073
(11.8%)
1586 (9.0%)

POD two

0.110

77 (6.5%)

378 (8.0%)

0.054

POD three

151 (3.6%)

566 (3.2%)

0.019

56 (4.7%)

144 (3.1%)

0.094

Mechanical
ventilation

105 (2.5%)

576 (3.3%)

0.042

59 (5.0%)

296 (6.3%)

0.069

Heart failure

1031
(24.3%)
603 (14.2%)

5738
(32.6%)
3301
(18.7%)
15476
(87.9%)
4090
(23.2%)
3752
(21.3%)
3431
(19.5%)
1892
(10.7%)
3174
(18.0%)
2024
(11.5%)

0.187

122 (10.3%)

691 (14.7%)

0.098

0.124

111 (9.4%)

464 (9.9%)

0.013

0.016

4346
(92.5%)
787 (16.7%)

0.073

0.100

1065
(90.2%)
175 (14.8%)

0.149

109 (9.2%)

598 (12.7%)

0.090

0.121

106 (9.0%)

556 (11.8%)

0.076

0.029

97 (8.2%)

511 (10.9%)

0.087

0.196

105 (8.9%)

799 (17.0%)

0.219

0.095

59 (5.0%)

311 (6.6%)

0.054

1222
(28.8%)

5233
(29.7%)

0.021

345 (29.2%)

1194
(25.4%)

0.084

215 (5.1%)

843 (4.8%)

0.012

60 (5.1%)

284 (6.0%)

0.044

2749
(64.7%)
1201
(28.3%)
300 (7.1%)

10559
(60.0%)
5374
(30.5%)
1677 (9.5%)

0.098

917 (77.6%)

0.111

0.050

212 (18.0%)

3399
(72.3%)
969 (20.6%)

0.087

52 (4.4%)

332 (7.1%)

0.094

Chronic kidney
disease
Weight loss

275 (6.5%)

0.210

84 (7.1%)

801 (17.0%)

0.298

270 (6.4%)

2375
(13.5%)
1121 (6.4%)

0.001

93 (7.9%)

376 (8.0%)

0.005

Fluid and
electrolyte
disorder
Cancer

1067
(25.1%)

4700
(26.7%)

0.036

326 (27.6%)

1379
(29.3%)

0.039

939 (79.5%)

0.087

0.002

157 (13.3%)

3580
(76.2%)
748 (15.9%)

Metastatic

207 (4.9%)

14717
(83.6%)
1983
(11.3%)
910 (5.2%)

0.006

Non-metastatic

3562
(83.8%)
481 (11.3%)

0.013

85 (7.2%)

372 (7.9%)

0.031

2736
(15.5%)

0.005

140 (11.9%)

620 (13.2%)

0.037

Comorbidities

Myocardial
infarction
Hypertension
Cardiac
arrhythmias
Atrial fibrillation

3756
(88.4%)
814 (19.2%)
660 (15.5%)

Valvular disease

635 (14.9%)

Stroke

419 (9.9%)

Peripheral
vascular disease
Pulmonary
circulation
disorder
Chronic
pulmonary
disease
Liver disease

458 (10.8%)
367 (8.6%)

0.047

Diabetes mellitus
None
Noncomplicated
Complicated

None

Obstructive sleep
apnea

653 (15.4%)
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0.059

0.080

HIV/AIDS

66 (1.6%)

241 (1.4%)

0.016

18 (1.5%)

61 (1.3%)

0.019

82.3 (23.2)

72.6 (24.5)

0.422

458 (9.7%)

0.019

Kidney function
GFR, ml/min/1.73
m2, mean (SD)
Prior acute
kidney injury

78.8 (22.2)

WBC, x 108
cells/L
Hemoglobin, g/dL

9.7 (3.9)

9.8 (3.9)

0.019

10.3 (4.2)

10.2 (4.2)

0.028

11.4 (2.0)

11.1 (2.0)

0.177

11.2 (1.9)

10.9 (1.9)

0.147

Platelets, x 1011
cells/L
Chloride, mEq/L

242.5 (96.7)

234.8 (99.6)

0.077

235.2 (99.2)

0.111

103.7 (4.5)

103.5 (4.7)

0.045

246.3
(108.9)
104.0 (4.5)

104.1 (4.6)

0.030

Potassium,
mEq/L

4.1 (0.5)

4.1 (0.5)

0.086

4.0 (0.5)

4.1 (0.5)

0.096

0.010

375 (8.8%)

72.1 (22.5)

0.294

1929
0.070 122 (10.3%)
(11.0%)
Laboratory values, mean (SD)

Medications
Selective beta1blockers
Combined alpha
+ beta blockers
Loop diuretics
Thiazide diuretics

1093
(25.7%)
806 (19.0%)

Hydralazine

301 (7.1%)

7456
(42.3%)
2828
(16.1%)
5659
(32.1%)
2914
(16.5%)
1712 (9.7%)

Other
antihypertensives
Acid
suppressants
None

341 (8.0%)

1679 (9.5%)

0.053

84 (7.1%)

363 (7.7%)

0.021

1715
(40.4%)
947 (22.3%)

0.022

477 (40.4%)

0.007

0.053

289 (24.5%)

0.026

415 (35.1%)

0.004

149 (12.6%)

1914
(40.7%)
1126
(24.0%)
1660
(35.3%)
627 (13.3%)

0.126

498 (42.2%)

0.120

243 (20.6%)

0.046

24 (2.0%)

2197
(46.7%)
1384
(29.4%)
141 (3.0%)

0.093

95 (2.2%)

6919
(39.3%)
4327
(24.6%)
6364
(36.1%)
2109
(12.0%)
7064
(40.1%)
3940
(22.4%)
528 (3.0%)

126 (3.0%)

568 (3.2%)

0.015

58 (4.9%)

171 (3.6%)

0.071

62 (1.5%)

346 (2.0%)

0.035

22 (1.9%)

161 (3.4%)

0.108

125 (2.9%)

769 (4.4%)

0.070

77 (6.5%)

217 (4.6%)

0.094

H2RA
PPI
Broad spectrum
antibiotics
Narrow spectrum
antibiotics
Vancomycin
Sulfamethoxazole
/ Trimethoprim
Other nephrotoxic
antibiotics
Other
nephrotoxins
Vasopressors

1644
(38.7%)
482 (11.3%)

1588
(37.4%)
504 (11.9%)
1442
(33.9%)
738 (17.4%)

0.074

444 (37.6%)

0.135

90 (7.6%)

1791
(38.1%)
524 (11.1%)

0.143

225 (19.1%)

813 (17.3%)

0.039

0.067

126 (10.7%)

437 (9.3%)

0.038

0.090

109 (9.2%)

484 (10.3%)

0.037

0.101

0.012
0.004
0.022

0.212
0.058

NR- NSAID+RAS inhibitor group; NC- NSAID + calcium channel blocker (amlodipine) group;
OXR- oxycodone + RAS inhibitor group; OXC- oxycodone + calcium channel blocker (amlodipine)
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group; IQR- interquartile range; SMD-standardized mean difference; SD- standard deviation;
BMI- body mass index; CCH- Chester County Hospital; HUP- Hospital of the University of
Pennsylvania; PMC- Presbyterian Medical Center; PAH- Pennsylvania Hospital; ED- emergency
department; ICU- intensive care unit; OR- operating room; LOS- length of stay; PODpostoperative day; AIDS- acquired immunodeficiency syndrome; HIV- human immunodeficiency
virus; GFR- glomerular filtration rate; WBC- white blood cells; H2RA-histamine-2 receptor
antagonist; PPI- proton pump inhibitor
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Table 5.4. Baseline characteristics in the weighted population
NR
(n=4250)

OXR
(n=17610)

SMD

NC
(n=1181)

OXC
(n=4700)

SMD

Demographics
Age, years, mean
(SD)
Female sex

62.8

63.2

0.030

63.6

63.9

0.019

48.7

47.1

0.032

50.5

48.9

0.030

White

54.3

54.0

0.006

52.8

52.0

0.016

Black

36.1

36.2

0.002

39.0

38.6

0.008

Other / Unk

9.6

9.8

0.006

8.2

9.4

0.040

BMI, mean (SD)

31.2

31.1

0.006

30.6

31.2

0.070

Race

Hospital admission characteristics
Center
CCH

0.8

0.8

0.004

0.8

0.5

0.032

HUP

46.1

47.1

0.021

45.5

46.2

0.015

PAH

24.0

23.8

0.005

24.7

26.1

0.033

PMC

29.1

28.3

0.017

29.1

27.2

0.042

Surgical Admission

61.1

61.9

0.017

62.4

62.0

0.008

Location of initial
presentation
ED

30.8

29.5

0.028

32.1

29.2

0.064

ICU

8.0

7.8

0.009

6.6

7.0

0.016

OR

26.1

25.7

0.010

27.4

27.1

0.008

Floor

29.0

29.8

0.018

27.9

29.0

0.024

Other

6.1

7.3

0.042

6.0

7.6

0.061

LOS prior to index,
days, mean (SD)
ICU care at index date

3.0

3.0

0.001

2.8

2.9

0.013

15.6

16.4

0.020

16.1

16.0

0.001

Peri-operative
recency
Not peri-op

74.7

74.0

0.016

71.3

72.2

0.020

POD zero

2.0

1.8

0.017

2.0

1.8

0.013

POD one

12.3

12.6

0.010

14.6

13.2

0.040

POD two

7.7

8.4

0.024

8.1

9.4

0.047

POD three

3.3

3.2

0.005

4.0

3.4

0.039

2.8

3.5

0.040

4.2

3.7

0.024

Mechanical ventilation

Comorbidities
Heart failure

26.8

27.7

0.021

21.6

22.9

0.030

Myocardial infarction

15.6

16.5

0.024

12.5

14.0

0.040
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Hypertension

89.2

88.8

0.016

92.0

91.2

0.027

Cardiac arrhythmias

20.8

21.3

0.014

17.0

17.4

0.009

Atrial fibrillation

18.0

18.7

0.019

15.2

15.6

0.009

Valvular disease

17.0

17.3

0.007

15.3

15.7

0.012

Stroke

10.2

10.6

0.012

9.3

11.4

0.067

Peripheral vascular
disease
Pulmonary circulation
disorder
Chronic pulmonary
disease
Liver disease

15.6

16.6

0.027

13.5

16.9

0.092

9.7

10.1

0.013

8.4

8.0

0.013

29.4

28.7

0.016

29.0

27.7

0.029

4.9

4.9

0.003

4.4

5.2

0.034

None

63.7

63.0

0.015

66.7

65.6

0.023

Non-complicated

28.4

28.3

0.000

26.1

26.4

0.007

Diabetes mellitus

Complicated

8.0

8.7

0.026

7.2

8.0

0.028

Chronic kidney
disease
Weight loss

10.9

12.8

0.056

12.9

12.4

0.013

6.5

6.5

0.002

6.7

6.9

0.008

Fluid and electrolyte
disorder
Cancer

26.9

26.6

0.006

28.4

27.2

0.027

None

82.6

82.3

0.007

80.7

81.6

0.023

Non-metastatic

12.0

12.0

0.000

13.3

12.6

0.024

Metastatic

5.4

5.7

0.012

6.0

5.9

0.004

15.1

14.9

0.008

11.6

14.3

0.074

1.2

1.4

0.013

1.2

1.0

0.015

Obstructive sleep
apnea
HIV/AIDS

Kidney function
GFR, ml/min/1.73 m2,
mean (SD)
Prior acute kidney
injury

74.5

73.4

0.048

74.2

73.5

0.030

9.7

10.4

0.024

9.2

9.6

0.014

Laboratory values, mean (SD)
8

WBC, x 10 cells/L

9.8

9.8

0.010

9.8

10.0

0.029

Hemoglobin, g/dL

11.2

11.1

0.033

11.1

11.1

0.041

235.7

236.0

0.003

233.4

236.6

0.032

103.7

103.6

0.019

103.9

103.7

0.040

4.1

4.1

0.008

4.1

4.1

0.037
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Platelets, x 10
cells/L
Chloride, mEq/L
Potassium, mEq/L

Medications
Selective beta1blockers
Combined alpha +
beta blockers

40.9

41.2

0.006

43.6

41.4

0.046

13.3

14.4

0.030

10.6

11.2

0.018
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Loop diuretics

27.9

28.3

0.009

23.4

24.9

0.034

Thiazide diuretics

15.9

15.8

0.003

15.0

15.9

0.024

Hydralazine

7.9

9.6

0.058

9.6

10.5

0.031

Other
antihypertensives
Acid suppressants

7.7

8.9

0.040

8.1

8.7

0.020

None

39.5

39.6

0.002

38.5

38.2

0.006

H2RA

24.4

24.4

0.000

26.3

26.4

0.002

PPI

36.1

36.0

0.003

35.1

35.3

0.004

Broad spectrum
antibiotics
Narrow spectrum
antibiotics
Vancomycin

11.7

12.1

0.013

10.6

13.1

0.077

39.0

40.3

0.025

44.1

42.5

0.033

21.5

22.4

0.022

20.2

22.2

0.047

Sulfamethoxazole /
Trimethoprim
Other nephrotoxic
antibiotics
Other nephrotoxins

2.5

2.9

0.023

1.8

2.9

0.065

3.0

3.2

0.010

3.5

3.3

0.011

1.6

2.1

0.034

1.6

2.1

0.036

Vasopressors

3.5

4.2

0.034

4.2

4.1

0.004

NR- NSAID+RAS inhibitor group; NC- NSAID + calcium channel blocker (amlodipine) group;
OXR- oxycodone + RAS inhibitor group; OXC- oxycodone + calcium channel blocker (amlodipine)
group; IQR- interquartile range; SMD-standardized mean difference; SD- standard deviation;
BMI- body mass index; CCH- Chester County Hospital; HUP- Hospital of the University of
Pennsylvania; PMC- Presbyterian Medical Center; PAH- Pennsylvania Hospital; ED- emergency
department; ICU- intensive care unit; OR- operating room; LOS- length of stay; PODpostoperative day; AIDS- acquired immunodeficiency syndrome; HIV- human immunodeficiency
virus; GFR- glomerular filtration rate; WBC- white blood cells; H2RA-histamine-2 receptor
antagonist; PPI- proton pump inhibitor
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Table 5.5. Unadjusted associations between acute kidney injury and mortality

Any AKI
No
Yes
AKI stage
No AKI
Stage 1
Stage 2
Stage 3
Renal replacement therapy
No
Yes
AKI duration
No AKI
≤ 2 days
3-6 days
≥ 7 days

Mortality incidence (%)

Relative risk (95%CI)

70 / 25255 (0.45)
62 / 2486 (2.49)

ref.
8.9 (6.4, 12.6)

70 / 25255 (0.45)
30 / 2005 (1.5)
20 / 338 (5.92)
12 / 143 (8.39)

ref.
5.4 (3.5, 8.3)
21.3 (13.1, 34.7)
30.3 (16.8, 54.6

125 / 27715 (0.45)
7 / 26 (26.9)

ref.
59.7 (30.9, 115.1)

70 / 25255 (0.3)
18 / 1099 (1.6)
2 / 218 (0.9)
42 / 1169 (3.6)

ref.
5.9 (3.5, 9.9)
3.3 (0.8,13.4)
12.9 (8.9, 18.9)
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Table 5.6. Unadjusted Poisson regression estimates of acute kidney injury rates, main
effects and measures of interaction on multiplicative and additive scales
Oxycodone
ratea

NSAID
ratea

NSAID IRR within
BP strata (95% CI)

NSAID IRDa within
BP strata (95% CI)

Amlodipine

22.4

22.5

1.00 (0.79, 1.26)

0.1 (-5.1, 5.4)

RAS

26.0

25.5

0.98 (0.87, 1.10)

-0.5 (-3.5, 2.5)

RAS IRR within
pain strata
(95% CI)

1.16

1.13

Interaction measure,
multiplicative scale

(1.03, 1.29)

0.89, 1.43)

3.62

3.00

1.04, 6.19)

(-2.77, 8.43)

RAS IRDa within
pain strata
(95% CI)

0.97 (0.75, 1.26)
Interaction measure,
additive scale
-0.62 (-6.64, 5.39)

a. Acute kidney injury events / thousand person days; IRR- incidence rate ratio; IRD- incidence
rate difference; CI- confidence interval; BP- blood pressure group (RAS vs. amlodipine)

Table 5.7. Inverse probability of treatment weighted Poisson regression estimates of
acute kidney injury rates, main effects and measures of interaction on multiplicative and
additive scales
Oxycodone
ratea

NSAID
ratea

NSAID IRR within
BP strata (95% CI)

NSAID IRDa within
BP strata (95% CI)

Amlodipine

20.6

24.7

1.19 (0.89, 1.62)

4.1 (-3.1, 11.3)

RAS

23.5

29.4

1.25 (1.09, 1.44)

5.9 (1.9, 9.8)

RAS IRR within
pain strata
(95% CI)

1.14

1.18

Interaction measure,
multiplicative scale

(0.99, 1.31)

0.88, 1.60)

2.8

4.7

(-0.11, 5.78)

(-3.0, 12.3)

RAS IRDa within
pain strata
(95% CI)

1.04 (0.75, 1.45)
Interaction measure,
additive scale
1.8 (-6.4, 10.0)

a. Acute kidney injury events / thousand person days; IRR- incidence rate ratio; IRD- incidence
rate difference; CI- confidence interval; BP- blood pressure group (RAS vs. amlodipine)
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Table 5.8. Main effects estimates of the exposures of interest
IRR (95% CI)

IRDa (95% CI)

IPTW Poisson regression

1.23 (1.06, 1.42)

5.08 (1.17, 8.98)

Multivariable Poisson regression

1.23 (1.11, 1.37)

5.59 (2.51, 8.66)

IPTW Poisson regression

1.16 (0.99, 1.36)

3.63 (-0.09, 7.35)

Multivariable Poisson regression

1.09 (0.98, 1.22)

2.27 (-0.23, 4.77)

Exposure
NSAID

RAS inhibitors

a. Acute kidney injury events / thousand person days; IRR- incidence rate ratio; IRD- incidence
rate difference; CI- confidence interval; IPTW-inverse probability of treatment weighting
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Table 5.9. Inverse probability of treatment weighted multinomial logistic regression
model for acute kidney injury severity stage
Model

Odds ratio (95% CI)

Stage 1

Interaction estimate

1.13 (0.77, 1.65)

Stratified NSAID effect estimates
RAS group

1.13 (0.96, 1.33)

Amlodipine group

1.01 (0.71, 1.42)

Stratified RAS effect estimates
NSAID group

1.19 (0.84, 1.69)

Oxycodone group

1.06 (0.90, 1.24)

Stage 2

Interaction estimate

0.84 (0.32, 2.23)

Stratified NSAID effect estimates
RAS group

0.95 (0.66, 1.35)

Amlodipine group

1.13 (0.45, 2.79)

Stratified RAS effect estimates
NSAID group

1.40 (0.57, 3.44)

Oxycodone group

1.67 (1.12, 2.48)
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Stage 3

Interaction estimate

0.46 (0.13, 1.66)

Stratified NSAID effect estimates
RAS group

0.93 (0.46, 1.89)

Amlodipine group

2.00 (0.69, 5.75)

Stratified RAS effect estimates
NSAID group

0.86 (0.29, 2.57)

Oxycodone group

1.85 (1.03, 3.31)

Estimates derived from IPT weighted multinomial logistic regression model. The odds
ratios reported for each stage represent the effect of exposure on the odds of being in
the specified stage versus the reference outcome, which is specified as the group
without acute kidney injury of any stage. The omnibus test for significance of the
interaction between pain group (NSAID vs. oxycodone) and antihypertensive group
(RAS vs. amlodipine) across all severity stages was not significant (Wald test, p=0.586).
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Table 5.10. Inverse probability of treatment weighted multinomial logistic regression
model for acute kidney injury duration category
Model

Odds ratio (95% CI)

Stage 1

Interaction estimate

1.17 (0.72, 1.86)

Stratified NSAID effect estimates
RAS group

0.92 (0.75, 1.13)

Amlodipine group

0.79 (0.52, 1.20)

Stratified RAS effect estimates
NSAID group

1.23 (0.81, 1.88)

Oxycodone group

1.05 (0.86, 1.29)

Stage 2

Interaction estimate

1.00 (0.39, 2.55)

Stratified NSAID effect estimates
RAS group

1.16 (0.84, 1.59)

Amlodipine group

1.16 (0.48, 2.76)

Stratified RAS effect estimates
NSAID group

1.43 (0.61, 3.34)

Oxycodone group

1.43 (0.98, 2.06)
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Stage 3

Interaction estimate

0.91 (0.53, 1.57)

Stratified NSAID effect estimates
RAS group

1.28 (1.00, 1.63)

Amlodipine group

1.40 (0.86, 2.26)

Stratified RAS effect estimates
NSAID group

1.08 (0.66, 1.75)

Oxycodone group

1.18 (0.93, 1.50)

Estimates derived from an IPT weighted multinomial logistic regression model. The odds
ratios reported for each stage represent the effect of exposure on the odds of being in
the specified duration category versus the reference outcome, which is specified as the
group without acute kidney injury of any duration. The omnibus test for significance of
the interaction between pain group (NSAID vs. oxycodone) and antihypertensive group
(RAS vs. amlodipine) across all duration categories was not significant (wald test,
p=0.909).

102

Table 5.11. Multivariable adjusted Poisson regression estimates of acute kidney injury
rates, main effects and measures of interaction on multiplicative and additive scales
Oxycodone
ratea

NSAID
ratea

NSAID IRR within
BP strata (95% CI)

NSAID IRDa within
BP strata (95% CI)

Amlodipine

22.0

27.9

1.26 (0.99, 1.60)

5.8 (-0.5, 12.2)

RAS

24.4

29.9

1.22 (1.09, 1.38)

5.5 (2.1, 8.9)

RAS IRR within
pain strata
(95% CI)

1.10

1.07

Interaction measure,
multiplicative scale

(0.98, 1.24)

0.85, 1.36)

2.31

2.03

(-0.33, 4.95)

(-4.68, 8.74)

RAS IRDa within
pain strata
(95% CI)

0.97 (0.75, 1.26)
Interaction measure,
additive scale
-0.3 (-7.4, 6.9)

a. Acute kidney injury events / thousand person days; IRR- incidence rate ratio; IRDincidence rate difference; CI- confidence interval; BP- blood pressure group (RAS vs.
amlodipine)
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Table 5.12. Multivariable adjusted multinomial logistic regression model for acute kidney
injury severity stage
Model

Odds ratio (95% CI)

Stage 1

Interaction estimate

0.98 (0.72, 1.33)

Stratified NSAID effect estimates
RAS group

1.15 (0.99, 1.32)

Amlodipine group

1.17 (0.88, 1.53)

Stratified RAS effect estimates
NSAID group

1.03 (0.78, 1.36)

Oxycodone group

1.05 (0.91, 1.20)

Stage 2

Interaction estimate

0.70 (0.33, 1.48)

Stratified NSAID effect estimates
RAS group

0.85 (0.61, 1.17)

Amlodipine group

1.21 (0.61, 2.38)

Stratified RAS effect estimates
NSAID group

1.05 (0.53, 2.05)

Oxycodone group

1.49 (1.05, 2.12)
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Stage 3

Interaction estimate

0.37 (0.12, 1.12)

Stratified NSAID effect estimates
RAS group

0.77 (0.44, 1.36)

Amlodipine group

2.06 (0.79, 5.33)

Stratified RAS effect estimates
NSAID group

0.69 (0.27, 1.84)

Oxycodone group

1.86 (1.09, 3.16)

Estimates derived from multivariable adjusted multinomial logistic regression model. The
odds ratios reported for each stage represent the effect of exposure on the odds of being
in the specified stage versus the reference outcome, which is specified as the group
without acute kidney injury of any stage. The omnibus test for significance of the
interaction between pain group (NSAID vs. oxycodone) and antihypertensive group
(RAS vs. amlodipine) across all severity stages was not significant (likelihood ratio test,
p=0.306).
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Table 5.13. Multivariable adjusted multinomial logistic regression model for acute kidney
injury duration category
Model

Odds ratio (95% CI)

Stage 1

Interaction estimate

0.84 (0.56, 1.25)

Stratified NSAID effect estimates
RAS group

1.00 (0.83, 1.21)

Amlodipine group

1.19 (0.84, 1.71)

Stratified RAS effect estimates
NSAID group

0.87 (0.61, 1.25)

Oxycodone group

1.04 (0.87, 1.23)

Stage 2

Interaction estimate

1.18 (0.54, 2.55)

Stratified NSAID effect estimates
RAS group

1.18 (0.88, 1.59)

Amlodipine group

1.00 (0.48, 2.06)

Stratified RAS effect estimates
NSAID group

1.64 (0.80, 3.36)

Oxycodone group

1.39 (1.01, 1.91)

106

Stage 3

Interaction estimate

0.89 (0.59, 1.36)

Stratified NSAID effect estimates
RAS group

1.12 (0.93, 1.35)

Amlodipine group

1.25 (0.86, 1.83)

Stratified RAS effect estimates
NSAID group

1.04 (0.72, 1.84)

Oxycodone group

1.16 (0.95, 1.51)

Estimates derived from multivariable adjusted multinomial logistic regression model. The
odds ratios reported for each stage represent the effect of exposure on the odds of being
in the specified duration category versus the reference outcome, which is specified as
the group without acute kidney injury of any duration. The omnibus test for significance
of the interaction between pain group (NSAID vs. oxycodone) and antihypertensive
group (RAS vs. amlodipine) across all duration categories was not significant (likelihood
ratio test, p=0.764).
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Table 5.14. Inverse probability of treatment weighted Poisson regression estimates of
acute kidney injury rates, main effects and measures of interaction on multiplicative and
additive scales in patients exposed to at least three days of concomitant drug exposure
Oxycodone
ratea

NSAID
ratea

NSAID IRR within
BP strata (95% CI)

NSAID IRDa within
BP strata (95% CI)

Amlodipine

22.0

21.4

0.97 (0.65, 1.46)

-0.6 (-9.3, 8.1)

RAS

21.7

25.9

1.19 (0.98, 1.44)

4.2 (-0.8, 9.1)

RAS IRR within
pain strata
(95% CI)

0.98

1.21

Interaction measure,
multiplicative scale

(0.84, 1.16)

0.79, 1.84)

-0.3

4.5

(-3.9, 3.3)

(-4.9, 13.9)

RAS IRDa within
pain strata
(95% CI)

1.22 (0.78, 1.91)
Interaction measure,
additive scale
4.8 (-5.2, 14.7)

a. Acute kidney injury events / thousand person days; IRR- incidence rate ratio; IRDincidence rate difference; CI- confidence interval; BP- blood pressure group (RAS vs.
amlodipine)
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Figure 5.1. Patient selection

Adult patients with > 24 hours of exposure to drug pairs of interest
n=61360 courses in 43201 patients

Exclusions
n (courses)
• ESRD / Creat>2
5029
• Baseline AKI
2184
• Platelets < 100
3087
• No baseline creatinine
1055
• No follow-up creatinine
3998
• Pregnancy
1979
• Solid organ transplant
315
• Other missing data
724

Eligible courses
n=42989 courses in 27741 patients
First eligible course per patient
n=15248 repeat courses dropped

NSAID + RAS
n=4250

NSAID + CCB
n=1181

Oxy + RAS
n=17610
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Oxy + CCB
n=4700

Figure 5.2. Standardized differences

RAS vs.
Amlodipine

NSAID exposed

RAS vs.
Amlodipine

NSAID vs.
oxycodone

Oxycodone exposed

RAS exposed

NSAID vs.
oxycodone

Amlodipine exposed

Each panel shows the summary of absolute standardized mean differences (SMD)
before and after inverse probability of treatment weighting.
39
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Figure 5.3. Predicted acute kidney injury stage by treatment group

Predicted AKI Stage Stratified by DDI-Group
100.00
90.00
80.00

Percent

70.00
60.00
50.00
40.00
30.00

NSAID
Oxycodone

20.00
10.00
0.00

7.69 6.84 6.56 6.56

RAS

CCB

Stage 1

1.16 1.24 0.85 0.75

0.53 0.58 0.63 0.32

RAS

RAS

CCB

Stage 2

CCB

Stage 3

The figure depicts the predicted distribution of acute kidney injury severity across strata
of analgesia and antihypertensive exposure groups. Estimates are derived from IPT
weighted multinomial logistic regression model. The omnibus test for significance of the
interaction between pain group (NSAID vs. oxycodone) and antihypertensive group
(RAS vs. amlodipine) across all severity stages was not significant (Wald test, p=0.586).
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Figure 5.4. Predicted acute kidney injury duration by treatment group

Predicted AKI Duration Stratified by DDI-Group
100.00
90.00
80.00

Percent

70.00
60.00
50.00
40.00
30.00

NSAID
Oxycodone

20.00
10.00
0.00

3.68 4.03 3.04 3.86

RAS

CCB

Short

1.58 1.38 1.13 0.99

4.11 3.25 3.88 2.78

RAS

RAS

CCB

Medium

CCB

Long

The figure depicts the predicted distribution of acute kidney injury duration across strata
of analgesia and antihypertensive exposure groups. Estimates are derived from IPT
weighted multinomial logistic regression model. The omnibus test for significance of the
interaction between pain group (NSAID vs. oxycodone) and antihypertensive group
(RAS vs. amlodipine) across all severity stages was not significant (Wald test, p=0.909).
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Figure 5.5. Distribution of estimated glomerular filtration rate change at hospital
discharge

Distribution of GFR change at hospital discharge
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CHAPTER 6: EFFECT OF KIDNEY DISEASE ON THE INTERACTION OF COMBINED
AMIODARONE AND WARFARIN EXPOSURE

Introduction
Although a primary goal of DDI pharmacoepidemiology is to determine which
potential DDIs represent truly harmful DDIs, quantification of adverse effects at the
population level is often insufficient because of substantial interindividual variability in
DDI response.32,95 Indeed, most patients tolerate drug combinations that are known to
cause harm.32 The unpredictability of DDI associated adverse events confounds
treatment decisions, leading to unnecessary avoidance of potentially beneficial
combinations in many patients, while also resulting in harmful combinations being
prescribed to those susceptible to adverse effects.20 Elucidation of the sources of DDI
heterogeneity is thus a clinical imperative.
Kidney disease may be an underappreciated source of DDI variability, due to
changes in CYP enzyme expression and drug protein binding that occur as kidney
disease progresses. Recent evidence has shown that renal impairment directly
suppresses hepatic and intestinal CYP P450 activity via reduced CYP enzyme
expression and potential direct inhibitory effects of uremia on specific CYP
enzymes.105,164 Pharmacokinetic theory predicts that CYP enzyme suppression will
reduce the severity of CYP inhibition DDIs, because there is less active enzyme to be
inhibited.97
In contrast, kidney disease mediated reductions in protein binding may increase DDI
severity. Protein binding sequesters drug from the liver,105,164 which has a rate-limiting
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effect on the hepatic clearance of highly protein bound drugs. Reduction in protein
binding increase the amount of drug available to the liver for metabolism, which would
be expected to increase the effect of a CYP inhibition DDI. Given these potentially
counteracting effects of kidney disease on DDI pharmacology, the net effect of kidney
disease on the severity of a CYP-inhibition DDIs is unclear.
Warfarin is an oral vitamin-k antagonist that has been a cornerstone of long-term
anticoagulation regimens for over 50 years.2 Prior evidence suggests that warfarin
metabolism is suppressed by renal impairment: CYP2C9 activity is downregulated in
renal impairment;35,142,165 several clinical studies show significantly reduced dosage
requirements in patients with renal impairment;92,93,74 and increased rates of
supratherapeutic anticoagulation and bleeding have been documented as renal function
worsens.80,92,110 Amiodarone is a potent inhibitor of CYP 2C9 metabolism, the
predominant clearance mechanism for warfarin.60,100,108 Concomitant exposure to this
drug combination can result in exaggerated INR response and the need for reduced
dosages to avoid supratherapeutic exposure. 60,100,108 Although the DDI between warfarin
and amiodarone is well established, the magnitude can vary substantially among
patients, 60,108 and the mechanisms of heterogeneity are poorly understood. The
objective of this study was to determine whether kidney disease alters the effect of
amiodarone on warfarin dose response. We hypothesized that the magnitude of
amiodarone’s effect will vary significantly across levels of baseline renal function.
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Methods
Overview of study design
We conducted a retrospective cohort study of hospitalized patients with atrial
fibrillation that compared the INR response during concomitant warfarin and amiodarone
exposure vs. control patients exposed to warfarin and an active comparator. Within this
cohort, we examined how the difference in INR response between the two groups varied
across levels of renal function. Metoprolol, a β1 receptor selective beta-blocker, was
chosen as the active comparator for amiodarone exposure because it is one of the most
commonly used drugs for rate control in patients with atrial fibrillation163 and it does not
exhibit any pharmacokinetic interaction with warfarin.
Warfarin cohort entry criteria
The study population was sampled from the population of patients admitted to
one of three hospitals within the University of Pennsylvania Health System (UPHS) from
January 1, 2004 – June 30, 2017. The base cohort of warfarin person time included
patients who were age > 18 years at the time of admission and had a past medical
history of atrial fibrillation. The rationale for limiting the population to patients with atrial
fibrillation was to enrich the population with patients that have a similar indication for
treatment with warfarin and the precipitant drugs of interest.
Drug-drug interaction cohort entry criteria and follow-up
Within the source population of warfarin person-time, we identified patients who
received ≥ 24 hours of exposure to either amiodarone or metoprolol with at least one
follow-up INR measurement that was obtained ≥ three days after cohort entry. This
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minimum follow-up requirement was to ensure that all patients had a measure of
warfarin response that was obtained at a time that accounts for the delayed effects of
warfarin on the INR.44,45,149 The minimum duration of concomitant exposure of 24 hours
was chosen to avoid potential immortal time bias, which could result from missing early
supratherapeutic INR responses that lead to warfarin discontinuation. Although the full
response to a warfarin dose is not observed until two to four days after administration,149
early response (e.g. within 24 hours) is possible, resulting from changes in vitamin-K
dependent clotting factors with short half-lives (namely, Factor VII). Rapid changes in
INR after initial doses are most likely observed when the initial dose is
supratherapeutic.45 Thus, these short courses are of particular interest when assessing
the effects of a CYP-enzyme inhibition DDI mechanism.
Exclusion criteria were a past medical history of solid organ transplant; baseline
exposure to an intravenous direct thrombin inhibitor (argatroban, bivalirudin, lepirudin),
because these drugs have effects on INR measurement; lack of a baseline INR within 72
hours of cohort entry, or other missing baseline data.
In the primary analysis of the dose-corrected INR response, follow up began on
the third day after the first dose of concomitant exposure (i.e. the index date) and
continued until one of the following: lapse in concomitant exposure of more than three
days, hospital discharge, death, or when 10 days had elapsed from index date. The
rationale for censoring follow-up at 10 days was that pilot data suggested that the
majority of patients are discharged within 10 days of the index date; and, 10 days allows
sufficient time for warfarin to achieve an approximate steady state after precipitant
initiation. In the secondary analysis that examined the occurrence of supratherapeutic
INR values, follow-up began on the day after the index date, to capture early
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supratherapeutic values as described above. In patients with multiple courses, only the
first course meeting study criteria was included.
Outcomes
The primary outcome was the warfarin sensitivity index (WSI), a dose-normalized
INR measure that has been used in prior warfarin dose response studies.54,69,118 WSI
values were defined beginning with the third day of observation after the index date. The
measure is a ratio of INR and warfarin dose history. Specifically, for each day of
observation di, warfarin dose history (DHi) was defined as the average of warfarin doses
administered on days di-4 to di-2 (i.e., the time period from four days before to 2 days
before the observation day). For day three (the initial day of follow-up), the measure was
defined as the average of the two doses given on days di-3 and di-2 . With dose history so
defined, the WSIi was calculated for each day of observation as follows:
WSIi = INRi / DHi
The rationale for normalizing the INR with the average warfarin dose over a three-day
period is to account for the delayed effects of warfarin on INR.44,45,149
The secondary outcome was the occurrence of supratherapeutic INR values,
defined as an INR ³ 4. This value was chosen because it is above any INR value
currently targeted for any warfarin indication; and it has been shown to represent a
clinically important threshold of anticoagulation intensity-- major hemorrhage rates
(including intracranial hemorrhage) increase exponentially at values above this
threshold.40,73
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Data Collection
All study data were obtained from the Penn Data Store (PDS), a data warehouse
that contains medications, laboratory values, demographics, procedures, and discharge
diagnosis data from all patients admitted to UPHS. PDS contains information on all
medication orders placed into the hospital’s computer physician order entry system,
including dose, frequency, route, and the dates and times of dosage administration.
Laboratory data within PDS includes the result values, date and time that the laboratory
tests were ordered, and the date and time of the result report.
Potential confounding variables were selected a priori based on clinical
knowledge and prior literature and included only those with biologically plausible
associations with warfarin dose response or severity of illness (demographics, hospital
admission characteristics, comorbidities, laboratory measures, and concomitant
medication exposures (Table 6.2). Comorbidities of interest were ascertained from
discharge diagnosis codes following the algorithms of Quan117 and Elixhauser.38 Preexposure AKI was defined by applying the Kidney Disease: Improving Global Outcomes
(KDIGO) criteria from hospital admission up to the time of exposure. Baseline creatinine
for the pre-exposure AKI assessment was defined as the average of prior outpatient and
/ or prior hospital discharge values available during the period from 365 days before to 7
days before the index hospitalization admission date. Where this data was missing, the
baseline value was defined as the lowest value available during the initial seven days of
hospitalization, up to the index date. Medications and laboratory data were assessed
during the 72-hour period prior to the index date. For each laboratory measure, the value
most proximate to cohort entry was collected. Baseline renal function was estimated
using the Cockcroft-Gault creatinine clearance equation,30 using the lesser of ideal body
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weight or total body weight in non-obese patients, adjusted bodyweight15,162 in obese
patients (body mass index >25), and lean body weight for morbidly obese patients
(BMI>40).162 To facilitate stratified propensity score matching, creatinine clearance
(CrCl) was categorized into five strata as follows: CrCl 0-30 ml/min, 31-60 ml/ min, 61-90
ml/min, 91-120 ml/min, and >120 ml/min. These categories were chosen a priori based
on prior literature to reflect groups with clinically meaningful differences in warfarin dose
response.
Data Analysis
Descriptive statistics
The distributions of baseline covariates were compared using standardized mean
differences (SMD).6 Absolute values of SMDs >0.1 were considered as evidence for
meaningful differences between groups. SMDs for characteristics of the amiodarone vs.
metoprolol groups were examined in the full cohort, and in the five CrCl strata previously
defined. Stratified examination of covariate balance was undertaken because the
primary contrast of interest involved the interaction between drug exposures and renal
function. The trends of WSI over time in each group and the rate of supratherapeutic
INR values were examined graphically.
Propensity score matching
We matched amiodarone patients to metoprolol patients who had similar
baseline characteristics using propensity scores. Propensity scores are defined as the
probability of receiving the study treatment (amiodarone) conditional on observed
baseline covariates.124 Propensity scores were estimated using logistic regression.
Amiodarone was the dependent variable, and the covariates listed in Table 6.2 were the
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independent variables. Amiodarone courses were matched 1:1 with metoprolol courses
using a greedy matching algorithm without replacement. The caliper width for matching
was set to 0.2 standard deviations of the logit of the PS.5 PS estimation and matching
was conducted separately in each of the five previously defined CrCl strata. We chose
this approach because the primary contrast of interest involved the interaction between
drug exposures and renal function, and covariate balance across the range of renal
function is required to obtain an unconfounded estimate.154,157 Stratification has been
shown to ensure optimal covariate balance within subgroups.157 We chose five strata of
renal function based on sample size considerations; and because stratifying on the
quintiles of a continuous confounding variable has been shown to eliminate
approximately 90% of the bias due to that variable.29
After matching, the exposure groups were re-examined for covariate balance in
in the full cohort and within renal function strata. If any covariates retained an absolute
SMD >0.1 after matching, the PS model was revised by including interaction and/or nonlinear terms and the matching procedure repeated. These steps continued until maximal
balance in the covariates was obtained, but before outcome was examined.
Primary outcome model
The change in WSI over time in the matched cohort was modeled with a mixed
effects linear regression model.41 Mixed-effects models account for the correlation
among repeated measures through the inclusion of random, subject specific variables.
To account for the expected curvilinear trend in WSI over time (as warfarin regimens
approach steady-state), time was modeled as a restricted cubic spline function, with four
knots chosen according to Harrell's recommended percentiles.57
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The primary contrast of interest was the interaction term between treatment
group (amiodarone vs. metoprolol) and baseline CrCl. Pilot data suggested a potential
non-linear relationship between CrCl and warfarin dose response, and was CrCl thus
modeled as a restricted cubic spline function with four knots chosen according to
Harrell's recommended percentiles.57 The fit of a model with the CrCl spline function was
compared to a simple linear model for CrCl using the Akaike Information Criterion (AIC),
which confirmed a better fit for the spline function as evidenced by a lower AIC value
(spline model: p<0.0001, AIC = 35882.59; linear model: p<0.0001, AIC 35927.64). We
allowed the slopes for exposure category and renal function categories to vary over time
by introducing interaction terms with time, resulting in a three-way interaction model. The
base model specification was as follows:
E(Yij) = β0 + β1(time) + β2(group) + β3(CrCl) + β4(group*CrCl) + β5(group*time) +
β6(CrCl*time) + β7(group*CrCl*time) + b1 + b2(t)
where i is the patient, j the patient group (amiodarone vs. metoprolol), b1 is a random
effects terms for patient, and b2 is a random slope term. Estimates for the
amiodarone+renal function interaction (i.e., the difference in amiodarone effects across
renal function strata) were obtained by contrasting the model predicted marginal mean
WSI estimates for amiodarone vs. metoprolol exposure obtained at various levels of
renal function, estimated at day seven of follow-up when the warfarin regimen
approximates steady-state.149 Significance of the interaction was tested by contrasting
models with and without the interaction term using a likelihood ratio test. WSI was logtransformed for modeling to account for moderate right-skewness of the distribution.
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Secondary outcome model
The rate of supratherapeutic INR (>4) values was modeled using Cox
proportional hazards regression. The primary contrast of interest was the interaction
term between baseline CrCl and treatment group (amiodarone vs. metoprolol). CrCl was
modeled as a restricted cubic spline function with four knots chosen according to
Harrell's recommended percentiles.57 The fit of a model with the CrCl spline function was
compared to a simple linear model for CrCl using the AIC, which confirmed a better fit for
the spline function as evidenced by a lower AIC value (spline model: p<0.0001, AIC =
14,414.18; linear model: p<0.0001, AIC 14,419.43). Significance of the interaction was
tested by contrasting models with and without the interaction term using a likelihood ratio
test. The proportional hazards assumption was evaluated by introducing interaction
terms between model covariates and time.
Results
The selection of patients into the study is depicted in figure 6.1. We identified
28,506 patients who had atrial fibrillation and received at least one warfarin dose as an
inpatient during the study period. From this population, 16,184 patients received
concomitant amiodarone or metoprolol and met all study criteria. The median duration of
exposure was 5 days in the amiodarone and 6 days in the metoprolol group, and
approximately 80% of all DDI courses began on the first day of warfarin treatment.
Characteristics of the unmatched population
The characteristics of the unmatched population is shown in table 6.2. The
average age of the cohort was 69 years, with a majority being male gender. Amiodarone
patients were more often surgical patients in the intensive care unit, with a longer
123

duration of stay prior to the index date. Amiodarone patients also more frequently had
heart failure and valvular disease, had lower baseline renal function, and were more
frequently receiving antibiotics and vasopressors.
Characteristics of the matched cohort
The distributions of propensity scores in the full cohort (Figure 6.2) and in each of
the CrCl strata (Figure 6.3) show sufficient overlap of the distributions in each treatment
group. Notably, the stratified propensity scores show decreasing overlap as CrCl
increases, suggesting that the balance of covariates in the unmatched population was
not constant across renal function levels. Propensity score matching resulted in 4518
matched pairs. The characteristics of the matched population are shown in Table 6.3,
and the distribution of SMD values in the overall matched cohort and in each CrCl strata
are shown in Figure 6.4. Baseline characteristics were well balanced in the full matched
cohort and in each of the CrCl strata. The frequency of follow-up INR measurements in
the matched cohort is shown in Table 6.4, which shows the two groups to have nearly
identical INR monitoring over time. In each group, the majority of patients had exited the
cohort by study day ten.
Analysis of warfarin sensitivity index
Log transformation resulted in an approximately normal distribution of WSI
values (Figure 6.5). The trends of WSI over time in metoprolol and amiodarone groups
and the corresponding model estimates are shown in Figure 6.6. As expected,
amiodarone exposure was associated with a significantly higher WSI throughout study
follow-up. Additionally, the model with restricted cubic spline terms for time successfully
reproduced the curvilinear trends in WSI over time. The trends of WSI in each strata of
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baseline CrCl is shown in Figure 6.7, which shows a substantial separation of WSI
trends across levels of renal function.
The trends of WSI in the amiodarone and metoprolol groups, stratified by baseline
renal function group, are shown in Figure 6.8. The figure is notable for a smaller
difference in trends between treatment groups in the lowest CrCl strata compared to
higher strata. In the mixed effects linear regression analysis, a significant interaction
between treatment group and renal function was observed (Table 6.5). The results show
that the effect of amiodarone increased with increasing levels of renal function in a nonlinear fashion, with the biggest changes in magnitude observed at lower levels of renal
function.
Analysis of supratherapeutic INR values
There were a total of 832 high INR values observed during 46,466 person-days
of follow-up (rate 17.9 / 1000 days). The rate of high INR stratified by treatment group
and renal function strata is shown in Figure 6.9. The results are notable for an increasing
rate as renal function declines, and a smaller increase in rate associated with
amiodarone exposure as renal function declines. Similar results were observed in the
cox proportional hazards analysis (Table 6.5) of the interaction between amiodarone
exposure and renal function, which showed an increasing hazard ratio for amiodarone
exposure as renal function increased. Figure 6.10 shows the predicted survival curve
estimates for amiodarone exposure at CrCl of 15 ml/min and 75 ml/min, showing no
apparent effect of amiodarone at low renal function, and a markedly stronger effect at
higher renal function.
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Discussion
Interindividual variability in the response to DDI exposure has long been
recognized as one of the most challenging aspects of DDI management. Drug pairs that
are known to interact may lead to minimal changes in drug exposure in some patients
but result in life-threatening increases in others. Understanding and quantifying the
sources of DDI variability could improve the management of DDI in individual patients,
while also improving the effectiveness of DDI alerting systems that are common in
electronic health records.
In this study, we hypothesized that kidney disease is a novel factor that leads to
variability in DDI response. We tested this hypothesis by determining whether the
magnitude of the well characterized DDI between warfarin and amiodarone varies
across levels of baseline renal function. Using a large propensity score matched cohort
of warfarin patients exposed to concomitant amiodarone or metoprolol, we confirmed
that amiodarone exposure has substantial effects on warfarin response: WSI, an indirect
measure of warfarin metabolism, was significantly higher during amiodarone exposure,
consistent with an inhibitory effect of amiodarone on warfarin’s metabolism; and, the risk
of experiencing a supratherapeutic level of anticoagulation was significantly higher
during amiodarone exposure. Our key finding, however, was that both of these effects
depend on the patient’s baseline renal function. Amiodarone’s effect on WSI varied
three-fold across the range of renal function observed in our study, increasing WSI by
11.8% in patients with severe kidney disease (CrCl 15 ml/min) and by 36% in patients
with normal renal function (CrCl 115 ml/min). Similar variability was observed in the
analysis of supratherapeutic INR values. Amiodarone exposure showed no apparent
association with supratherapeutic INR values in the setting of severe renal dysfunction.
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In contrast, amiodarone exposure was associated with an approximately 80% relative
increase in risk in patients with CrCl of 75 ml/min or higher.
In the analyses of both WSI and supratherapeutic INR values, the modifying
action of baseline renal function on amiodarone’s effect was non-linear: most of the
variability in amiodarone’s effect was observed in patients with severe kidney disease
(e.g. CrCl < 30 ml/min). This is consistent with the hypothesized mechanisms by which
kidney disease exerts its effects on hepatic metabolism. It is thought that CYP activity
suppression is mediated by the accumulation of uremic substances, which typically only
occurs in patients with stage 4 chronic kidney disease or end stage renal disease.105,164
We observed the effects of amiodarone on warfarin INR response to diminish as
renal function decreased, which suggests that the inhibitory effect of amiodarone on
warfarin’s metabolism decreases as baseline renal function decreases. This finding
could be explained by the known reductions in CYP2C9 activity in patients with kidney
disease.35,142,165 Variation of baseline CYP-enzyme activity has previously been
suggested to be source of variability in the effects of enzyme inhibition.95 Any given level
of CYP inhibition is expected to have stronger effects in patients with high baseline CYPenzyme activity and weaker effects in patients with low baseline CYP-enzyme activity.95
This phenomenon has been observed in studies of patients with CYP genetic
polymorphisms, the effects of enzyme inhibition were shown to be larger in patients with
an extensive metabolizer phenotype compared to those with a poor metabolizer
phenotype.90 For example, in a study of the interaction between quinidine and
venlafaxine, quinidine had no effect on venlafaxine exposure in poor metabolizers, but
led to an eight-fold increase in venlafaxine exposure in extensive metabolizers.90 Our
study is the first to show that similar variation in DDI magnitude might be caused by
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kidney disease, driven by differences in basal CYP-enzyme activity across levels of
renal function.
In addition to suppression of CYP-enzyme activity, kidney disease leads to
reductions in drug protein binding.130,134,160 Drug that is bound to plasma proteins is
sequestered from hepatic metabolism. Thus, reductions in drug protein binding will lead
to increases hepatic clearance, which should in turn increase the effect of any given
degree of CYP enzyme inhibition. This suggests that the suppressive effects of kidney
disease may be counterbalanced, at least in part, by the magnifying effects of protein
binding. If this were true, then the effects of kidney disease on DDI variability will depend
on the degree of protein binding exhibited by the drugs in question. Since both warfarin
and amiodarone are highly protein bound, we hypothesize that the observed reductions
in amiodarone’s inhibitory effect across levels of renal function may have been mitigated
by the magnifying effects of reduced protein binding. Moreover, we hypothesize that
DDIs involving drugs that have lower degrees of protein binding will exhibit larger
decrements in DDI magnitude as renal function decreases, as the suppressive effects of
kidney disease CYP activity should not be counterbalanced by the magnifying effects of
reduced protein binding.
Our study has a number of limitations. First, the nonrandomized cohort design is
susceptible to residual confounding. We minimized bias from confounding by comparing
amiodarone with a negative control (metoprolol) that is given for the same indication.62,97
In addition, we measured an extensive set of baseline covariates and controlled for them
via stratified propensity score matching to ensure an unconfounded assessment of the
interaction. Second, the results of this study may not generalize to other DDIs involving
drugs with different pharmacokinetic properties (e.g. lower degrees of protein binding,
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partial renal elimination, low hepatic extraction). Additional studies of DDIs that represent
common PK profiles are warranted to better understand the range of effects of DDI
pharmacology. Third, our results stem from a population of patients receiving warfarin
during a hospitalization, which may not be generalizable to outpatient settings. In
particular, the risk of supratherapeutic anticoagulation may differ substantially across
inpatient vs. outpatient population, due to differences in monitoring (e.g. daily INR
measurements during hospitalization vs. weekly measurements in outpatient setting).
Lastly, although the results of this study are consistent with our hypothesized
mechanisms, we did not examine mechanisms directly. The observed variations in the
magnitude of amiodarone’s effect on warfarin response may not be due to kidney
disease, but instead be due to other unmeasured factors that are correlated with kidney
disease, such as inflammation. However, regardless of the specific mechanism, the
observed variation of amiodarone’s effect is relevant for patients who may need this drug
combination.
Conclusion
In this large cohort of patients receiving warfarin during hospitalization, we
observed substantial variation in the magnitude of the known interaction between
warfarin and amiodarone across levels of baseline renal function. Additional studies are
required to understand the effects of kidney disease on DDIs involving drugs with low
protein binding.
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Tables and Figures

Table 6.1. Exposures and international normalized ratio monitoring
Metoprolol,
n=8,628

Amiodarone,
n=7,556

Exposure duration, days, median
(IQR)

5.0 (4.0, 7.0)

6.0 (5.0, 8.0)

Follow-up INR measurements,
median (IQR)
Warfarin duration at index
One day
Two days
Three or more days
Amiodarone dose at index, mg/day,
median (IQR)

2.0 (1.0, 4.0)

3.0 (1.0, 5.0)

7073 (82.0%)
907 (10.5%)
648 (7.5%)
na

6108 (80.8%)
773 (10.2%)
675 (8.9%)
1200.0 (400.0,
1200.0)

Amiodarone loading regimen at
index

na

5472 (72.4%)

Baseline metoprolol exposure
Baseline metoprolol dose, mg,
median (IQR)

8627 (100.0%)
50.0 (25.0, 81.2)

4674 (95.7%)
50.0 (25.0, 87.5)

INR- international normalized ratio; IQR- interquartile range
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Table 6.2 Baseline characteristics in the unmatched cohort
Metoprolol,
n=8,628

Amiodarone,
n=7,556

Demographics
68.8 (13.8)
68.9 (12.0)
3752 (43.5%)
2637 (34.9%)

smd

Age, years, mean (SD)
Female sex
Race
White
5527 (64.1%)
5430 (71.9%)
Black
2062 (23.9%)
1155 (15.3%)
Other / Unk
1039 (12.0%)
971 (12.9%)
Height, cm, mean (SD)
171.2 (11.6)
172.5 (11.3)
Weight, kg, mean (SD)
86.8 (25.7)
86.4 (22.6)
BSA, mean (SD)
2.0 (0.3)
2.0 (0.3)
BMI, mean (SD)
29.5 (8.1)
29.0 (7.1)
Hospital admission characteristics
Center
HUP
4701 (54.5%)
4656 (61.6%)
PAH
1557 (18.0%)
757 (10.0%)
PMC
2370 (27.5%)
2143 (28.4%)
Surgical Admission
5062 (58.7%)
5657 (74.9%)
Location of initial
presentation

0.010
-0.177

ED
ICU
OR
Floor
Other
LOS prior to index, days,
mean (SD)

2603 (30.2%)
997 (11.6%)
1302 (15.1%)
3417 (39.6%)
309 (3.6%)
5.5 (7.0)

1319 (17.5%)
1514 (20.0%)
1641 (21.7%)
2847 (37.7%)
235 (3.1%)
7.5 (7.3)

-0.302
0.234
0.172
-0.040
-0.026
0.281

ICU care at index
Peri-operative recency
Not peri-op
POD 0-1
POD 2
POD 3+
Mechanical ventilation

3072 (35.6%)

4388 (58.1%)

0.462

6730 (78.0%)
916 (10.6%)
391 (4.5%)
591 (6.8%)
1165 (13.5%)
Comorbidities
4923 (57.1%)
1893 (21.9%)
6811 (78.9%)
3514 (40.7%)
1513 (17.5%)

5220 (69.1%)
606 (8.0%)
494 (6.5%)
1236 (16.4%)
1998 (26.4%)

-0.203
-0.089
0.088
0.300
0.328

5737 (75.9%)
2070 (27.4%)
5773 (76.4%)
4655 (61.6%)
1235 (16.3%)

0.408
0.127
-0.061
0.427
-0.032

Heart failure
Myocardial infarction
Hypertension
Valvular disease
Stroke
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0.168
-0.218
0.024
0.108
-0.016
0.035
-0.067

0.145
-0.233
0.020
0.349

Chronic pulmonary
disease
Diabetes mellitus
None
Non-complicated
Complicated
Liver disease
Thyroid disease
Paraplegia
Cancer
None
Non-Metastatic
Metastatic
Weight loss
Fluid and electrolyte
disorder
Anemia
Depression
Alcohol abuse
Drug abuse
Prior VTE
DVT
Pulmonary embolism
Creatinine clearance,
ml/min, mean (SD)

3220 (37.3%)

3254 (43.1%)

0.117

5702 (66.1%)
2144 (24.8%)
782 (9.1%)
533 (6.2%)
1331 (15.4%)
234 (2.7%)

5096 (67.4%)
1859 (24.6%)
601 (8.0%)
533 (7.1%)
1250 (16.5%)
144 (1.9%)

0.029
-0.006
-0.040
0.035
0.030
-0.054

7293 (84.5%)
1017 (11.8%)
318 (3.7%)
959 (11.1%)
3528 (40.9%)

6650 (88.0%)
775 (10.3%)
131 (1.7%)
1033 (13.7%)
3823 (50.6%)

0.101
-0.049
-0.120
0.078
0.196

513 (5.9%)
1321 (15.3%)
356 (4.1%)
293 (3.4%)
1027 (11.9%)
1026 (11.9%)
557 (6.5%)
Kidney function
66.8 (39.3)

354 (4.7%)
1028 (13.6%)
300 (4.0%)
209 (2.8%)
586 (7.8%)
797 (10.5%)
268 (3.5%)

-0.056
-0.049
-0.008
-0.036
-0.140
-0.043
-0.134

61.9 (32.1)

-0.137

Creatinine clearance category
0-30 ml/min
1293 (15.0%)
1224 (16.2%)
31-60 ml/min
2920 (33.8%)
2784 (36.9%)
61-90 ml/min
2482 (28.8%)
2247 (29.7%)
91-120 ml/min
1255 (14.5%)
927 (12.3%)
>120 ml/min
678 (7.9%)
372 (4.9%)
Chronic kidney disease
2193 (25.4%)
2239 (29.6%)
End stage renal disease 584 (6.8%)
498 (6.6%)
Dialysis dependence
431 (5.0%)
373 (4.9%)
Baseline AKI
None
6472 (75.0%)
4389 (58.1%)
Prior
1227 (14.2%)
1491 (19.7%)
Current
929 (10.8%)
1676 (22.2%)
Laboratory values
INR, median (IQR)
1.3 (1.1, 1.7)
1.3 (1.1, 1.5)
Hemoglobin, g/dL, mean 11.0 (2.2)
10.3 (1.9)
(SD)

132

0.033
0.063
0.022
-0.067
-0.120
0.094
-0.007
-0.003
-0.365
0.147
0.310
-0.126
-0.340

Platelets, x 1011 cells/L,
mean (SD)

211.7 (98.6)

190.7 (96.9)

-0.216

WBC, x 108 cells/L,
mean (SD)

9.7 (4.4)

11.1 (4.8)

0.299

Medications
5351 (62.0%)
845 (9.8%)
4178 (48.4%)
755 (8.8%)
1213 (14.1%)
1250 (14.5%)
908 (10.5%)
4066 (47.1%)
2013 (23.3%)
1803 (20.9%)

5412 (71.6%)
661 (8.7%)
5361 (71.0%)
848 (11.2%)
958 (12.7%)
1140 (15.1%)
331 (4.4%)
5744 (76.0%)
2903 (38.4%)
1935 (25.6%)

0.205
-0.036
0.472
0.083
-0.041
0.017
-0.236
0.622
0.331
0.112

Narrow spectrum
antibiotics

2497 (28.9%)

2791 (36.9%)

0.171

Sulfamethoxazole /
trimethoprim

183 (2.1%)

110 (1.5%)

-0.050

Metronidazole
Rosuvastatin
Simvastatin
Atorvastatin
Antiepileptic
SSRI
Fibrate
Other CYP-enzyme
inhibitors

536 (6.2%)
448 (5.2%)
1609 (18.6%)
1933 (22.4%)
200 (2.3%)
392 (4.5%)
143 (1.7%)
181 (2.1%)

331 (4.4%)
523 (6.9%)
1385 (18.3%)
2039 (27.0%)
115 (1.5%)
367 (4.9%)
136 (1.8%)
102 (1.3%)

-0.082
0.073
-0.008
0.106
-0.058
0.015
0.011
-0.057

Heparin
LMWH
Aspirin
Clopidogrel
Calcium channel blocker
Digoxin
Other antiarrhythmic
Loop diuretic
Gram positive antibiotics
Gram negative
antibiotics

Phytonadione
502 (5.8%)
366 (4.8%)
-0.043
Acid suppression
None
3294 (38.2%)
1614 (21.4%)
-0.374
H2RA
2000 (23.2%)
2080 (27.5%)
0.100
PPI
3334 (38.6%)
3862 (51.1%)
0.253
Vasopressors
655 (7.6%)
1697 (22.5%)
0.425
IQR- interquartile range; SMD-standardized mean difference; SD- standard deviation; BSA- body
surface area; BMI- body mass index; cm- centimeters; kg- kilogram; HUP- Hospital of the
University of Pennsylvania; PMC- Presbyterian Medical Center; PAH- Pennsylvania Hospital; EDemergency department; ICU- intensive care unit; OR- operating room; LOS- length of stay; PODpostoperative day; WBC- white blood cells; VTE- venous thromboembolism; DVT- deep vein
thrombosis; AKI- acute kidney injury; INR- international normalized ratio; LMWH- low molecular
weight heparin; SSRI- selective serotonin release inhibitors; H2RA-histamine-2 receptor
antagonist; PPI- proton pump inhibitor
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Table 6.3. Baseline characteristics in the matched cohort
Metoprolol,
n=4518

Amiodarone,
n=4518

Demographics
Age, years, mean (SD)
69.6 (13.3)
69.6 (12.3)
Female sex
1798 (39.8%)
1795 (39.7%)
Race
White
3093 (68.5%)
3060 (67.7%)
Black
873 (19.3%)
883 (19.5%)
Other / Unk
552 (12.2%)
575 (12.7%)
Height, cm, mean (SD)
171.5 (11.4)
171.5 (11.3)
Weight, kg, mean (SD)
85.5 (23.4)
85.6 (23.5)
BSA, mean (SD)
2.0 (0.3)
2.0 (0.3)
BMI, mean (SD)
29.0 (7.4)
29.1 (7.4)
Hospital admission characteristics
Center
HUP
2582 (57.1%)
2591 (57.3%)
PAH
613 (13.6%)
611 (13.5%)
PMC
1323 (29.3%)
1316 (29.1%)
Surgical Admission
2936 (65.0%)
2928 (64.8%)
Location of initial
presentation

smd

-0.001
-0.001
-0.016
0.006
0.015
-0.004
0.006
0.004
0.007

0.004
-0.001
-0.003
-0.004

ED
ICU
OR
Floor
Other
LOS prior to index, days,
mean (SD)

1095 (24.2%)
764 (16.9%)
722 (16.0%)
1795 (39.7%)
142 (3.1%)
6.6 (7.9)

1116 (24.7%)
751 (16.6%)
721 (16.0%)
1797 (39.8%)
133 (2.9%)
6.5 (6.7)

0.011
-0.008
-0.001
0.001
-0.012
-0.019

ICU care at index
Peri-operative recency
Not peri-op
POD 0-1
POD 2
POD 3+
Mechanical ventilation

2178 (48.2%)

2071 (45.8%)

-0.047

3415 (75.6%)
405 (9.0%)
250 (5.5%)
448 (9.9%)
932 (20.6%)
Comorbidities
3217 (71.2%)
1163 (25.7%)
3536 (78.3%)
2411 (53.4%)

3452 (76.4%)
428 (9.5%)
243 (5.4%)
395 (8.7%)
892 (19.7%)

0.019
0.018
-0.007
-0.040
-0.022

3164 (70.0%)
1155 (25.6%)
3543 (78.4%)
2372 (52.5%)

-0.026
-0.004
0.004
-0.017

Heart failure
Myocardial infarction
Hypertension
Valvular disease
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Stroke
Chronic pulmonary disease
Diabetes mellitus
None
Non-complicated
Complicated
Liver disease
Thyroid disease
Paraplegia
Cancer
None
Non-Metastatic
Metastatic
Weight loss
Fluid and electrolyte
disorder

767 (17.0%)
1932 (42.8%)

770 (17.0%)
1929 (42.7%)

0.002
-0.001

2994 (66.3%)
1121 (24.8%)
403 (8.9%)
295 (6.5%)
780 (17.3%)
104 (2.3%)

2946 (65.2%)
1162 (25.7%)
410 (9.1%)
308 (6.8%)
731 (16.2%)
93 (2.1%)

-0.022
0.021
0.005
0.012
-0.029
-0.017

3882 (85.9%)
531 (11.8%)
105 (2.3%)
555 (12.3%)
2123 (47.0%)

3852 (85.3%)
549 (12.2%)
117 (2.6%)
525 (11.6%)
2078 (46.0%)

-0.019
0.012
0.017
-0.020
-0.020

Anemia
Depression
Alcohol abuse
Drug abuse
Prior VTE
DVT
Pulmonary embolism

251 (5.6%)
658 (14.6%)
178 (3.9%)
140 (3.1%)
430 (9.5%)
498 (11.0%)
196 (4.3%)
Kidney function
61.1 (32.8)

240 (5.3%)
647 (14.3%)
182 (4.0%)
142 (3.1%)
423 (9.4%)
499 (11.0%)
212 (4.7%)

-0.011
-0.007
0.005
0.003
-0.005
0.001
0.017

61.1 (32.7)

0.000

762 (16.9%)
1705 (37.7%)
1300 (28.8%)
527 (11.7%)
224 (5.0%)
1345 (29.8%)
333 (7.4%)
256 (5.7%)

762 (16.9%)
1705 (37.7%)
1300 (28.8%)
527 (11.7%)
224 (5.0%)
1338 (29.6%)
337 (7.5%)
259 (5.7%)

0.000
0.000
0.000
0.000
0.000
-0.003
0.003
0.003

3059 (67.7%)
784 (17.4%)
675 (14.9%)

0.039
-0.024
-0.025

1.3 (1.1, 1.6)

-0.005

Creatinine clearance,
ml/min, mean (SD)
Creatinine clearance
category
0-30 ml/min
31-60 ml/min
61-90 ml/min
91-120 ml/min
>120 ml/min
Chronic kidney disease
End stage renal disease
Dialysis dependence
Baseline AKI
None
Prior
Current
INR, median (IQR)

2977 (65.9%)
826 (18.3%)
715 (15.8%)
Laboratory values
1.3 (1.2, 1.6)
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Hemoglobin, g/dL, mean
(SD)

10.6 (2.0)

10.7 (2.0)

0.040

Platelets, x 1011 cells/L,
mean (SD)

202.4 (99.3)

203.1 (98.7)

0.007

WBC, x 108 cells/L, mean
(SD)

10.4 (4.7)

10.2 (4.5)

-0.043

Medications
3062 (67.8%)
406 (9.0%)
2765 (61.2%)
475 (10.5%)
631 (14.0%)
774 (17.1%)
253 (5.6%)
2987 (66.1%)
1365 (30.2%)
1084 (24.0%)
1444 (32.0%)
83 (1.8%)

3019 (66.8%)
405 (9.0%)
2708 (59.9%)
474 (10.5%)
639 (14.1%)
755 (16.7%)
267 (5.9%)
2932 (64.9%)
1301 (28.8%)
1042 (23.1%)
1425 (31.5%)
84 (1.9%)

-0.020
-0.001
-0.026
-0.001
0.005
-0.011
0.013
-0.026
-0.031
-0.022
-0.009
0.002

234 (5.2%)
285 (6.3%)
836 (18.5%)
1149 (25.4%)
86 (1.9%)
216 (4.8%)
74 (1.6%)
79 (1.7%)

239 (5.3%)
266 (5.9%)
855 (18.9%)
1142 (25.3%)
84 (1.9%)
231 (5.1%)
77 (1.7%)
73 (1.6%)

0.005
-0.018
0.011
-0.004
-0.003
0.015
0.005
-0.010

Heparin
LMWH
Aspirin
clopidogrel
Calcium channel blocker
Digoxin
Other antiarrhythmic
Loop diuretic
Gram positive antibiotics
Gram negative antibiotics
Narrow spectrum antibiotics
Sulfamethoxazole /
trimethoprim
Metronidazole
Rosuvastatin
Simvastatin
Atorvastatin
Antiepileptic
SSRI
Fibrate
Other CYP-enzyme
inhibitors

Phytonadione
264 (5.8%)
258 (5.7%)
-0.006
Acid suppression
None
1265 (28.0%)
1316 (29.1%)
0.025
H2RA
1120 (24.8%)
1116 (24.7%)
-0.002
PPI
2133 (47.2%)
2086 (46.2%)
-0.021
Vasopressors
588 (13.0%)
529 (11.7%)
-0.040
IQR- interquartile range; SMD-standardized mean difference; SD- standard deviation; BSA- body
surface area; BMI- body mass index; cm- centimeters; kg- kilogram; HUP- Hospital of the
University of Pennsylvania; PMC- Presbyterian Medical Center; PAH- Pennsylvania Hospital; EDemergency department; ICU- intensive care unit; OR- operating room; LOS- length of stay; PODpostoperative day; WBC- white blood cells; VTE- venous thromboembolism; DVT- deep vein
thrombosis; AKI- acute kidney injury; INR- international normalized ratio; LMWH- low molecular
weight heparin; SSRI- selective serotonin release inhibitors; H2RA-histamine-2 receptor
antagonist; PPI- proton pump inhibitor
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Table 6.4. Follow-up international normalized ratio measurements in the matched
population

Day

Metoprolol,
n=4518
patients

Amiodarone,
n=4518
patients

% with INR on each day
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
³ 21

9.1
18.4
97.0
97.7
70.1
49.1
35.8
25.2
18.7
14.2
10.8
8.1
6.7
5.4
4.2
3.8
2.9
2.5
2.1
1.7
1.5
1.1

9.1
20.2
97.1
97.9
70.7
50.2
35.3
25.4
18.1
13.7
10.6
8.2
6.4
5.4
4.2
3.4
2.7
2.3
2.1
1.8
1.5
1.2

Metoprolol,
n=22,297 INR
values

Amiodarone,
n=22,301 INR
values

Number (%) of total INR
measurements
413 (1.9%)
410 (1.8%)
833 (3.7%)
914 (4.1%)
4382 (19.7%)
4387 (19.7%)
4412 (19.8%)
4424 (19.8%)
3165 (14.2%)
3196 (14.3%)
2219 (10.0%)
2266 (10.2%)
1619 (7.3%)
1596 (7.2%)
1139 (5.1%)
1148 (5.1%)
846 (3.8%)
819 (3.7%)
641 (2.9%)
618 (2.8%)
488 (2.2%)
479 (2.1%)
367 (1.6%)
372 (1.7%)
303 (1.4%)
287 (1.3%)
243 (1.1%)
242 (1.1%)
190 (0.9%)
191 (0.9%)
171 (0.8%)
152 (0.7%)
129 (0.6%)
120 (0.5%)
113 (0.5%)
105 (0.5%)
95 (0.4%)
94 (0.4%)
76 (0.3%)
82 (0.4%)
68 (0.3%)
70 (0.3%)
385 (1.7%)
329 (1.5%)

smd

-0.001
0.019
0.000
0.001
0.004
0.007
-0.004
0.002
-0.006
-0.006
-0.003
0.002
-0.006
0.000
0.000
-0.010
-0.005
-0.005
-0.001
0.005
0.002
-0.020

INR- international normalized ratio; smd- standardized mean difference
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Table 6.5. Effect estimates for amiodarone exposure at different levels of renal function
Amiodarone vs.
metoprolol, percentage
change in WSI (95% CI)a

Amiodarone vs. metoprolol,
HR for supratherapeutic INR
(95% CI)

CrCl 15 ml/min

11.8 (0.3, 24.6)

1.01 (0.75, 1.37)

CrCl 45ml/min

34.6 (25.7, 44.2)

1.39 (1.10, 1.77)

CrCl 75 ml/min

33.1 (24.7, 42.1)

1.83 (1.37, 2.43)

CrCl 115 ml/min

36.5 (25.9, 48.1)

1.79 1.19, 2.67)

Renal function level

a. Estimates derived from a mixed effects linear regression analysis of log-transformed WSI
values. Model coefficients were exponentiated to provide the percentage change in WSI for
amiodarone vs. metoprolol at each level of renal function. Increases in WSI are consistent with
decreases in warfarin clearance. The omnibus test for significance of the interaction between
creatinine clearance and amiodarone exposure was at the threshold of significance (Likelihood
ratio test, p=0.048). c. Estimates derived from a cox proportional hazards model for time to first
INR>4. The omnibus test for significance of the interaction between creatinine clearance and
amiodarone exposure was significant (Likelihood ratio test, p=0.033) CrCl- creatinine clearance;
CI- confidence interval; HR- hazard ratio; WSI- warfarin sensitivity index; INR- international
normalized ratio
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Figure 6.1. Selection of patients into the study

UPHS patients with atrial fibrillation who received >1 dose
warfarin from January 1, 2004 – June 30, 2017
n=28,506 patients
At least 24 hours of amiodarone or metoprolol
with at least one follow-up INR
n = 16,888
Exclusion
• Solid organ transplant
• Missing data
• Direct thrombin inhibitor

n
219
341
144
Study cohort
n=16,184 patients

Warfarin + Amiodarone
n=7,556 patients

Warfarin + Metoprolol
n=8,628 patients
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Figure 6.2. Propensity score distributions in each group
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Figure 6.3. Propensity score distribution in each group, stratified by renal function level
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Figure 6.4. Standardized mean differences

a. Overall cohort; b. subgroup with creatinine clearance 0-30 ml/min; c. subgroup with
creatinine clearance 31-60 ml/min; d. subgroup with creatinine clearance 61-90 ml/min;
e. subgroup with creatinine clearance 91-120 ml/min; f. subgroup with creatinine
clearance > 120 ml/min. In each figure, the reference lines are set at standardized mean
difference values of -0.10 and 0.10.
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Figure 6.5. Distribution of the log-transformed warfarin sensitivity index
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Figure 6.6. Observed vs. predicted average trends of warfarin sensitivity index

The panel on the left shows the observed values (error bars are 95% confidence
intervals) and the panel on the right shows the corresponding model predictions.
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Figure 6.7. Trends of warfarin sensitivity index stratified by creatinine clearance level

Trend lines show the within-group averages at each time point and the error bars are
95% confidence intervals
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Figure 6.8. Comparisons of warfarin sensitivity index in metoprolol vs. amiodarone
groups, stratified by creatinine clearance level

Trend lines show the within-group averages at each time point and the error bars are
95% confidence intervals. a. subgroup with creatinine clearance 0-30 ml/min; b.
subgroup with creatinine clearance 31-60 ml/min; c. subgroup with creatinine clearance
61-90 ml/min; d. subgroup with creatinine clearance 91-120 ml/min; e. subgroup with
creatinine clearance > 120 ml/min.
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Figure 6.9. Comparisons of the rate of supratherapeutic international normalized ratio
values in metoprolol vs. amiodarone groups, stratified by creatinine clearance level

INR- international normalized ratio; CrCl- creatinine clearance; A- amiodarone; Mmetoprolol
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Figure 6.10. Comparisons of predicted survivals curves for time to first supratherapeutic
international normalized ratio value in amiodarone vs. metoprolol groups, estimated at
low and high levels of renal function
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CHAPTER 7: USING PHARMACOEPIDEMIOLOGIC APPROACHES TO STUDY THE
BIDIRECTIONAL RELATIONSHIPS BETWEEN DRUG-DRUG INTERACTIONS AND
KIDNEY DISEASE

Overview
Adverse health effects that result from exposure to DDIs are an important and
growing public health problem.62,67 Previous studies suggest that DDIs are linked to an
increased risk for hospitalization due to a variety of adverse drug effects, including
anticoagulant related bleeding, hypoglycemia, hypoglycemia, sudden cardiac death,
acute kidney injury, and many others.67,19,114,81,89,119,133 Although thousands of potential
DDIs have been suggested, the true burden of disease that is due to DDIs is poorly
understood. The clinical management of DDIs is challenging, due to a lack of evidence
that distinguishes truly harmful DDIs from those that have a negligible risk of adverse
effects. Management is further complicated by substantial variability of DDI severity at
the individual level.
One of the least understood aspects of DDI pharmacoepidemiology is the risk of
adverse outcomes from DDIs in the hospital setting, where existing regimens of chronic
medications intersect with often multiple new medications that are prescribed for acute
illness. Moreover, the variability of DDI severity may be increased in the hospital setting,
due to the impacts of acute and chronic organ dysfunction, the most common of which is
kidney disease. Up to half of patients have acute or chronic kidney disease at the time of
hospital admission, and a substantial proportion will develop kidney dysfunction during
admission.17,59,138,161,167 Further, the potential for bidirectional relationships between
kidney disease and DDIs—with kidney disease functioning as both an outcome of DDIs
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and a baseline factor that alters DDI severity, highlights kidney disease as a priority area
for DDI research in the hospital setting.
To address these challenges, this dissertation undertook three distinct but related
projects that explored the potential bidirectional relationships between kidney disease
and DDIs. In the first study, we proposed and provided theoretical justification for a novel
study design, the dual control design, which specifically addresses unique challenges
that are posed by the study of pharmacodynamic DDIs. In the second study, we applied
the dual-control design to determine the risk of acute kidney injury during concomitant
exposure to nonsteroidal anti-inflammatory drugs and inhibitors of the renin angiotensin
system during inpatient admission, a DDI with a purported pharmacodynamic
mechanism. While the second study examined the impact of a potential DDI on kidney
disease, the third study examined whether changes in kidney function in turn produce
variability in DDI severity. In a cohort of inpatients receiving warfarin therapy, we
examined the effect of renal dysfunction on the magnitude of the known interaction
between warfarin and amiodarone, a DDI that is mediated by CYP2C9 enzyme
inhibition. In this final chapter, we review the findings of these studies and consider the
both the methodologic implications for the field of DDI pharmacoepidemiology; and
clinical implications for the management of DDI in the hospitalized population.
Methodologic implications relevant to DDI pharmacoepidemiology
Chapter two of this dissertation focused on the theoretical underpinnings of
common epidemiologic measures of interaction. We demonstrated the well-known scale
dependence of statistical interaction – when considering two exposures in the same
statistical model, where both exposures have effects on the study outcome, there must
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be some degree of statistical interaction on at least one scale.129 Rothman proves this by
relating the additive scale to the multiplicative scale using the “Relative Excess Risk due
to Interaction” measure.129 Approaching this phenomenon from a different perspective,
we show that the scale dependence can be understood as being due to the resultant
differences in base rate that exist when both factors have effects. Further, we show that
this scale dependence only applies pharmacodynamic DDIs, where both drugs involved
have direct effects on the outcome. In contrast, we show that there is no scale
dependence of interaction if the DDI mechanism is purely pharmacokinetic, where only
one drug has a direct effect on the outcome.
Beyond merely understanding the mathematical dependencies between the
additive and multiplicative scale, researchers have long sought to understand how these
scales of measurement relate to the underlying biologic phenomena that give rise to
interdependent effects between two exposures. This is of particular relevance to the DDI
research, where understanding the mechanism of interaction is essential for clinical
management and risk assessment.
Leveraging previous work in the potential outcomes and sufficient cause
frameworks,129,154,102,50,128,150,55,103,127,153,152 we replicate findings showing that departures
from additivity on the difference scale have the closes relation to mechanistic notions of
interaction such as synergistic causation and antagonism. The results suggest that the
additive scale might be the preferred scale of basement for DDI studies. Finally, we note
the findings of Greenland that show that the potential outcomes interaction response
types are dependent on the indicator variable coding scheme. This dependence of
interaction types on coding is of particular interest when interpreting the results of DDI
studies that employ the use of active comparators, where it may be impossible to
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distinguish causal effects of an exposure of interest from preventative effects of the
chosen active comparator. Taken together, these findings should prove helpful for
researchers during the analytic planning stages, when choices on the primary scale of
interaction analyses are made.
In chapters three and four, we use causal models and the potential outcomes
causal model to establish a framework for linking the active comparator design to causal
interaction contrasts. We identified the “treatment decision event” as the key causal
structure, which defines the target population of causal parameters, and serves as the
causal link between confounding by indication and treatment choice. We show that
active comparator designs control confounding by conditioning on the treatment event,
and clearly show that the validity of causal inferences that are drawn from active
comparator studies hinges on the assumption that the treatment decision event
represents the singular event through which factors associated with treatment indication
condition treatment probability.
Building on these insights in chapter four, we demonstrated that
pharmacodynamic interactions cannot be identified with the standard design used for the
study of pharmacokinetic DDIs, the nested active comparator design, because the
interaction contrast is undefined unless it can be assumed that only one drug involved in
the interaction has a direct effect on the outcome of interest. To address this limitation,
we introduced the dual control design, an extension of the nested active comparator
designs that employs a second active comparator, which removes the need for
restriction of the base cohort to population that is uniformly treated with one of the drugs.
We show how this design, like other active comparator designs, is linked to causal
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parameters through conditioning on the set of treatment decision events involved in the
DDI, and identify conditions that are sufficient to identify causal interaction parameters.
Finally, we demonstrated the utility of the dual control design in a study of the
potential pharmacodynamic DDI between NSAID analgesics and RAS inhibitor
antihypertensives. Notably, use of the dual control design did not show evidence of
clinically meaningful causal interaction between the two drugs, while a secondary
analysis that compared NSAID exposure to control (a main effects analysis, analogous
to the nested active comparator design) showed a significant increase in AKI associated
with NSAID exposure. This result demonstrates how use of a nested active comparator
design to evaluate pharmacodynamic DDIs might lead researchers to mistake a drug’s
main effect for one for causal interaction. This result highlights the potential value of
using the dual control design.
Clinical implications relevant to inpatient pharmacotherapy
The key motivation for the applied studies in this dissertation was the notion of
potential bidirectional relationships between DDIs and kidney disease: many DDIs may
cause kidney toxicity, while changes in kidney function may in turn alter the severity of a
variety of DDIs. We thus conducted two studies that addressed each aspect of this
conceptual framework.
The NSAID class of analgesics is a key alternative to opioids, but their use is
often hindered by concerns for nephrotoxicity, particularly in the setting of predisposing
risk factors such as DDIs. Using the dual control design, we examined the potential
pharmacodynamic DDI between NSAIDs and RAS inhibitors in a large cohort of
hospitalized patients. As noted above, the key finding of the study was a lack of
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evidence to suggest a clinically meaningful interaction between NSAID and RAS
exposures. This finding has important clinical implications, given the widespread use of
opioids in the inpatient population and an increasing need to consider alternative agents.
This result suggests that, at least for short term (2-3 day) exposure, RAS exposure does
not alter the probability of experiencing AKI during NSAID analgesia. Thus, in patients
who would otherwise be deemed candidates for NSAID therapy, RAS inhibitor exposure
may not be a reason to choose an alternative analgesic (e.g. opioid) in lieu of an NSAID.
In the third and final aim of the dissertation, we used the CYP-inhibition DDI
between warfarin and amiodarone as a model for the potential drug-drug-disease
interaction between kidney disease and DDIs. Based on prior evidence that suggesting
that CYP metabolism is suppressed in patients with kidney disease,164 and the
pharmacokinetic models that describe CYP inhibition, we hypothesized that baseline
kidney disease would alter the magnitude of the interaction between amiodarone and
warfarin. The key findings of the study support this hypothesis. We showed for the first
time that the magnitude of amiodarone’s effect on warfarin dose response varied across
levels of baseline renal function in an inverse manner. In addition, we showed that the
impact of amiodarone on the risk of supratherapeutic anticoagulation varied in a similar
pattern across renal function levels, with there being no apparent effect in patients with
low baseline renal function, but a strong effect in patients with normal renal function.
These results provide actionable evidence for clinicians who prescribe warfarin and
amiodarone in the inpatient, and setting the foundation for numerous future studies that
examine this mechanisms the effect of kidney disease on the numerous DDIs that are
mediated by inhibition of CYP enzyme metabolism.
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APPENDIX

Methods for multivariable regression outcome modeling in the NSAID-RAS analysis in
chapter 5
The set of potential confounders for each model was the same set used in the
primary analysis based on IPT weighting. The variables were selected a priori based on
clinical knowledge and prior literature to include only those with biologically plausible
associations with acute kidney injury. No variable selection procedure was applied in any
of the models. The rationale for not applying variable selection is based on the following:
1) the events per variable ratio in the fully adjusted models was well above minimum
thresholds for valid estimation and inference (2486 events and 78 covariate terms in the
full models corresponds to an EVP of 32); and 2) variable selection procedures do not
result in superior control of confounding and may in fact introduce bias.140
All models included the assessment of collinearity among candidate variables.
This was done by using Pearson and Spearman correlation coefficients and with crossclassification of categorical variables before multivariable modeling commenced, and
with the variance inflation factor to assess the variables in the multivariable models.
Linearity of the relationships between continuous variables and acute kidney injury risk
was examined visually with locally weighted regression (LOWESS) smoother plots. If
evidence of non-linearity was observed, the variable was included in outcome models as
a restricted cubic spline function, with four knots chosen according to Harrell's
recommended percentiles.57
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Poisson regression models were checked for overdispersion by running a
negative binomial regression model and evaluating the likelihood ratio test of the overdispersion parameter (alpha). If overdispersion was detected, analysis proceeded with
the negative binomial model. For multinomial logistic regression models, the
independence of Irrelevant Alternatives (IIA) assumption (i.e. adding or deleting
alternative outcome categories does not affect the odds among the remaining outcomes)
was checked with the mlogtest command in Stata. Lastly, model fit of the linear
regression models was checked by examining residuals plots.
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